[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "vicuna-13b_response": "Answer: Acrokeratosis paraneoplastica is a synonym of Bazex syndrome.",
    "vicuna-13b_fact_raw": "1. Acrokeratosis paraneoplastica is a synonym of Bazex syndrome.",
    "vicuna-13b_fact": [
      "Acrokeratosis paraneoplastica is a synonym of Bazex syndrome."
    ],
    "vicuna-13b_judge_raw": "1. TRUE",
    "vicuna-13b_judge": [
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "vicuna-13b_response": "Based on the given information, Weaver syndrome and Sotos syndrome are both autosomal dominant overgrowth and intellectual disability (OGID) syndromes, which are caused by pathogenic variants in different genes. Weaver syndrome is caused by pathogenic variants in the UBE3B gene, while Sotos syndrome is caused by pathogenic variants in the SDHB gene. Both syndromes are characterized by overgrowth, intellectual disability, and other features such as facial anomalies and skeletal abnormalities. However, the specific features and severity of each syndrome can vary among individuals. While there may be some similarities between Weaver syndrome and Sotos syndrome, they are distinct conditions with different underlying genetic causes.",
    "vicuna-13b_fact_raw": "1. Weaver syndrome and Sotos syndrome are both autosomal dominant overgrowth and intellectual disability syndromes.\n2. Weaver syndrome is caused by pathogenic variants in the EZH2 gene.\n3. Sotos syndrome is caused by pathogenic variants in the NSD1 gene.\n4. Both syndromes are characterized by overgrowth, intellectual disability, facial anomalies, and skeletal abnormalities.\n5. Weaver syndrome and Sotos syndrome are distinct conditions with different underlying genetic causes.",
    "vicuna-13b_fact": [
      "Weaver syndrome and Sotos syndrome are both autosomal dominant overgrowth and intellectual disability syndromes.",
      "Weaver syndrome is caused by pathogenic variants in the EZH2 gene.",
      "Sotos syndrome is caused by pathogenic variants in the NSD1 gene.",
      "Both syndromes are characterized by overgrowth, intellectual disability, facial anomalies, and skeletal abnormalities.",
      "Weaver syndrome and Sotos syndrome are distinct conditions with different underlying genetic causes."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "vicuna-13b_response": "The releases of JASPAR database are:\n1. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles - PMC Journal List Nucleic Acids Res v.50 (D1); 2022 Jan 7 PMC8728201",
    "vicuna-13b_fact_raw": "1. JASPAR 2022 is the 9th release of the JASPAR database.\n2. The JASPAR 2022 release is documented in the Nucleic Acids Research journal, volume 50, issue D1, on January 7, 2022.\n3. The JASPAR database is an open-access database of transcription factor binding profiles.",
    "vicuna-13b_fact": [
      "JASPAR 2022 is the 9th release of the JASPAR database.",
      "The JASPAR 2022 release is documented in the Nucleic Acids Research journal, volume 50, issue D1, on January 7, 2022.",
      "The JASPAR database is an open-access database of transcription factor binding profiles."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: JASPAR 2022 is the 8th release of the JASPAR database.\n2. TRUE\n3. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "vicuna-13b_response": "The function of the viral KP4 protein is to kill sensitive Ustilago strains and inhibit Fusarium and plant root growth by inhibiting calcium uptake. This is based on the information provided in both Document 0 and Document 1.",
    "vicuna-13b_fact_raw": "1. The viral KP4 protein functions to kill sensitive Ustilago strains.\n2. The KP4 protein inhibits Fusarium growth.\n3. The KP4 protein inhibits plant root growth.\n4. The KP4 protein works by inhibiting calcium uptake.",
    "vicuna-13b_fact": [
      "The viral KP4 protein functions to kill sensitive Ustilago strains.",
      "The KP4 protein inhibits Fusarium growth.",
      "The KP4 protein inhibits plant root growth.",
      "The KP4 protein works by inhibiting calcium uptake."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The KP4 protein does not inhibit plant root growth; it is a viral protein that targets fungal pathogens.\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "vicuna-13b_response": "Answer: Yes, DITPA is a thyroid hormone analog that has been utilized in experimental and clinical studies. It has been shown to have beneficial hemodynamic effects in animal studies and in a pilot trial in patients with congestive heart failure. DITPA is synthetic thyroid hormone analog that has positive inotropic effects similar to thyroid hormone but with minimal systemic effects.",
    "vicuna-13b_fact_raw": "1. DITPA is a thyroid hormone analog.\n2. DITPA has been used in experimental studies.\n3. DITPA has been used in clinical studies.\n4. DITPA has shown beneficial hemodynamic effects in animal studies.\n5. DITPA was used in a pilot trial with patients with congestive heart failure.",
    "vicuna-13b_fact": [
      "DITPA is a thyroid hormone analog.",
      "DITPA has been used in experimental studies.",
      "DITPA has been used in clinical studies.",
      "DITPA has shown beneficial hemodynamic effects in animal studies.",
      "DITPA was used in a pilot trial with patients with congestive heart failure."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nDITPA, or 3,5-diiodothyropropionic acid, is indeed a thyroid hormone analog. It has been used in both experimental and clinical studies. In animal studies, DITPA has shown beneficial hemodynamic effects. Additionally, DITPA was used in a pilot trial with patients with congestive heart failure, indicating its application in clinical research.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "vicuna-13b_response": "The COUGER tool is not mentioned in the provided documents. It is possible that it is a tool specific to a particular domain or organization. Can you provide more context or information about the COUGER tool?",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "vicuna-13b_response": "Answer: There is no medication to treat Tick-borne Encephalitis, but a vaccine is available to prevent infection. Treatment is mainly supportive, involving rest, fluids, and over-the-counter pain medications to relieve symptoms.",
    "vicuna-13b_fact_raw": "1. There is no medication to treat Tick-borne Encephalitis.\n2. A vaccine is available to prevent Tick-borne Encephalitis infection.\n3. Treatment for Tick-borne Encephalitis is mainly supportive.\n4. Supportive treatment for Tick-borne Encephalitis includes rest and fluids.\n5. Over-the-counter pain medications are used to relieve symptoms of Tick-borne Encephalitis.",
    "vicuna-13b_fact": [
      "There is no medication to treat Tick-borne Encephalitis.",
      "A vaccine is available to prevent Tick-borne Encephalitis infection.",
      "Treatment for Tick-borne Encephalitis is mainly supportive.",
      "Supportive treatment for Tick-borne Encephalitis includes rest and fluids.",
      "Over-the-counter pain medications are used to relieve symptoms of Tick-borne Encephalitis."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "vicuna-13b_response": "Answer: GBshape is a genome browser database that provides DNA shape annotations for entire genomes. It offers annotations for minor groove width (MGW), propeller twist (ProT), Roll, helix twist (HelT), and hydroxyl radical cleavage (ORChID2) for 94 organisms, and additional genomes can be easily added to the database. The database aims to provide a framework for understanding how DNA shape can influence protein-DNA binding specificity, and how this knowledge can be used to develop new strategies for regulating gene expression. The database was developed to address the fact that nucleotide sequence alone is not sufficient to determine why a protein binds only to a small subset of the many putative binding sites in the genome that share the same core motif.",
    "vicuna-13b_fact_raw": "1. GBshape is a genome browser database that provides DNA shape annotations for entire genomes.\n2. GBshape offers annotations for minor groove width (MGW), propeller twist (ProT), Roll, helix twist (HelT), and hydroxyl radical cleavage (ORChID2).\n3. The database includes annotations for 94 organisms.\n4. GBshape was developed to help understand the influence of DNA shape on protein-DNA binding specificity.\n5. The database addresses the limitation that nucleotide sequence alone is not sufficient to determine specific protein binding sites.",
    "vicuna-13b_fact": [
      "GBshape is a genome browser database that provides DNA shape annotations for entire genomes.",
      "GBshape offers annotations for minor groove width (MGW), propeller twist (ProT), Roll, helix twist (HelT), and hydroxyl radical cleavage (ORChID2).",
      "The database includes annotations for 94 organisms.",
      "GBshape was developed to help understand the influence of DNA shape on protein-DNA binding specificity.",
      "The database addresses the limitation that nucleotide sequence alone is not sufficient to determine specific protein binding sites."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "vicuna-13b_response": "Based on the information provided, the p.Glu745Lys mutation in the EZH2 gene has been associated with Weaver Syndrome and the presence of acute lymphoblastic leukemia and lymphoma in patients. Additionally, oncogenic gain-of-function EZH2 mutations have been shown to result in the silencing of 1,034 genes within topologically associating domains, leading to the inactivation of genes. It is important to note that these associations are based on the information provided and further research may be necessary to confirm these findings.",
    "vicuna-13b_fact_raw": "1. The p.Glu745Lys mutation in the EZH2 gene is associated with Weaver Syndrome.\n2. Mutations in the EZH2 gene have been linked to the presence of acute lymphoblastic leukemia and lymphoma in patients.\n3. Oncogenic gain-of-function mutations in the EZH2 gene can lead to the silencing of 1,034 genes within topologically associating domains.\n4. The silencing of genes due to EZH2 mutations results in their inactivation.",
    "vicuna-13b_fact": [
      "The p.Glu745Lys mutation in the EZH2 gene is associated with Weaver Syndrome.",
      "Mutations in the EZH2 gene have been linked to the presence of acute lymphoblastic leukemia and lymphoma in patients.",
      "Oncogenic gain-of-function mutations in the EZH2 gene can lead to the silencing of 1,034 genes within topologically associating domains.",
      "The silencing of genes due to EZH2 mutations results in their inactivation."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "vicuna-13b_response": "Based on the given information, it is known that the accumulation of misfolded proteins drives the activation of three transmembrane proteins: Inositol-Requiring enzyme 1α (IRE1), protein kinase R (PKR)-like ER kinase (PERK), and activating transcription factor 6 (ATF6). Additionally, it is suggested that the dimer-to-tetramer transition might represent an intermediate point during the evolution of the more stable haemoglobin tetramer that is found in higher vertebrates, where cooperative ligand binding is based on switching between quaternary states with different affinities for oxygen.\nHowever, the question specifically asks for human proteins that are subject to a dimer-to-tetramer transition. While the information provided mentions the activation of certain transmembrane proteins in response to the accumulation of misfolded proteins, it does not specifically mention human proteins that undergo a dimer-to-tetramer transition. Therefore, it is not possible to provide a definitive answer to this question based on the given information.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "vicuna-13b_response": "The protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is HAX-1. This is stated in the abstract of the article \"Phospholamban Interacts with HAX-1, a Mitochondrial Protein with Anti-apoptotic Function\" by Elizabeth Vafiadaki et al. (2007).",
    "vicuna-13b_fact_raw": "1. HAX-1 is a protein that interacts with phospholamban (PLN).\n2. HAX-1 is an anti-apoptotic protein.\n3. The interaction between HAX-1 and phospholamban is discussed in the article titled \"Phospholamban Interacts with HAX-1, a Mitochondrial Protein with Anti-apoptotic Function.\"\n4. The article mentioning the interaction was authored by Elizabeth Vafiadaki et al.\n5. The article was published in 2007.",
    "vicuna-13b_fact": [
      "HAX-1 is a protein that interacts with phospholamban (PLN).",
      "HAX-1 is an anti-apoptotic protein.",
      "The interaction between HAX-1 and phospholamban is discussed in the article titled \"Phospholamban Interacts with HAX-1, a Mitochondrial Protein with Anti-apoptotic Function.\"",
      "The article mentioning the interaction was authored by Elizabeth Vafiadaki et al.",
      "The article was published in 2007."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nPlease note that without access to the specific article or additional context, the responses are based on the assumption that the statements provided are accurate reflections of the content of the article mentioned. If the article's details such as authorship or publication year were incorrect, I would not be able to verify this without additional information.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "vicuna-13b_response": "Based on the provided documents, it is suggested that vitamin D may have a role in reducing the incidence of falls in older people. Document 0 mentions a literature overview that found evidence for a vitamin D action on postural adaptations, which may explain decreased fall and bone fracture rates. However, it is important to note that Document 1 mentions that falls can be prevented through evidence-based interventions, and vitamin D may not be the only factor to consider. Therefore, further research and consultation with a healthcare professional may be necessary to determine the best course of action for individuals who are concerned about falls.",
    "vicuna-13b_fact_raw": "1. Vitamin D may have a role in reducing the incidence of falls in older people.\n2. A literature overview found evidence for a vitamin D action on postural adaptations.\n3. This action on postural adaptations may explain decreased fall and bone fracture rates.\n4. Falls can be prevented through evidence-based interventions, suggesting multiple factors may be involved.\n5. Vitamin D may not be the only factor to consider in preventing falls.",
    "vicuna-13b_fact": [
      "Vitamin D may have a role in reducing the incidence of falls in older people.",
      "A literature overview found evidence for a vitamin D action on postural adaptations.",
      "This action on postural adaptations may explain decreased fall and bone fracture rates.",
      "Falls can be prevented through evidence-based interventions, suggesting multiple factors may be involved.",
      "Vitamin D may not be the only factor to consider in preventing falls."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "vicuna-13b_response": "Based on the provided information, there is an association between Jarid2 and miR-155 in Th17 cells. Document 0, Figure 1, suggests that Jarid2 links posttranscriptional regulation by miR-155 to the transcriptional regulation of cytokine genes in Th17 cells. Additionally, Document 1 states that Jarid2 associates with the polycomb repressive complex 2 (PRC2) in a range of different cell types, including ESCs and thymocytes, suggesting that this association may also occur in Th17 cells.",
    "vicuna-13b_fact_raw": "1. Jarid2 is associated with miR-155 in Th17 cells.\n2. Jarid2 is involved in linking posttranscriptional regulation by miR-155 to the transcriptional regulation of cytokine genes in Th17 cells.\n3. Jarid2 associates with the polycomb repressive complex 2 (PRC2) in various cell types, including ESCs and thymocytes.",
    "vicuna-13b_fact": [
      "Jarid2 is associated with miR-155 in Th17 cells.",
      "Jarid2 is involved in linking posttranscriptional regulation by miR-155 to the transcriptional regulation of cytokine genes in Th17 cells.",
      "Jarid2 associates with the polycomb repressive complex 2 (PRC2) in various cell types, including ESCs and thymocytes."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n\nThe statements provided are specific and technical, and they relate to the role of Jarid2 in cellular processes. Jarid2 is known to be associated with various regulatory complexes and pathways in different cell types, including its interaction with miR-155 and involvement with the polycomb repressive complex 2 (PRC2). However, without specific context or a passage to reference, the responses are based on general scientific knowledge up to the knowledge cutoff date. If the passage contained different or more specific information, the answers could vary.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "vicuna-13b_response": "The human hoxD cluster contains 13 genes.",
    "vicuna-13b_fact_raw": "1. The human hoxD cluster contains 13 genes.",
    "vicuna-13b_fact": [
      "The human hoxD cluster contains 13 genes."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The human HOXD cluster contains 9 genes.",
    "vicuna-13b_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "vicuna-13b_response": "Based on the given documents, the consensus motifs for phosphorylation by Casein Kinase 1 (CK1) are not explicitly mentioned. However, it is known that CK1s typically recognize substrates with acidic motifs N-terminal to phosphorylation sites and tend to generate clusters of consecutive phosphoserines on their substrates. Additionally, it is known that CK1 is involved in the phosphorylation of Ser-45 of β-catenin, which \"primes\" subsequent phosphorylation by glycogen synthase-3 and signals the degradation of β-catenin, preventing its function in triggering cell division.",
    "vicuna-13b_fact_raw": "1. Casein Kinase 1 (CK1) typically recognizes substrates with acidic motifs N-terminal to phosphorylation sites.\n2. CK1 tends to generate clusters of consecutive phosphoserines on their substrates.\n3. CK1 is involved in the phosphorylation of Ser-45 of β-catenin.\n4. Phosphorylation of β-catenin by CK1 \"primes\" subsequent phosphorylation by glycogen synthase kinase-3.\n5. Phosphorylation by CK1 signals the degradation of β-catenin, preventing its function in triggering cell division.",
    "vicuna-13b_fact": [
      "Casein Kinase 1 (CK1) typically recognizes substrates with acidic motifs N-terminal to phosphorylation sites.",
      "CK1 tends to generate clusters of consecutive phosphoserines on their substrates.",
      "CK1 is involved in the phosphorylation of Ser-45 of β-catenin.",
      "Phosphorylation of β-catenin by CK1 \"primes\" subsequent phosphorylation by glycogen synthase kinase-3.",
      "Phosphorylation by CK1 signals the degradation of β-catenin, preventing its function in triggering cell division."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Casein Kinase 1 (CK1) is known to recognize substrates that have acidic motifs near the phosphorylation sites, typically N-terminal to these sites.\n2. TRUE: CK1 can indeed generate clusters of consecutive phosphoserines on their substrates, which is a characteristic feature of its activity.\n3. TRUE: CK1 is involved in the phosphorylation of Ser-45 of β-catenin. This is a well-documented step in the phosphorylation cascade that regulates β-catenin stability.\n4. TRUE: The phosphorylation of β-catenin by CK1 at Ser-45 does \"prime\" the subsequent phosphorylation by glycogen synthase kinase-3 (GSK-3) at other sites such as Thr-41, Ser-37, and Ser-33.\n5. TRUE: The phosphorylation of β-catenin by CK1 and subsequent phosphorylation by GSK-3 signal its recognition by the ubiquitin-proteasome system, leading to its degradation. This prevents β-catenin from accumulating in the nucleus and triggering the transcription of genes involved in cell division and proliferation.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "vicuna-13b_response": "Based on the given documents, the different proteins/isoforms encoded by the ASPH (aspartate beta-hydroxylase) gene in humans are:\n1. Protein C\n2. Coagulation factors VII, IX, and X\n3. Complement factors C1R and C1S\nThese proteins contain EGF-like domains that are hydroxylated by the C-terminal Aspartyl/Asparaginyl beta-hydroxylase domain of the ASPH protein.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "vicuna-13b_response": "The medication empagliflozin was first approved by the FDA in August 2014 to improve glucose control in adults with type 2 diabetes. In August 2021, it was approved to reduce the risk of cardiovascular death and HF hospitalization in adults with HF with reduced ejection fraction (HFrEF).",
    "vicuna-13b_fact_raw": "1. Empagliflozin was first approved by the FDA in August 2014.\n2. The initial FDA approval of empagliflozin was for improving glucose control in adults with type 2 diabetes.\n3. In August 2021, empagliflozin was approved by the FDA to reduce the risk of cardiovascular death.\n4. The FDA approved empagliflozin in August 2021 to reduce hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF).",
    "vicuna-13b_fact": [
      "Empagliflozin was first approved by the FDA in August 2014.",
      "The initial FDA approval of empagliflozin was for improving glucose control in adults with type 2 diabetes.",
      "In August 2021, empagliflozin was approved by the FDA to reduce the risk of cardiovascular death.",
      "The FDA approved empagliflozin in August 2021 to reduce hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF)."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Empagliflozin was approved by the FDA to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease in December 2016.\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "vicuna-13b_response": "Document 0: Loss of Lon1 in Arabidopsis Changes the Mitochondrial Proteome Leading to Altered Metabolite Profiles and Growth Retardation without an Accumulation of Oxidative Damage - PMC Journal List Plant Physiol v.160 (3); 2012 Nov PMC3490588\nIn this study, it was found that loss of Lon1 in Arabidopsis leads to changes in the mitochondrial proteome, which results in altered metabolite profiles and growth retardation. However, there was no accumulation of oxidative damage.\nDocument 1: The evidence suggests that loss of Lon1 significantly modifies respiratory function and plant performance by small but broad alterations in the mitochondrial proteome gained by subtly changing steady-state protein assembly, stability, and damage of a range of components that debilitate an anaplerotic role for mitochondria in cellular carbon metabolism. Lon1 is an ATP-dependent protease and plays a role in regulating the balance between protein synthesis and degradation in the mitochondria. The study suggests that Lon1 is important for maintaining the proper functioning of the mitochondria and that its loss can have a significant impact on plant growth and metabolism.",
    "vicuna-13b_fact_raw": "1. Loss of Lon1 in Arabidopsis leads to changes in the mitochondrial proteome.\n2. The changes in the mitochondrial proteome result in altered metabolite profiles and growth retardation in Arabidopsis.\n3. There was no accumulation of oxidative damage observed with the loss of Lon1 in Arabidopsis.\n4. Loss of Lon1 affects respiratory function and plant performance due to alterations in the mitochondrial proteome.\n5. Lon1 is an ATP-dependent protease that helps regulate the balance between protein synthesis and degradation in the mitochondria.",
    "vicuna-13b_fact": [
      "Loss of Lon1 in Arabidopsis leads to changes in the mitochondrial proteome.",
      "The changes in the mitochondrial proteome result in altered metabolite profiles and growth retardation in Arabidopsis.",
      "There was no accumulation of oxidative damage observed with the loss of Lon1 in Arabidopsis.",
      "Loss of Lon1 affects respiratory function and plant performance due to alterations in the mitochondrial proteome.",
      "Lon1 is an ATP-dependent protease that helps regulate the balance between protein synthesis and degradation in the mitochondria."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nNote: While statements 1, 2, 4, and 5 are consistent with general knowledge about the Lon1 protease's role in mitochondrial function and proteostasis, statement 3 requires specific experimental data to confirm or refute, and such data is not provided in the context.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "vicuna-13b_response": "Based on the given documents, it appears that a linker histone does exist in the yeast genome. While the exact identity of the linker histone in yeast has been a subject of controversy, with Hho1 and Hmo1 being two long-standing candidates, the study mentioned in Document 0 suggests that Hmo1 is involved in chromatin assembly in yeast nucleoplasmic extracts, indicating that it may play a role as a linker histone. Additionally, Document 1 notes that histone H1 associates with linker DNA in eukaryotic chromatin, and while Hho1 has sequence similarity to H1, it is not clear if it plays a role as a linker histone in yeast.",
    "vicuna-13b_fact_raw": "1. A linker histone exists in the yeast genome.\n2. Hho1 and Hmo1 are candidates for the identity of the linker histone in yeast.\n3. The study mentioned in Document 0 suggests that Hmo1 is involved in chromatin assembly in yeast nucleoplasmic extracts.\n4. Histone H1 is known to associate with linker DNA in eukaryotic chromatin.\n5. Hho1 has sequence similarity to histone H1.",
    "vicuna-13b_fact": [
      "A linker histone exists in the yeast genome.",
      "Hho1 and Hmo1 are candidates for the identity of the linker histone in yeast.",
      "The study mentioned in Document 0 suggests that Hmo1 is involved in chromatin assembly in yeast nucleoplasmic extracts.",
      "Histone H1 is known to associate with linker DNA in eukaryotic chromatin.",
      "Hho1 has sequence similarity to histone H1."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Yeast, specifically Saccharomyces cerevisiae, does not have a canonical linker histone H1, but it does have histone H1-like proteins.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "vicuna-13b_response": "Based on the information provided, there is evidence that tomato juice may help to lower cholesterol levels. Document 0 states that a high dietary intake of tomato products significantly reduced LDL cholesterol levels and increased LDL resistance to oxidation in healthy adults. Additionally, the study in Document 1 found that dietary tomato juice intake had atheroprotective effects, including reducing LDL cholesterol levels and improving insulin resistance. However, it is important to note that more research is needed to confirm these findings and to determine the optimal dosage and method of consumption for tomato juice to have a cholesterol-lowering effect.",
    "vicuna-13b_fact_raw": "1. Tomato products have been found to significantly reduce LDL cholesterol levels in healthy adults.\n2. Tomato products can increase LDL resistance to oxidation in healthy adults.\n3. Dietary tomato juice intake has been associated with atheroprotective effects.\n4. Consumption of tomato juice may improve insulin resistance.\n5. Further research is necessary to confirm the cholesterol-lowering effects of tomato juice and to determine the optimal dosage and method of consumption.",
    "vicuna-13b_fact": [
      "Tomato products have been found to significantly reduce LDL cholesterol levels in healthy adults.",
      "Tomato products can increase LDL resistance to oxidation in healthy adults.",
      "Dietary tomato juice intake has been associated with atheroprotective effects.",
      "Consumption of tomato juice may improve insulin resistance.",
      "Further research is necessary to confirm the cholesterol-lowering effects of tomato juice and to determine the optimal dosage and method of consumption."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "vicuna-13b_response": "Document 0 suggests that Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability, specifically AU-rich RNA. Document 1 explains that Hsp70 is a protein chaperone that prevents protein aggregation and aids protein folding by binding to hydrophobic peptide domains through a reversible mechanism directed by an ATPase cycle. It also mentions that Hsp70 binds U-rich RNA including some AREs (AU-rich elements) that regulate the decay kinetics of select mRNAs and has recently been shown to bind and stabilize some ARE-containing transcripts. Therefore, it can be inferred that Hsp70 and Hsp110 affect mRNA stability by binding to AU-rich RNA and U-rich RNA, respectively, and regulating the decay kinetics of select mRNAs.",
    "vicuna-13b_fact_raw": "1. Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability, specifically AU-rich RNA.\n2. Hsp70 is a protein chaperone that prevents protein aggregation and aids protein folding.\n3. Hsp70 binds to hydrophobic peptide domains through a reversible mechanism directed by an ATPase cycle.\n4. Hsp70 binds U-rich RNA including some AU-rich elements (AREs) that regulate the decay kinetics of select mRNAs.\n5. Hsp70 has been shown to bind and stabilize some ARE-containing transcripts.",
    "vicuna-13b_fact": [
      "Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability, specifically AU-rich RNA.",
      "Hsp70 is a protein chaperone that prevents protein aggregation and aids protein folding.",
      "Hsp70 binds to hydrophobic peptide domains through a reversible mechanism directed by an ATPase cycle.",
      "Hsp70 binds U-rich RNA including some AU-rich elements (AREs) that regulate the decay kinetics of select mRNAs.",
      "Hsp70 has been shown to bind and stabilize some ARE-containing transcripts."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Hsp70 and Hsp110 are known as molecular chaperones that assist in protein folding and protection against stress, not specifically for binding to RNA motifs involved in mRNA stability.\n2. TRUE\n3. TRUE\n4. UNKNOWN: While Hsp70 is primarily known for its role in protein folding and stabilization, its interaction with U-rich RNA and AU-rich elements (AREs) is not commonly described in the literature, and without specific context or references, it's difficult to confirm this statement.\n5. UNKNOWN: Similar to statement 4, the role of Hsp70 in binding and stabilizing ARE-containing transcripts is not well-established in the general knowledge of molecular biology, and specific references are needed to confirm this statement.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "vicuna-13b_response": "Answer: The type 2 and 3 iodothyronine deiodinases (DIO2 and DIO3) are present in skeletal muscle. DIO2 expression is tightly regulated and it catalyzes the outer-ring deiodination of thyroid hormones, while DIO3 is constitutively expressed and it catalyzes the inner-ring deiodination of thyroid hormones. These enzymes play a crucial role in the regulation of the systemic concentrations of thyroid hormones by controlling the activation and inactivation of thyroid hormone.",
    "vicuna-13b_fact_raw": "1. The type 2 iodothyronine deiodinase (DIO2) is present in skeletal muscle.\n2. The type 3 iodothyronine deiodinase (DIO3) is also present in skeletal muscle.\n3. DIO2 catalyzes the outer-ring deiodination of thyroid hormones.\n4. DIO3 is constitutively expressed and catalyzes the inner-ring deiodination of thyroid hormones.\n5. DIO2 and DIO3 play a role in regulating systemic concentrations of thyroid hormones by controlling their activation and inactivation.",
    "vicuna-13b_fact": [
      "The type 2 iodothyronine deiodinase (DIO2) is present in skeletal muscle.",
      "The type 3 iodothyronine deiodinase (DIO3) is also present in skeletal muscle.",
      "DIO2 catalyzes the outer-ring deiodination of thyroid hormones.",
      "DIO3 is constitutively expressed and catalyzes the inner-ring deiodination of thyroid hormones.",
      "DIO2 and DIO3 play a role in regulating systemic concentrations of thyroid hormones by controlling their activation and inactivation."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: The type 2 iodothyronine deiodinase (DIO2) is indeed present in skeletal muscle, where it plays a role in local thyroid hormone activation.\n2. TRUE: The type 3 iodothyronine deiodinase (DIO3) is also present in skeletal muscle, as well as in the central nervous system and placenta, among other tissues.\n3. TRUE: DIO2 catalyzes the outer-ring deiodination of thyroxine (T4) to produce triiodothyronine (T3), which is the more active form of thyroid hormone.\n4. TRUE: DIO3 is constitutively expressed in certain tissues and is responsible for the inner-ring deiodination of thyroid hormones, which leads to the production of inactive metabolites.\n5. TRUE: DIO2 and DIO3 indeed play a role in regulating systemic concentrations of thyroid hormones by controlling their activation (DIO2) and inactivation (DIO3), although much of this regulation occurs at a local tissue level rather than systemically.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "vicuna-13b_response": "Answer: The inflammatory caspases are a group of caspases that include caspase-1, caspase-4, caspase-5, and caspase-11. These caspases are characterized by the presence of a CARD-domain at the N-terminal end and are involved in the inflammatory response. They are also known as group I caspases. In humans, the main genes encoding inflammatory caspases are caspase-1, caspase-4, and caspase-5, while in mice, the main genes are caspase-1, caspase-11, and caspase-4.",
    "vicuna-13b_fact_raw": "1. Inflammatory caspases include caspase-1, caspase-4, caspase-5, and caspase-11.\n2. Inflammatory caspases are characterized by the presence of a CARD-domain at the N-terminal end.\n3. Inflammatory caspases are involved in the inflammatory response.\n4. In humans, the main genes encoding inflammatory caspases are caspase-1, caspase-4, and caspase-5.\n5. In mice, the main genes encoding inflammatory caspases are caspase-1, caspase-11, and caspase-4.",
    "vicuna-13b_fact": [
      "Inflammatory caspases include caspase-1, caspase-4, caspase-5, and caspase-11.",
      "Inflammatory caspases are characterized by the presence of a CARD-domain at the N-terminal end.",
      "Inflammatory caspases are involved in the inflammatory response.",
      "In humans, the main genes encoding inflammatory caspases are caspase-1, caspase-4, and caspase-5.",
      "In mice, the main genes encoding inflammatory caspases are caspase-1, caspase-11, and caspase-4."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: In humans, the main genes encoding inflammatory caspases are CASP1, CASP4, CASP5, and CASP12.\n5. FALSE [correction]: In mice, the main genes encoding inflammatory caspases are Casp1, Casp11 (which is analogous to human CASP4 and CASP5), and there is no Casp4 in mice.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "vicuna-13b_response": "Based on the given documents, there is a link between the Aurora B kinase and the polycomb protein Ring1B in regulating transcriptionally active genes in quiescent lymphocytes. Document 0 states that both Aurora B and Ring1B bind to a wide range of active promoters in resting B and T cells, suggesting that they play a role in regulating gene expression. Document 1 also supports this idea by highlighting the importance of reversible cellular quiescence in metazoan organisms and the role of Aurora B and Ring1B in regulating transcriptionally active genes during this process. Therefore, it can be inferred that Aurora B and Ring1B work together to regulate gene expression in quiescent lymphocytes.",
    "vicuna-13b_fact_raw": "1. Aurora B kinase and the polycomb protein Ring1B are linked in regulating transcriptionally active genes in quiescent lymphocytes.\n2. Both Aurora B and Ring1B bind to a wide range of active promoters in resting B and T cells.\n3. Aurora B and Ring1B play a role in regulating gene expression.\n4. Reversible cellular quiescence is important in metazoan organisms.\n5. Aurora B and Ring1B regulate transcriptionally active genes during the process of cellular quiescence.",
    "vicuna-13b_fact": [
      "Aurora B kinase and the polycomb protein Ring1B are linked in regulating transcriptionally active genes in quiescent lymphocytes.",
      "Both Aurora B and Ring1B bind to a wide range of active promoters in resting B and T cells.",
      "Aurora B and Ring1B play a role in regulating gene expression.",
      "Reversible cellular quiescence is important in metazoan organisms.",
      "Aurora B and Ring1B regulate transcriptionally active genes during the process of cellular quiescence."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe statements regarding Aurora B kinase, Ring1B, and their specific roles in regulating transcriptionally active genes in quiescent lymphocytes, as well as their binding to active promoters in resting B and T cells, are highly specific and would require access to the relevant scientific literature to verify. Without the specific context or source, it is not possible to determine the truthfulness of statements 1, 2, and 5. However, statement 3 is generally true as both Aurora B and Ring1B are known to be involved in gene expression regulation. Statement 4 is also true as reversible cellular quiescence is a well-established concept important for various processes in metazoan organisms.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "vicuna-13b_response": "Based on the given documents, it appears that the question is asking about the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates.\nDocument 0 suggests that sequence-specific transcription factors (TFs) recognize motifs of related nucleotide sequences at their DNA binding sites, and that TFs regulate critical molecular processes such as gene expression. It also mentions that it is widely assumed that a TF recognizes a single “canonical” motif, although recent studies have identified additional “non-canonical” motifs for some TFs.\nDocument 1 mentions that new methods for preparing and sequencing RNA sequencing libraries, as well as new alignment algorithms, have revealed many thousands of previously unknown transcripts and proteins. It does not directly address the question about non-canonical sequence motifs at splice sites.\nTherefore, without further information or context, it is difficult to provide a specific answer to the question.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "vicuna-13b_response": "Based on the given information, it is not directly stated which event results in the acetylation of S6K1. However, it is known that autophagy is a process that involves the degradation of macromolecules and organelles through the formation of autophagosomes, which are then delivered to the lysosome through the action of acetylated microtubules. It is possible that the acetylation of S6K1 may be involved in the regulation of autophagy, as S6K is known to play a role in cell size regulation and metabolism, which are processes that are affected by autophagy. However, further research would be needed to confirm this and determine the specific mechanisms by which S6K1 is acetylated in response to autophagy.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "vicuna-13b_response": "Based on the given documents, the cause of episodic ataxia type 6 is not specified. However, it is mentioned that episodic ataxia (EA) is a type of ataxia that causes periods (episodes) of movement and balance problems. These episodes have a clear beginning and end. The documents also mention that ataxia describes poor muscle control that causes clumsy voluntary movements, difficulty with walking and balance, hand coordination, speech and swallowing, and eye movements. However, the specific cause of EA is not mentioned in the given documents.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "vicuna-13b_response": "Yes, chromomethylases are present in animal genomes. While they are primarily associated with plant genomes, recent studies have shown the presence of chromomethylases in animal genomes as well. These enzymes play a crucial role in regulating gene expression and maintaining genomic stability in various organisms.",
    "vicuna-13b_fact_raw": "1. Chromomethylases are present in animal genomes.\n2. Chromomethylases are primarily associated with plant genomes.\n3. Recent studies have shown the presence of chromomethylases in animal genomes.\n4. Chromomethylases play a crucial role in regulating gene expression.\n5. Chromomethylases help maintain genomic stability in various organisms.",
    "vicuna-13b_fact": [
      "Chromomethylases are present in animal genomes.",
      "Chromomethylases are primarily associated with plant genomes.",
      "Recent studies have shown the presence of chromomethylases in animal genomes.",
      "Chromomethylases play a crucial role in regulating gene expression.",
      "Chromomethylases help maintain genomic stability in various organisms."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Chromomethylases are not typically found in animal genomes; they are enzymes associated with plants.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "vicuna-13b_response": "Answer: TFBSTools is an R/Bioconductor package for the analysis and manipulation of transcription factor binding sites (TFBSs) and their associated transcription factor profile matrices. It provides a toolkit for handling TFBS profile matrices, scanning sequences and alignments, including whole genomes, and querying the JASPAR database. The package includes classes for S4 classes in TFBSTools, such as XMatrix and its subclasses, XMatrixList and its subclasses, SiteSet, SiteSetList, SitePairSet and SitePairSetList, MotifSet, TFFM and its subclasses.",
    "vicuna-13b_fact_raw": "1. TFBSTools is an R/Bioconductor package used for the analysis and manipulation of transcription factor binding sites (TFBSs).\n2. TFBSTools provides tools for handling TFBS profile matrices and scanning sequences and alignments.\n3. The package allows for querying the JASPAR database.\n4. TFBSTools includes S4 classes such as XMatrix, XMatrixList, SiteSet, SiteSetList, SitePairSet, SitePairSetList, MotifSet, and TFFM.",
    "vicuna-13b_fact": [
      "TFBSTools is an R/Bioconductor package used for the analysis and manipulation of transcription factor binding sites (TFBSs).",
      "TFBSTools provides tools for handling TFBS profile matrices and scanning sequences and alignments.",
      "The package allows for querying the JASPAR database.",
      "TFBSTools includes S4 classes such as XMatrix, XMatrixList, SiteSet, SiteSetList, SitePairSet, SitePairSetList, MotifSet, and TFFM."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: TFBSTools includes S4 classes such as PFMatrix, PFMatrixList, PFMSet, SiteSet, SiteSetList, and TFFM. The classes XMatrix, XMatrixList, SitePairSet, SitePairSetList, and MotifSet are not part of TFBSTools.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "vicuna-13b_response": "Answer: Based on the recent clinical trials, the most effective strategy for preventing sarcopenia is physical exercise. This is supported by the information in both Document 0 and Document 1. Other potential interventions such as nutraceuticals and pharmaceuticals have not been shown to be effective in alleviating sarcopenia.",
    "vicuna-13b_fact_raw": "1. Recent clinical trials indicate that physical exercise is the most effective strategy for preventing sarcopenia.\n2. Nutraceuticals and pharmaceuticals have not been shown to be effective in alleviating sarcopenia according to recent clinical trials.",
    "vicuna-13b_fact": [
      "Recent clinical trials indicate that physical exercise is the most effective strategy for preventing sarcopenia.",
      "Nutraceuticals and pharmaceuticals have not been shown to be effective in alleviating sarcopenia according to recent clinical trials."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: The effectiveness of physical exercise in preventing sarcopenia is supported by research, but without specific details from the recent clinical trials mentioned, it is not possible to confirm if it is considered the \"most effective\" strategy.\n2. FALSE [correction]: While physical exercise is a key strategy in managing sarcopenia, some nutraceuticals and pharmaceuticals have been shown to have potential benefits in alleviating sarcopenia according to various clinical trials, although their effectiveness may vary and more research is often needed.",
    "vicuna-13b_judge": [
      "unknown",
      "false"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "vicuna-13b_response": "The database of molecular recognition features in membrane proteins is mpMoRFsDB. This database was described in a 2013 Bioinformatics paper by Foivos Gypas, Georgios N Tsaousis, and Stavros J Hamodrakas. Molecular recognition features (MoRFs) are small, intrinsically disordered regions in proteins that undergo a disorder-to-order transition on binding to their partners. These features are involved in protein-protein interactions and may function as the initial step in molecular recognition.",
    "vicuna-13b_fact_raw": "1. mpMoRFsDB is a database of molecular recognition features in membrane proteins.\n2. The database mpMoRFsDB was described in a 2013 Bioinformatics paper.\n3. Foivos Gypas, Georgios N Tsaousis, and Stavros J Hamodrakas authored the 2013 Bioinformatics paper describing mpMoRFsDB.\n4. Molecular recognition features (MoRFs) are small, intrinsically disordered regions in proteins.\n5. MoRFs undergo a disorder-to-order transition when binding to their partners.",
    "vicuna-13b_fact": [
      "mpMoRFsDB is a database of molecular recognition features in membrane proteins.",
      "The database mpMoRFsDB was described in a 2013 Bioinformatics paper.",
      "Foivos Gypas, Georgios N Tsaousis, and Stavros J Hamodrakas authored the 2013 Bioinformatics paper describing mpMoRFsDB.",
      "Molecular recognition features (MoRFs) are small, intrinsically disordered regions in proteins.",
      "MoRFs undergo a disorder-to-order transition when binding to their partners."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: The database mpMoRFsDB was described in a 2014 Bioinformatics paper.\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "vicuna-13b_response": "Yes, rivaroxaban is metabolized in the kidneys. In vitro kinetic analysis indicated that rivaroxaban is a selective, reversible, direct Factor Xa inhibitor that does not require cofactors for its anticoagulant effect [3-4]. Additionally, rivaroxaban is approved for the most indications within its class, which are: (1) reduction of risk of stroke and systemic embolism (SE) in nonvalvular atrial fibrillation, (2) treatment of deep vein thrombosis (DVT), (3) treatment of pulmonary embolism (PE), (4) reduction of the risk of recurrent DVT and PE, (5) treatment of acute coronary syndrome (ACS) in patients with non-ST-segment elevation ACS, (6) atrial flutter with atrial fibrillation, and (7) treatment of venous thromboembolism (VTE) in patients with cancer [1].",
    "vicuna-13b_fact_raw": "1. Rivaroxaban is metabolized in the kidneys.\n2. Rivaroxaban is a selective, reversible, direct Factor Xa inhibitor.\n3. Rivaroxaban does not require cofactors for its anticoagulant effect.\n4. Rivaroxaban is approved for the reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation.\n5. Rivaroxaban is approved for the treatment of venous thromboembolism in patients with cancer.",
    "vicuna-13b_fact": [
      "Rivaroxaban is metabolized in the kidneys.",
      "Rivaroxaban is a selective, reversible, direct Factor Xa inhibitor.",
      "Rivaroxaban does not require cofactors for its anticoagulant effect.",
      "Rivaroxaban is approved for the reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation.",
      "Rivaroxaban is approved for the treatment of venous thromboembolism in patients with cancer."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Rivaroxaban is primarily metabolized in the liver.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE (As of my knowledge cutoff in 2023, rivaroxaban is indeed used for the treatment of venous thromboembolism in cancer patients, although specific approvals can vary by country and over time.)",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "vicuna-13b_response": "Based on the given documents, it is suggested that TRalpha2 regulates genes involved in the regulation of heart rate and alternative splicing events required for functional and structural heart properties, such as the expression of TTN isoforms. However, the specific genes regulated by TRalpha2 in the heart are not mentioned in the documents provided.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "vicuna-13b_response": "There are several biomedical question answering systems available, including BioASQ 3. BioASQ 3 is a biomedical semantic indexing and question answering system that aims to provide highly precise biomedical information access systems through a series of evaluation campaigns. The development of BioASQ 3 is driven by the need for automatic answering of scientific questions, particularly in the context of the COVID-19 pandemic, where there has been a surge of COVID-19-related publications that human experts find difficult to keep up with.",
    "vicuna-13b_fact_raw": "1. BioASQ 3 is a biomedical question answering system.\n2. BioASQ 3 aims to provide highly precise biomedical information access.\n3. BioASQ 3 is involved in evaluation campaigns.\n4. The development of BioASQ 3 is motivated by the need for automatic answering of scientific questions.\n5. The COVID-19 pandemic has resulted in a surge of COVID-19-related publications.",
    "vicuna-13b_fact": [
      "BioASQ 3 is a biomedical question answering system.",
      "BioASQ 3 aims to provide highly precise biomedical information access.",
      "BioASQ 3 is involved in evaluation campaigns.",
      "The development of BioASQ 3 is motivated by the need for automatic answering of scientific questions.",
      "The COVID-19 pandemic has resulted in a surge of COVID-19-related publications."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: BioASQ is a biomedical question answering challenge, not a system. The \"3\" might refer to the third iteration of the challenge.\n2. TRUE: BioASQ aims to provide highly precise biomedical information access, which is in line with the goals of the BioASQ challenge.\n3. TRUE: BioASQ is involved in evaluation campaigns to benchmark biomedical information systems.\n4. TRUE: The development of challenges like BioASQ is motivated by the need for automatic answering of scientific questions, including those in the biomedical domain.\n5. TRUE: The COVID-19 pandemic has indeed resulted in a surge of COVID-19-related publications.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "vicuna-13b_response": "Based on the information provided in the documents, it is not explicitly stated which transcription factor activates the betalain pathway. The first document, \"Casting light on the pathway to betalain biosynthesis: A review,\" provides an overview of the betalain biosynthesis pathway and its regulation, but does not specify which transcription factor is responsible for activating the pathway. The second document, \"1. Introduction. Betalains are water-soluble and nitrogen-containing pigments with antioxidant properties, which were first extracted from the common beet (Beta vulgaris).Betalains can be divided into betacyanins and betaxanthins according to their chemical structures [].Betalains are restricted to 13 families of the order Caryophyllales, except thatMolluginaceae and Caryophyllaceae produce betalains in the chloroplast,\" provides general information about betalains and their distribution in plants, but does not provide any information about the transcription factor responsible for activating the betalain pathway.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "vicuna-13b_response": "Based on the information provided in Document 0 and Document 1, the preferred technologies for the enrichment of phosphorylated peptides are:\n1. Phospho-specific antibodies: These antibodies can be used to enrich for phosphorylated peptides by immunoprecipitation, which is a common method used in phosphoproteomics. In Document 0, the authors mention that phospho-specific antibodies are commonly used for the detection of phosphorylated proteins.\n2. Phospho-specific mass spectrometry: This method involves the use of mass spectrometry to detect and identify phosphorylated peptides. In Document 1, the authors use phospho-specific mass spectrometry to identify phosphorylated peptides in wild-type and AMPKα1/α2-double knockout cells.\nIt is important to note that the choice of technology may depend on the specific research question and the system being studied. Other technologies that may be used for the enrichment of phosphorylated peptides include phospho-affinity chromatography and stable isotope labeling with amino acids in cell culture (SILAC).",
    "vicuna-13b_fact_raw": "1. Phospho-specific antibodies can be used to enrich for phosphorylated peptides by immunoprecipitation in phosphoproteomics.\n2. Phospho-specific antibodies are commonly used for the detection of phosphorylated proteins.\n3. Phospho-specific mass spectrometry is a method used to detect and identify phosphorylated peptides.\n4. Phospho-specific mass spectrometry was used to identify phosphorylated peptides in wild-type and AMPKα1/α2-double knockout cells, as mentioned in Document 1.\n5. Technologies such as phospho-affinity chromatography and stable isotope labeling with amino acids in cell culture (SILAC) may also be used for the enrichment of phosphorylated peptides.",
    "vicuna-13b_fact": [
      "Phospho-specific antibodies can be used to enrich for phosphorylated peptides by immunoprecipitation in phosphoproteomics.",
      "Phospho-specific antibodies are commonly used for the detection of phosphorylated proteins.",
      "Phospho-specific mass spectrometry is a method used to detect and identify phosphorylated peptides.",
      "Phospho-specific mass spectrometry was used to identify phosphorylated peptides in wild-type and AMPKα1/α2-double knockout cells, as mentioned in Document 1.",
      "Technologies such as phospho-affinity chromatography and stable isotope labeling with amino acids in cell culture (SILAC) may also be used for the enrichment of phosphorylated peptides."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "vicuna-13b_response": "The Palmini classification divides focal cortical dysplasias into three groups: mild malformation of cortical development (mild MCD), type I and type II. Mild MCD is further divided into two subtypes: mild MCD type I, characterized by ectopically placed neurons in or adjacent to layer I, and mild MCD type II, characterized by microscopic neuronal heterotopia outside layer I.",
    "vicuna-13b_fact_raw": "1. The Palmini classification is used to rate focal cortical dysplasias.\n2. The Palmini classification divides focal cortical dysplasias into three groups.\n3. Mild malformation of cortical development (mild MCD) is one of the groups in the Palmini classification.\n4. Mild MCD type I is characterized by ectopically placed neurons in or adjacent to layer I.\n5. Mild MCD type II is characterized by microscopic neuronal heterotopia outside layer I.",
    "vicuna-13b_fact": [
      "The Palmini classification is used to rate focal cortical dysplasias.",
      "The Palmini classification divides focal cortical dysplasias into three groups.",
      "Mild malformation of cortical development (mild MCD) is one of the groups in the Palmini classification.",
      "Mild MCD type I is characterized by ectopically placed neurons in or adjacent to layer I.",
      "Mild MCD type II is characterized by microscopic neuronal heterotopia outside layer I."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The term \"mild malformation of cortical development\" (mild MCD) is not one of the groups in the Palmini classification. The Palmini classification specifically refers to focal cortical dysplasias and they are categorized as Type I or Type II, which may have further subtypes.\n4. FALSE [correction]: Mild MCD type I is not a term used in the Palmini classification for focal cortical dysplasias. In the Palmini classification, Type I focal cortical dysplasias are characterized by architectural abnormalities without evident balloon cells or dysmorphic neurons.\n5. FALSE [correction]: Mild MCD type II is not a term used in the Palmini classification for focal cortical dysplasias. In the Palmini classification, Type II focal cortical dysplasias are characterized by the presence of dysmorphic neurons and/or balloon cells, and they are further divided into Type IIa and Type IIb based on specific histological features.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "vicuna-13b_response": "Based on the information provided, it appears that viruses may be involved in the etiology of human subacute thyroiditis. Document 0 states that viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases. Document 1 also supports this, stating that viral infection may represent one of the major environmental factors related to common thyroid disorders, including subacute thyroiditis, nonthyroidal illness syndrome, and autoimmune thyroid diseases. Additionally, Table 1 in Document 1 lists viral infections as a possible cause of subacute thyroiditis.",
    "vicuna-13b_fact_raw": "1. Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis.\n2. Viral infections may represent one of the major environmental factors related to common thyroid disorders, including subacute thyroiditis.\n3. Document 1 lists viral infections as a possible cause of subacute thyroiditis.",
    "vicuna-13b_fact": [
      "Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis.",
      "Viral infections may represent one of the major environmental factors related to common thyroid disorders, including subacute thyroiditis.",
      "Document 1 lists viral infections as a possible cause of subacute thyroiditis."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "vicuna-13b_response": "Based on the information provided, it is possible that STAT3 is involved in EIF2AK2-dependent suppression of autophagy. Document 0 suggests that the dependence on eIF2α kinases is important in regulating autophagy in mammalian cells, and Document 1 states that STAT3 inhibits autophagy by sequestering EIF2AK2. EIF2AK2 is a known regulator of autophagy, and its suppression is often dependent on the activity of eIF2α kinases. Therefore, it is possible that STAT3 is involved in EIF2AK2-dependent suppression of autophagy by inhibiting the activity of EIF2AK2 through sequestration or interaction with other autophagy-related signaling molecules.",
    "vicuna-13b_fact_raw": "1. STAT3 may be involved in EIF2AK2-dependent suppression of autophagy.\n2. Document 0 indicates that eIF2α kinases play a role in regulating autophagy in mammalian cells.\n3. Document 1 suggests that STAT3 inhibits autophagy by sequestering EIF2AK2.\n4. EIF2AK2 is a known regulator of autophagy.\n5. The suppression of EIF2AK2 is often dependent on the activity of eIF2α kinases.",
    "vicuna-13b_fact": [
      "STAT3 may be involved in EIF2AK2-dependent suppression of autophagy.",
      "Document 0 indicates that eIF2α kinases play a role in regulating autophagy in mammalian cells.",
      "Document 1 suggests that STAT3 inhibits autophagy by sequestering EIF2AK2.",
      "EIF2AK2 is a known regulator of autophagy.",
      "The suppression of EIF2AK2 is often dependent on the activity of eIF2α kinases."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: The suppression of autophagy is often dependent on the activity of eIF2α kinases, not the suppression of EIF2AK2.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "vicuna-13b_response": "Theatre is a software tool used for genomic analysis, specifically for the comparative analysis of genomic sequences. It is designed to help identify and predict the positions of coding regions, repetitive sequences, and transcription factor binding sites in families of DNA sequences. Theatre is a web-based system that allows users to easily access and analyze genomic data from a variety of sources. It can be used to compare the sequences of different organisms and identify differences in the regulation of gene expression. In the study mentioned in Document 1, Theatre was used to analyze the p53 promoter region in four mammals and two fish species, and it reported the differences in the predicted p53 promoter regions for these species. Overall, Theatre is a useful tool for researchers studying genomic data and seeking to better understand the regulation of gene expression.",
    "vicuna-13b_fact_raw": "1. Theatre is a software tool used for the comparative analysis of genomic sequences.\n2. Theatre helps identify and predict the positions of coding regions, repetitive sequences, and transcription factor binding sites in DNA sequences.\n3. Theatre is a web-based system.\n4. Theatre can be used to compare the sequences of different organisms and identify differences in gene expression regulation.\n5. Theatre was used to analyze the p53 promoter region in four mammals and two fish species in a study mentioned in Document 1.",
    "vicuna-13b_fact": [
      "Theatre is a software tool used for the comparative analysis of genomic sequences.",
      "Theatre helps identify and predict the positions of coding regions, repetitive sequences, and transcription factor binding sites in DNA sequences.",
      "Theatre is a web-based system.",
      "Theatre can be used to compare the sequences of different organisms and identify differences in gene expression regulation.",
      "Theatre was used to analyze the p53 promoter region in four mammals and two fish species in a study mentioned in Document 1."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Theatre is not a known software tool for genomic sequences. The correct term might be \"Theater,\" but without specific context, it's unclear what the correct software tool is.\n2. UNKNOWN: Without the correct identification of the software tool \"Theatre,\" it's not possible to confirm the functions it performs.\n3. UNKNOWN: The web-based nature of the tool \"Theatre\" cannot be confirmed without proper identification of the software.\n4. UNKNOWN: Without confirmation of what \"Theatre\" is, it's not possible to verify its uses in comparing sequences of different organisms.\n5. UNKNOWN: Without additional context or verification of the software tool \"Theatre,\" the use of it in a specific study cannot be confirmed.",
    "vicuna-13b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "vicuna-13b_response": "The Smith-Waterman algorithm is a local alignment algorithm that is used to find the highest scoring alignment between two sequences. The time complexity of the Smith-Waterman algorithm is O(n log n) where n is the length of the sequences being aligned. This is because the algorithm uses dynamic programming to find the highest-weight path between the two sequences, which involves computing the alignment score and the alignment path in a matrix of size n x n. The time complexity can be reduced by using heuristics or approximations, but the accuracy of the alignment may also be reduced.",
    "vicuna-13b_fact_raw": "1. The Smith-Waterman algorithm is used for local alignment of two sequences.\n2. The time complexity of the Smith-Waterman algorithm is O(n log n), where n is the length of the sequences.\n3. The Smith-Waterman algorithm uses dynamic programming.\n4. The algorithm involves computing the alignment score and path in a matrix of size n x n.\n5. The time complexity of the Smith-Waterman algorithm can be reduced by using heuristics or approximations.",
    "vicuna-13b_fact": [
      "The Smith-Waterman algorithm is used for local alignment of two sequences.",
      "The time complexity of the Smith-Waterman algorithm is O(n log n), where n is the length of the sequences.",
      "The Smith-Waterman algorithm uses dynamic programming.",
      "The algorithm involves computing the alignment score and path in a matrix of size n x n.",
      "The time complexity of the Smith-Waterman algorithm can be reduced by using heuristics or approximations."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: The time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the sequences.\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "vicuna-13b_response": "Answer: FLVCR1 is a member of the SLC49 family of genes. It is a cell surface heme exporter and is essential for erythropoiesis. It has three paralogs in the human genome, SLC49A2, SLC49A3, and SLC49A4.",
    "vicuna-13b_fact_raw": "1. FLVCR1 is a member of the SLC49 family of genes.\n2. FLVCR1 functions as a cell surface heme exporter.\n3. FLVCR1 is essential for erythropoiesis.\n4. FLVCR1 has three paralogs in the human genome: SLC49A2, SLC49A3, and SLC49A4.",
    "vicuna-13b_fact": [
      "FLVCR1 is a member of the SLC49 family of genes.",
      "FLVCR1 functions as a cell surface heme exporter.",
      "FLVCR1 is essential for erythropoiesis.",
      "FLVCR1 has three paralogs in the human genome: SLC49A2, SLC49A3, and SLC49A4."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: FLVCR1 does not have three paralogs in the human genome named SLC49A2, SLC49A3, and SLC49A4. FLVCR1 itself is also known as SLC49A1, and the SLC49 family includes SLC49A2 (also known as FLVCR1-AS1 or FLVCR1 antisense RNA 1), SLC49A3, and SLC49A4, but these are not paralogs of FLVCR1; they are other members of the same gene family.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "vicuna-13b_response": "Based on the information provided, the document 0 is a news article reporting the publication of a research article in the journal Nucleic Acids Research, which was conducted by a team led by Prof. Liu Jizhe from the Institute of Life Sciences, School of Basic Medical Sciences, Central South University, China. The research article titled \"The novel GATA1-interacting protein HES6 is an essential transcriptional cofactor for human erythropoiesis\" (Document 1) found that HES6 is an essential transcriptional cofactor for human erythropoiesis, which is required for the normal regulation of gene expression patterns. The study suggests that deregulation of HES6 expression or function may contribute to erythroid disorders. The study used gene expression profiling to identify HES6 as an abundant cofactor expressed at the gene level during erythropoiesis. The study also identified GATA1 as a key transcription factor that interacts with HES6 to regulate erythropoiesis. Therefore, HES6 can be considered as a GATA1-interacting partner as discovered with the help of biotinylation tagging approach.",
    "vicuna-13b_fact_raw": "1. The research article titled \"The novel GATA1-interacting protein HES6 is an essential transcriptional cofactor for human erythropoiesis\" was published in the journal Nucleic Acids Research.\n2. Prof. Liu Jizhe from the Institute of Life Sciences, School of Basic Medical Sciences, Central South University, China, led the team that conducted the research.\n3. The study found that HES6 is an essential transcriptional cofactor for human erythropoiesis.\n4. The study suggests that deregulation of HES6 expression or function may contribute to erythroid disorders.\n5. GATA1 interacts with HES6 to regulate erythropoiesis according to the study.",
    "vicuna-13b_fact": [
      "The research article titled \"The novel GATA1-interacting protein HES6 is an essential transcriptional cofactor for human erythropoiesis\" was published in the journal Nucleic Acids Research.",
      "Prof. Liu Jizhe from the Institute of Life Sciences, School of Basic Medical Sciences, Central South University, China, led the team that conducted the research.",
      "The study found that HES6 is an essential transcriptional cofactor for human erythropoiesis.",
      "The study suggests that deregulation of HES6 expression or function may contribute to erythroid disorders.",
      "GATA1 interacts with HES6 to regulate erythropoiesis according to the study."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE\n\nWithout access to the specific research article or additional context, I cannot verify the publication details or the lead researcher's identity. However, the statements about the study's findings (statements 3, 4, and 5) are consistent with the title of the article and are assumed to be true based on the context provided.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "vicuna-13b_response": "Based on the information provided in Document 0, it is stated that TAF10 interacts directly with GATA1 and is enriched on the GATA1 locus in human fetal erythroid cells. This suggests that the outcome of TAF10 interacting with the GATA1 transcription factor is related to the regulation of transcription during development and differentiation of erythroid cells.\nHowever, there is no direct information in the documents provided about the outcome of TAF10 interacting with the GATA1 transcription factor in terms of its effect on gene expression or protein synthesis.",
    "vicuna-13b_fact_raw": "1. TAF10 interacts directly with GATA1.\n2. TAF10 is enriched on the GATA1 locus in human fetal erythroid cells.\n3. The interaction between TAF10 and GATA1 is related to the regulation of transcription during the development and differentiation of erythroid cells.",
    "vicuna-13b_fact": [
      "TAF10 interacts directly with GATA1.",
      "TAF10 is enriched on the GATA1 locus in human fetal erythroid cells.",
      "The interaction between TAF10 and GATA1 is related to the regulation of transcription during the development and differentiation of erythroid cells."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n\nThe statements provided are specific and suggest a level of detail that implies they are based on scientific findings. However, without access to the specific scientific literature or studies that these statements are derived from, it is not possible to fact-check them with absolute certainty. The responses are based on the assumption that the statements are drawn from accurate scientific research. If the context were different or if the statements were less specific, the responses might vary.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "vicuna-13b_response": "Yes, there are decision support systems for chronic pain management. These systems are designed to assist healthcare professionals, such as physicians and nurses, in making informed decisions about patient care. One example is the use of computerized decision-support systems (CDSSs), which have been shown to have great potential for improving chronic pain management, particularly in the primary care setting. These systems can provide physicians with information and guidance on the most appropriate treatment options for a given patient, based on their specific needs and medical history. Additionally, CDSSs can help physicians communicate more effectively with patients, by providing patient education materials and helping to facilitate discussions about treatment options.",
    "vicuna-13b_fact_raw": "1. Decision support systems exist for chronic pain management.\n2. These systems are designed to assist healthcare professionals in making informed decisions about patient care.\n3. Computerized decision-support systems (CDSSs) have potential for improving chronic pain management in the primary care setting.\n4. CDSSs can provide physicians with information and guidance on treatment options based on a patient's specific needs and medical history.\n5. CDSSs can help physicians communicate more effectively with patients by providing patient education materials and facilitating discussions about treatment options.",
    "vicuna-13b_fact": [
      "Decision support systems exist for chronic pain management.",
      "These systems are designed to assist healthcare professionals in making informed decisions about patient care.",
      "Computerized decision-support systems (CDSSs) have potential for improving chronic pain management in the primary care setting.",
      "CDSSs can provide physicians with information and guidance on treatment options based on a patient's specific needs and medical history.",
      "CDSSs can help physicians communicate more effectively with patients by providing patient education materials and facilitating discussions about treatment options."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll statements are generally consistent with the purpose and potential benefits of computerized decision-support systems (CDSSs) in healthcare, particularly in the context of chronic pain management. CDSSs are indeed designed to assist healthcare professionals by providing information and guidance, which can improve decision-making and patient communication.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "vicuna-13b_response": "Based on the given documents, the subcellular localization of the protein angiogenin is not mentioned. Angiogenin is a protein that is involved in regulating cell proliferation, survival, migration, and invasion, and it has been recognized to play important roles in various physiological and pathological processes. However, the documents do not provide information on the subcellular localization of angiogenin.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "vicuna-13b_response": "Based on the given documents, it is stated that ranolazine inhibits the late phase of the inward sodium current in ventricular myocardial cells, which reduces intracellular calcium overload and associated diastolic contractile dysfunction. However, there is no direct information provided in the documents about how ranolazine affects kinase signaling activation in the heart. Therefore, it is not possible to provide a definite answer to the question.",
    "vicuna-13b_fact_raw": "1. Ranolazine inhibits the late phase of the inward sodium current in ventricular myocardial cells.\n2. Ranolazine reduces intracellular calcium overload.\n3. Ranolazine is associated with reducing diastolic contractile dysfunction.",
    "vicuna-13b_fact": [
      "Ranolazine inhibits the late phase of the inward sodium current in ventricular myocardial cells.",
      "Ranolazine reduces intracellular calcium overload.",
      "Ranolazine is associated with reducing diastolic contractile dysfunction."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n\nRanolazine is known to inhibit the late phase of the inward sodium current in ventricular myocardial cells, which can reduce intracellular calcium overload. By doing so, it can help to reduce diastolic contractile dysfunction.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "vicuna-13b_response": "Based on the information provided in the documents, it can be inferred that the regulation of Vsr endonuclease is not independent of the growth phase of bacteria. The first document states that the levels of Dcm cytosine methylase are maintained at a constant level during cell growth, while Vsr endonuclease levels are growth phase dependent. The second document supports this finding and further suggests that the decreased production of Vsr relative to Dcm during the log phase may contribute to the mutability of 5-methylcytosine. These observations suggest that the regulation of Vsr endonuclease is closely linked to the growth phase of bacteria and may play a role in the mutability of 5-methylcytosine during different phases of growth.",
    "vicuna-13b_fact_raw": "1. The regulation of Vsr endonuclease is not independent of the growth phase of bacteria.\n2. Levels of Dcm cytosine methylase are maintained constant during cell growth.\n3. Vsr endonuclease levels are growth phase dependent.\n4. Decreased production of Vsr relative to Dcm during the log phase may contribute to the mutability of 5-methylcytosine.\n5. The regulation of Vsr endonuclease may play a role in the mutability of 5-methylcytosine during different phases of bacterial growth.",
    "vicuna-13b_fact": [
      "The regulation of Vsr endonuclease is not independent of the growth phase of bacteria.",
      "Levels of Dcm cytosine methylase are maintained constant during cell growth.",
      "Vsr endonuclease levels are growth phase dependent.",
      "Decreased production of Vsr relative to Dcm during the log phase may contribute to the mutability of 5-methylcytosine.",
      "The regulation of Vsr endonuclease may play a role in the mutability of 5-methylcytosine during different phases of bacterial growth."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "vicuna-13b_response": "Answer: The computational tools for the prediction of beta-barrel transmembrane proteins include the TMBHMM method, which is a hidden Markov model-based method that predicts transmembrane beta-barrel proteins and their exposure status. The TMBHMM method has been compared with two other methods from the literature and has been implemented as a web server. Additionally, BetAware-Deep is a deep learning-based method that outperforms state-of-the-art methods for topology prediction, predicting correct topologies of 10 out of 15 proteins. TMBB detection has also been assessed on a larger dataset, comprising 1009 TMBB proteins and 7571 non-TMBB proteins.",
    "vicuna-13b_fact_raw": "1. The TMBHMM method is a computational tool that predicts transmembrane beta-barrel proteins and their exposure status.\n2. The TMBHMM method is based on a hidden Markov model.\n3. The TMBHMM method has been implemented as a web server.\n4. BetAware-Deep is a deep learning-based method for predicting the topology of beta-barrel transmembrane proteins.\n5. BetAware-Deep correctly predicted the topologies of 10 out of 15 proteins in an assessment.",
    "vicuna-13b_fact": [
      "The TMBHMM method is a computational tool that predicts transmembrane beta-barrel proteins and their exposure status.",
      "The TMBHMM method is based on a hidden Markov model.",
      "The TMBHMM method has been implemented as a web server.",
      "BetAware-Deep is a deep learning-based method for predicting the topology of beta-barrel transmembrane proteins.",
      "BetAware-Deep correctly predicted the topologies of 10 out of 15 proteins in an assessment."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "vicuna-13b_response": "The Galassi classification is used for arachnoid cysts in the middle cranial fossa.",
    "vicuna-13b_fact_raw": "1. The Galassi classification is used for arachnoid cysts.\n2. The Galassi classification applies to cysts located in the middle cranial fossa.",
    "vicuna-13b_fact": [
      "The Galassi classification is used for arachnoid cysts.",
      "The Galassi classification applies to cysts located in the middle cranial fossa."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "vicuna-13b_response": "Based on the given documents, the common features of Shapiro syndrome are:\n* Spontaneous periodic hypothermia: This is the main characteristic of Shapiro syndrome, which is characterized by a sudden drop in body temperature that occurs repeatedly and unpredictably.\n* Occurs to patients regardless of age or sex: Shapiro syndrome affects both men and women of all ages, although most reported cases are in adults.\n* Limited knowledge of pathogenesis and etiology: The exact cause of Shapiro syndrome is still unknown and controversial.\n* Clinical feature is the main source of knowledge: Most of the current knowledge about Shapiro syndrome comes from clinical observations and studies, rather than from pathological or laboratory investigations.",
    "vicuna-13b_fact_raw": "1. Shapiro syndrome is characterized by spontaneous periodic hypothermia, which involves a sudden and unpredictable drop in body temperature.\n2. Shapiro syndrome can affect both men and women of all ages.\n3. Most reported cases of Shapiro syndrome are in adults.\n4. The exact cause of Shapiro syndrome is still unknown.\n5. Current knowledge about Shapiro syndrome primarily comes from clinical observations and studies.",
    "vicuna-13b_fact": [
      "Shapiro syndrome is characterized by spontaneous periodic hypothermia, which involves a sudden and unpredictable drop in body temperature.",
      "Shapiro syndrome can affect both men and women of all ages.",
      "Most reported cases of Shapiro syndrome are in adults.",
      "The exact cause of Shapiro syndrome is still unknown.",
      "Current knowledge about Shapiro syndrome primarily comes from clinical observations and studies."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Most reported cases of Shapiro syndrome are in children and adolescents.\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "vicuna-13b_response": "Based on the given documents, it is suggested that mutations within the BRAG1 gene are linked to nonsyndromic X-chromosome-linked intellectual disability (XLID). The gene encodes a protein called BRAG1 or IQSEC2, which is involved in regulating synaptic function and is highly expressed in the brain. Dysfunction of this protein can cause imbalance in synaptic plasticity, leading to neurological disorders such as intellectual disability.",
    "vicuna-13b_fact_raw": "1. Mutations within the BRAG1 gene are linked to nonsyndromic X-chromosome-linked intellectual disability (XLID).\n2. The BRAG1 gene encodes a protein called BRAG1 or IQSEC2.\n3. The protein encoded by the BRAG1 gene is involved in regulating synaptic function.\n4. BRAG1 or IQSEC2 is highly expressed in the brain.\n5. Dysfunction of the BRAG1 or IQSEC2 protein can lead to neurological disorders such as intellectual disability.",
    "vicuna-13b_fact": [
      "Mutations within the BRAG1 gene are linked to nonsyndromic X-chromosome-linked intellectual disability (XLID).",
      "The BRAG1 gene encodes a protein called BRAG1 or IQSEC2.",
      "The protein encoded by the BRAG1 gene is involved in regulating synaptic function.",
      "BRAG1 or IQSEC2 is highly expressed in the brain.",
      "Dysfunction of the BRAG1 or IQSEC2 protein can lead to neurological disorders such as intellectual disability."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Mutations within the ARHGEF9 gene are linked to nonsyndromic X-chromosome-linked intellectual disability (XLID), not the BRAG1 gene.\n2. FALSE [correction]: The IQSEC2 gene encodes a protein called IQSEC2 or BRAG1.\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "vicuna-13b_response": "Based on the information provided, it is not explicitly stated which protein is the main inhibitor of Protein Phosphatase 1 (PP1). However, the first document mentions that Inhibitor-3 inhibits PP1 via a metal binding dynamic protein-protein interaction. It is important to note that there are several isoforms of PP1 and over 200 PP1-interacting proteins (PIPs) that can interact with PP1 and modulate its activity. Additionally, the second document highlights that genetically engineered mice of 49 PIPs display human disease-associated phenotypes, suggesting that PP1-PIP interactions play a role in various diseases. Therefore, it is possible that there are multiple proteins that can act as inhibitors of PP1, and further research is needed to identify the specific inhibitors and their mechanisms of action.",
    "vicuna-13b_fact_raw": "1. Inhibitor-3 inhibits Protein Phosphatase 1 (PP1) via a metal binding dynamic protein-protein interaction.\n2. There are several isoforms of Protein Phosphatase 1 (PP1).\n3. There are over 200 PP1-interacting proteins (PIPs) that can interact with PP1.\n4. Genetically engineered mice of 49 PIPs display human disease-associated phenotypes.\n5. PP1-PIP interactions play a role in various diseases.",
    "vicuna-13b_fact": [
      "Inhibitor-3 inhibits Protein Phosphatase 1 (PP1) via a metal binding dynamic protein-protein interaction.",
      "There are several isoforms of Protein Phosphatase 1 (PP1).",
      "There are over 200 PP1-interacting proteins (PIPs) that can interact with PP1.",
      "Genetically engineered mice of 49 PIPs display human disease-associated phenotypes.",
      "PP1-PIP interactions play a role in various diseases."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nThe statements about the specific functions and interactions of Protein Phosphatase 1 (PP1), such as the inhibition by Inhibitor-3 and the exact number of genetically engineered mice displaying human disease-associated phenotypes, would require specific scientific knowledge or literature that is not provided. Therefore, without additional context, the veracity of statements 1 and 4 cannot be determined. However, statements 2, 3, and 5 are generally consistent with the broad understanding of PP1 in the scientific community. PP1 is known to have several isoforms, to interact with a multitude of proteins, and these interactions are implicated in various diseases.",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "vicuna-13b_response": "The mechanisms underlying adaptive mutagenesis (also known as stationary-phase mutagenesis) in Bacillus subtilis include mutations that arise in nondividing or stationary-phase bacteria when the cells are subjected to nonlethal selective pressure, such as nutrient-limited environments. These mutations can provide models for mutational escape of growth control and may be important in the development of antibiotic resistance mutations, colonization of new bacterial hosts, phase variation in bacterial pathogens, and other processes.",
    "vicuna-13b_fact_raw": "1. Adaptive mutagenesis in Bacillus subtilis involves mutations that arise in nondividing or stationary-phase bacteria.\n2. The cells undergo adaptive mutagenesis when subjected to nonlethal selective pressure.\n3. Nutrient-limited environments can act as a nonlethal selective pressure that triggers adaptive mutagenesis in Bacillus subtilis.\n4. Adaptive mutagenesis may play a role in the development of antibiotic resistance mutations in Bacillus subtilis.\n5. Adaptive mutagenesis can be important for colonization of new bacterial hosts and phase variation in bacterial pathogens.",
    "vicuna-13b_fact": [
      "Adaptive mutagenesis in Bacillus subtilis involves mutations that arise in nondividing or stationary-phase bacteria.",
      "The cells undergo adaptive mutagenesis when subjected to nonlethal selective pressure.",
      "Nutrient-limited environments can act as a nonlethal selective pressure that triggers adaptive mutagenesis in Bacillus subtilis.",
      "Adaptive mutagenesis may play a role in the development of antibiotic resistance mutations in Bacillus subtilis.",
      "Adaptive mutagenesis can be important for colonization of new bacterial hosts and phase variation in bacterial pathogens."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAdaptive mutagenesis is a process where mutations occur in response to environmental stress, such as nonlethal selective pressures, which can include nutrient limitation. These mutations can indeed contribute to antibiotic resistance and may also be important for bacterial adaptation to new hosts or conditions, such as phase variation in pathogens.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "vicuna-13b_response": "Erucism is caused by the injuries caused by moth larvae in humans. The lesions are provoked by caterpillar bristles filled with toxins that penetrate the skin. The bristles are hollow and when they enter the skin and break, toxins that contain thermolabile proteins, proteolytic enzymes, and histamine are released. Erucism is a specific type of skin reaction that occurs due to contact with moth and butterfly larvae or caterpillars, which are members of the order Lepidoptera. It is worth noting that the adult forms of moths and butterflies do not sting, and erucism refers specifically to the cutaneous reactions caused by the larvae.",
    "vicuna-13b_fact_raw": "1. Erucism is caused by injuries from moth larvae in humans.\n2. Caterpillar bristles that cause erucism are filled with toxins.\n3. The bristles that cause erucism are hollow and release toxins when they break upon entering the skin.\n4. Toxins released by caterpillar bristles include thermolabile proteins, proteolytic enzymes, and histamine.\n5. Erucism is a skin reaction specifically caused by contact with moth and butterfly larvae or caterpillars.",
    "vicuna-13b_fact": [
      "Erucism is caused by injuries from moth larvae in humans.",
      "Caterpillar bristles that cause erucism are filled with toxins.",
      "The bristles that cause erucism are hollow and release toxins when they break upon entering the skin.",
      "Toxins released by caterpillar bristles include thermolabile proteins, proteolytic enzymes, and histamine.",
      "Erucism is a skin reaction specifically caused by contact with moth and butterfly larvae or caterpillars."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "vicuna-13b_response": "Hydrochlorothiazide is used to treat high blood pressure (hypertension) and fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, or kidney disorders, or edema caused by taking steroids or estrogen. It is also used to treat hypertension in pregnant women. You should not use hydrochlorothiazide if you are unable to urinate. It is also important to note that this activity comprehensively reviews the specific indications, mechanism of action, dosing, associated adverse events, contraindications, monitoring, and other clinically relevant information for healthcare professionals involved in managing hypertension and monitoring the effects of hydrochlorothiazide.",
    "vicuna-13b_fact_raw": "1. Hydrochlorothiazide is used to treat high blood pressure (hypertension).\n2. Hydrochlorothiazide is used to treat fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, or kidney disorders.\n3. Hydrochlorothiazide can be used to treat edema caused by taking steroids or estrogen.\n4. Hydrochlorothiazide is used to treat hypertension in pregnant women.\n5. Hydrochlorothiazide should not be used by individuals who are unable to urinate.",
    "vicuna-13b_fact": [
      "Hydrochlorothiazide is used to treat high blood pressure (hypertension).",
      "Hydrochlorothiazide is used to treat fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, or kidney disorders.",
      "Hydrochlorothiazide can be used to treat edema caused by taking steroids or estrogen.",
      "Hydrochlorothiazide is used to treat hypertension in pregnant women.",
      "Hydrochlorothiazide should not be used by individuals who are unable to urinate."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrochlorothiazide is generally not recommended for the treatment of hypertension in pregnant women due to the risk of decreased plasma volume and the potential for decreased placental perfusion. Alternative medications are preferred.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "vicuna-13b_response": "Yes, silicon has been used in the treatment of incontinence. Periurethral or transurethral injection of bulking agents is a minimally invasive surgical procedure used to treat stress urinary incontinence (SUI) in adult women. The procedure involves injecting a bulking agent, such as silicon, into the area around the urethra to help prevent urine leakage. The use of vaginal pessaries, which are also made of silicon, is another commonly used treatment for incontinence that offers symptomatic improvement for women.",
    "vicuna-13b_fact_raw": "1. Silicon has been used in the treatment of incontinence.\n2. Periurethral or transurethral injection of bulking agents is a procedure used to treat stress urinary incontinence in adult women.\n3. Silicon can be used as a bulking agent injected into the area around the urethra.\n4. Vaginal pessaries made of silicon are used as a treatment for incontinence.\n5. Vaginal pessaries offer symptomatic improvement for women with incontinence.",
    "vicuna-13b_fact": [
      "Silicon has been used in the treatment of incontinence.",
      "Periurethral or transurethral injection of bulking agents is a procedure used to treat stress urinary incontinence in adult women.",
      "Silicon can be used as a bulking agent injected into the area around the urethra.",
      "Vaginal pessaries made of silicon are used as a treatment for incontinence.",
      "Vaginal pessaries offer symptomatic improvement for women with incontinence."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Silicone, not silicon, has been used in the treatment of incontinence. Silicon is a chemical element, while silicone is a polymer used in medical treatments.\n2. TRUE\n3. FALSE [correction]: Silicone can be used as a bulking agent injected into the area around the urethra, not silicon.\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "vicuna-13b_response": "Based on the available literature, there is no clear association between moon cycle and rupture risk of intracranial aneurysms. The study by Bunevicius et al. (2017) found no evidence to support the idea that the lunar phase is associated with the incidence of intracranial aneurysm rupture. In fact, the authors suggest that more sensitive approaches are needed to investigate this potential association. Therefore, it is not recommended to rely on moon phases when assessing the rupture risk of intracranial aneurysms.",
    "vicuna-13b_fact_raw": "1. There is no clear association between moon cycle and rupture risk of intracranial aneurysms based on available literature.\n2. The study by Bunevicius et al. (2017) found no evidence supporting an association between lunar phase and the incidence of intracranial aneurysm rupture.\n3. The authors of the study by Bunevicius et al. (2017) suggest that more sensitive approaches are needed to investigate the potential association between moon cycle and aneurysm rupture risk.",
    "vicuna-13b_fact": [
      "There is no clear association between moon cycle and rupture risk of intracranial aneurysms based on available literature.",
      "The study by Bunevicius et al. (2017) found no evidence supporting an association between lunar phase and the incidence of intracranial aneurysm rupture.",
      "The authors of the study by Bunevicius et al. (2017) suggest that more sensitive approaches are needed to investigate the potential association between moon cycle and aneurysm rupture risk."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "vicuna-13b_response": "Based on the given documents, it appears that HuR protein does regulate the splicing process. Document 0 states that HuR regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle, and it modulates a gene signature associated with this process. Document 1 also supports this, as it describes experiments in which HuR regulates the splicing of the Fas gene in HeLa cells, and the authors suggest that this regulation is mediated by antagonism between HuR and the TIA-1/TIAR complex.",
    "vicuna-13b_fact_raw": "1. HuR protein regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle.\n2. HuR modulates a gene signature associated with the S phase of the cell cycle.\n3. HuR regulates the splicing of the Fas gene in HeLa cells.\n4. The regulation of the Fas gene splicing by HuR is suggested to be mediated by antagonism between HuR and the TIA-1/TIAR complex.",
    "vicuna-13b_fact": [
      "HuR protein regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle.",
      "HuR modulates a gene signature associated with the S phase of the cell cycle.",
      "HuR regulates the splicing of the Fas gene in HeLa cells.",
      "The regulation of the Fas gene splicing by HuR is suggested to be mediated by antagonism between HuR and the TIA-1/TIAR complex."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe statements provided are specific and technical, and they all relate to the functions of the HuR protein. Without additional context that contradicts these statements, they are consistent with the known roles of HuR in mRNA regulation. HuR is indeed known to regulate mRNA splicing and stability, which can affect gene expression during the cell cycle, including the S phase. It is also known to regulate the splicing of various genes, including Fas in certain cell types, and the interplay between HuR and other RNA-binding proteins like TIA-1/TIAR is a recognized mechanism in the regulation of mRNA splicing. However, without specific references to scientific literature or studies, the accuracy of these statements cannot be independently verified, but they are consistent with current scientific understanding.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "vicuna-13b_response": "Based on the given documents, the known functions for the prothymosin alpha c-terminal peptide are not explicitly stated. However, it is suggested that the structure of Prothymosin alpha in a complex with the Keap1 Kelch domain and its nearly identical Kelch-binding domain with Neh2 have been investigated by crystallographic and NMR methods. Additionally, it is mentioned that the cell type, cell status, and specific localization of Prothymosin alpha within cells seem to determine its function, and that it undergoes two types of protease proteolytic modifications that are useful in elucidating its interactions with other molecules.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "vicuna-13b_response": "Based on the given information, the peptide that plays a pivotal role in human cystatin C fibrillization is the pentapeptide LQVVR. This has been established in a study published in FEBS Letters in 2015, which found that the pentapeptide LQVVR plays a crucial role in the fibrillization of human cystatin C.",
    "vicuna-13b_fact_raw": "1. The pentapeptide LQVVR plays a pivotal role in human cystatin C fibrillization.\n2. A study published in FEBS Letters in 2015 established the role of the pentapeptide LQVVR in the fibrillization of human cystatin C.",
    "vicuna-13b_fact": [
      "The pentapeptide LQVVR plays a pivotal role in human cystatin C fibrillization.",
      "A study published in FEBS Letters in 2015 established the role of the pentapeptide LQVVR in the fibrillization of human cystatin C."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: The study that established the role of the pentapeptide LQVVR in the fibrillization of human cystatin C was published in the Journal of Biological Chemistry in 1993, not in FEBS Letters in 2015.",
    "vicuna-13b_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "vicuna-13b_response": "Based on the given documents, it is not directly stated whether the concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol). Document 0 suggests that HIF-1α protein levels transiently increase during the G1 phase of the cell cycle in an AMP-activated protein kinase (AMPK)-dependent manner, but it does not mention \"amifostine\" or ethyol. Document 1 discusses the HIF-1α pathway as a crucial survival pathway for cancer and highlights the challenges and progresses in targeting this pathway for cancer therapy, but again, it does not mention \"amifostine\" or ethyol.\nWithout further information or specific studies, it is difficult to determine whether the concentration of protein HIF-1α increases after the administration of \"amifostine\" (ethyol).",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "vicuna-13b_response": "Answer: Based on the given information, it is not explicitly stated which histone marks are deposited by Set7. However, it is known that Set7 is a histone methyltransferase that deposits methyl groups on histone H3 at position K4 (H3K4) and H3 at position K27 (H3K27). These modifications have been implicated in transcriptional repression and have been shown to be involved in various cellular processes such as cell cycle progression, gene expression regulation, and DNA repair.",
    "vicuna-13b_fact_raw": "1. Set7 is a histone methyltransferase.\n2. Set7 deposits methyl groups on histone H3 at position K4 (H3K4).\n3. Set7 also deposits methyl groups on histone H3 at position K27 (H3K27).\n4. The modifications by Set7 on H3K4 and H3K27 have been implicated in transcriptional repression.\n5. Set7-related histone modifications are involved in cellular processes such as cell cycle progression, gene expression regulation, and DNA repair.",
    "vicuna-13b_fact": [
      "Set7 is a histone methyltransferase.",
      "Set7 deposits methyl groups on histone H3 at position K4 (H3K4).",
      "Set7 also deposits methyl groups on histone H3 at position K27 (H3K27).",
      "The modifications by Set7 on H3K4 and H3K27 have been implicated in transcriptional repression.",
      "Set7-related histone modifications are involved in cellular processes such as cell cycle progression, gene expression regulation, and DNA repair."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Set7, also known as Set7/9 or SETD7, is a histone methyltransferase, but it specifically methylates lysine 4 of histone H3 (H3K4), not histones in general.\n2. TRUE\n3. FALSE [correction]: Set7 specifically methylates lysine 4 of histone H3 (H3K4) and does not typically methylate histone H3 at position K27 (H3K27). That modification is associated with other histone methyltransferases like EZH2.\n4. FALSE [correction]: The methylation of H3K4 by Set7 is generally associated with transcriptional activation, not repression. H3K27 methylation is the one that has been implicated in transcriptional repression, but Set7 does not methylate H3K27.\n5. TRUE - Set7-related histone modifications, particularly methylation of H3K4, are involved in various cellular processes, including cell cycle progression, gene expression regulation, and DNA repair.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "vicuna-13b_response": "Based on the information provided, the protein hepcidin contains 25 amino acids and four disulfide bridges.",
    "vicuna-13b_fact_raw": "1. The protein hepcidin contains 25 amino acids.\n2. Hepcidin has four disulfide bridges.",
    "vicuna-13b_fact": [
      "The protein hepcidin contains 25 amino acids.",
      "Hepcidin has four disulfide bridges."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The protein hepcidin typically contains about 20-25 amino acids, but the most common biologically active form in humans is 25 amino acids long.\n2. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "vicuna-13b_response": "Based on the given documents, the localization of the protein encoded by the gene DNAJC11 is not mentioned or discussed. The first document discusses Alzheimer's disease and its pathologic hallmarks, but does not provide any information about the localization of the protein encoded by the gene DNAJC11. The second document describes the process of nuclear protein import through NPC and the role of Ran GTPase, but again, does not provide any information about the localization of the protein encoded by the gene DNAJC11.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "vicuna-13b_response": "Based on the information provided, it can be inferred that ultraconserved elements are depleted among copy number variants (CNVs) in mammals. This is supported by the first document, which states that \"Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants.\" The second document also confirms this finding, stating that \"Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants.\"",
    "vicuna-13b_fact_raw": "1. Ultraconserved elements are depleted among copy number variants (CNVs) in mammals.\n2. The first document states that mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants.\n3. The second document confirms the depletion of mammalian ultraconserved elements among segmental duplications and copy number variants.",
    "vicuna-13b_fact": [
      "Ultraconserved elements are depleted among copy number variants (CNVs) in mammals.",
      "The first document states that mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants.",
      "The second document confirms the depletion of mammalian ultraconserved elements among segmental duplications and copy number variants."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "vicuna-13b_response": "Based on the information provided, it can be inferred that the substrate of the haspin kinase during mitosis is histone H3 (H3T3). This is because the haspin kinase plays an important role in mitosis and specifically phosphorylates Thr-3 in histone H3. Additionally, the information in Document 1 supports this conclusion, as it states that the haspin kinase is involved in mitosis and that it specifically phosphorylates H3T3. The information in Document 0 also supports this conclusion, as it states that the haspin kinase is involved in mitosis and that it is the H3T3 kinase, rather than VRKs.",
    "vicuna-13b_fact_raw": "1. The substrate of the haspin kinase during mitosis is histone H3 (H3T3).\n2. Haspin kinase phosphorylates Thr-3 in histone H3.\n3. Haspin kinase plays an important role in mitosis.",
    "vicuna-13b_fact": [
      "The substrate of the haspin kinase during mitosis is histone H3 (H3T3).",
      "Haspin kinase phosphorylates Thr-3 in histone H3.",
      "Haspin kinase plays an important role in mitosis."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "vicuna-13b_response": "The mechanism of viroid replication is through an RNA-based rolling-circle mechanism with three steps. The first step is the synthesis of longer-than-unit strands of RNA, which is catalyzed by either the nuclear RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase. In both instances, the RNA polymerase is redirected to transcribe RNA templates. The second step involves the annealing of the longer RNA strands to form a circular RNA intermediate. The third step is the synthesis of new RNA strands from the circular intermediate, which is again catalyzed by the RNA polymerase. This mechanism operates in both polarity strands, with some variations. Viroids are single-stranded circular noncoding RNAs that infect plants, and their noncoding nature indicates that they must harness their RNA genomes to redirect host machinery for infection. Therefore, the viroid model provides invaluable opportunities for delineating fundamental principles of RNA strand displacement and virus replication.",
    "vicuna-13b_fact_raw": "1. Viroid replication occurs through an RNA-based rolling-circle mechanism.\n2. The synthesis of longer-than-unit strands of RNA is the first step in viroid replication.\n3. RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase catalyzes the synthesis of longer-than-unit RNA strands.\n4. The annealing of the longer RNA strands to form a circular RNA intermediate is the second step in viroid replication.\n5. Viroids are single-stranded circular noncoding RNAs that infect plants.",
    "vicuna-13b_fact": [
      "Viroid replication occurs through an RNA-based rolling-circle mechanism.",
      "The synthesis of longer-than-unit strands of RNA is the first step in viroid replication.",
      "RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase catalyzes the synthesis of longer-than-unit RNA strands.",
      "The annealing of the longer RNA strands to form a circular RNA intermediate is the second step in viroid replication.",
      "Viroids are single-stranded circular noncoding RNAs that infect plants."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE (However, it should be noted that while RNA polymerase II is involved in the replication of some viroids, the specific polymerase can vary depending on the viroid species. Some viroids replicate in the chloroplast and are indeed replicated by a nuclear-encoded chloroplastic RNA polymerase.)\n4. FALSE [correction]: The annealing of the longer RNA strands to form a circular RNA intermediate is not the second step; the cleavage of the longer-than-unit strands to unit-length viroid RNA, which may then circularize, is the second step in viroid replication.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "vicuna-13b_response": "Based on the information provided, it appears that fibronectin has been suggested as a potential biomarker for Duchenne muscular dystrophy (DMD). Document 0 states that differences in peptide spectral counts and sequence coverage were observed between the DMD and control groups, suggesting that fibronectin may be useful in monitoring disease progression. Document 1 further supports this idea, stating that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients. However, it is important to note that this information is based on research studies and further validation is needed to confirm the utility of fibronectin as a biomarker for DMD.",
    "vicuna-13b_fact_raw": "1. Fibronectin has been suggested as a potential biomarker for Duchenne muscular dystrophy (DMD).\n2. Differences in peptide spectral counts and sequence coverage between DMD and control groups were observed, indicating fibronectin's potential utility in monitoring disease progression.\n3. Serum fibronectin levels may be a promising biomarker to monitor disease progression in DMD patients according to Document 1.\n4. Further validation is needed to confirm the utility of fibronectin as a biomarker for DMD.",
    "vicuna-13b_fact": [
      "Fibronectin has been suggested as a potential biomarker for Duchenne muscular dystrophy (DMD).",
      "Differences in peptide spectral counts and sequence coverage between DMD and control groups were observed, indicating fibronectin's potential utility in monitoring disease progression.",
      "Serum fibronectin levels may be a promising biomarker to monitor disease progression in DMD patients according to Document 1.",
      "Further validation is needed to confirm the utility of fibronectin as a biomarker for DMD."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "vicuna-13b_response": "Based on the information provided in the two documents, the major epigenome projects contained in the DeepBlue epigenomic data server are ENCODE, ROADMAP, BLUEPRINT, and DEEP.",
    "vicuna-13b_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE project.\n2. The DeepBlue epigenomic data server contains data from the ROADMAP project.\n3. The DeepBlue epigenomic data server contains data from the BLUEPRINT project.\n4. The DeepBlue epigenomic data server contains data from the DEEP project.",
    "vicuna-13b_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE project.",
      "The DeepBlue epigenomic data server contains data from the ROADMAP project.",
      "The DeepBlue epigenomic data server contains data from the BLUEPRINT project.",
      "The DeepBlue epigenomic data server contains data from the DEEP project."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe DeepBlue epigenomic data server is known for integrating data from various epigenomic research projects, including ENCODE (Encyclopedia of DNA Elements), ROADMAP, BLUEPRINT, and DEEP (Deutsches Epigenom Programm).",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "vicuna-13b_response": "The tool that employs self organizing maps for analyzing synonymous codon usage is CUBAP (Codon Usage Biases Analyzer). It is an interactive web portal for analyzing codon usage biases across populations, and it uses self organizing maps to visualize codon usage data. The tool was developed by Meinicke, Thomas Brodag, W. F. Fricke, and S. Waack, and it was published in the journal Nucleic Acids Research in 2006.",
    "vicuna-13b_fact_raw": "1. CUBAP (Codon Usage Biases Analyzer) is a tool that employs self organizing maps for analyzing synonymous codon usage.\n2. CUBAP is an interactive web portal for analyzing codon usage biases across populations.\n3. The tool CUBAP was developed by Meinicke, Thomas Brodag, W. F. Fricke, and S. Waack.\n4. CUBAP was published in the journal Nucleic Acids Research in 2006.",
    "vicuna-13b_fact": [
      "CUBAP (Codon Usage Biases Analyzer) is a tool that employs self organizing maps for analyzing synonymous codon usage.",
      "CUBAP is an interactive web portal for analyzing codon usage biases across populations.",
      "The tool CUBAP was developed by Meinicke, Thomas Brodag, W. F. Fricke, and S. Waack.",
      "CUBAP was published in the journal Nucleic Acids Research in 2006."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: CUBAP is not specifically described as an interactive web portal for analyzing codon usage biases across populations. It is a tool for analyzing synonymous codon usage, but without additional context, it's unclear if it's designed as a web portal or for cross-population analysis.\n3. UNKNOWN\n4. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "vicuna-13b_response": "MINDY-1 is not mentioned in the given documents. The first source, a scientific paper titled \"MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes\" published in 2016, describes a protein called MINDY-1 that is involved in deubiquitinating enzyme activity. The second source is a character description from a TV show or movie, likely \"The Mindy Project,\" which features a character named Mindy Chen, a singer, emcee, and drag cabaret performer. It is possible that the character is named after the protein, but this is not confirmed.",
    "vicuna-13b_fact_raw": "1. MINDY-1 is a protein involved in deubiquitinating enzyme activity.\n2. A scientific paper titled \"MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes\" was published in 2016.\n3. There is a character named Mindy Chen who is a singer, emcee, and drag cabaret performer in a TV show or movie.\n4. The TV show or movie that features the character Mindy Chen is likely \"The Mindy Project\".",
    "vicuna-13b_fact": [
      "MINDY-1 is a protein involved in deubiquitinating enzyme activity.",
      "A scientific paper titled \"MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes\" was published in 2016.",
      "There is a character named Mindy Chen who is a singer, emcee, and drag cabaret performer in a TV show or movie.",
      "The TV show or movie that features the character Mindy Chen is likely \"The Mindy Project\"."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The character Mindy Chen is from the TV show \"Emily in Paris,\" not \"The Mindy Project.\"",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "vicuna-13b_response": "PHYLUCE is a software package for the analysis of conserved genomic loci. It was developed by Brant C. Faircloth and published in the journal Bioinformatics in 2016. The software is designed to identify and analyze conserved genomic loci in DNA sequences. It can be used to identify conserved non-coding elements, such as transcription factor binding sites, and to study the evolutionary history of genomic regions. PHYLUCE is available for use by researchers in the field of genomics and bioinformatics.",
    "vicuna-13b_fact_raw": "1. PHYLUCE is a software package for the analysis of conserved genomic loci.\n2. Brant C. Faircloth developed PHYLUCE.\n3. PHYLUCE was published in the journal Bioinformatics in 2016.\n4. The software is designed to identify conserved non-coding elements, such as transcription factor binding sites.\n5. PHYLUCE can be used to study the evolutionary history of genomic regions.",
    "vicuna-13b_fact": [
      "PHYLUCE is a software package for the analysis of conserved genomic loci.",
      "Brant C. Faircloth developed PHYLUCE.",
      "PHYLUCE was published in the journal Bioinformatics in 2016.",
      "The software is designed to identify conserved non-coding elements, such as transcription factor binding sites.",
      "PHYLUCE can be used to study the evolutionary history of genomic regions."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: PHYLUCE was published in the journal Bioinformatics in 2012.\n4. FALSE [correction]: PHYLUCE is designed to identify ultraconserved elements (UCEs) and other loci, which are primarily coding regions, not non-coding elements like transcription factor binding sites.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "vicuna-13b_response": "Based on the given documents, three diseases associated with the PIEZO2 gene are:\n1. Autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis.\n2. Distal arthrogryposis type 1, 2, and 3.\nNote: The information provided by the documents may not be up-to-date or comprehensive, and there may be other diseases associated with the PIEZO2 gene that are not mentioned.",
    "vicuna-13b_fact_raw": "1. The PIEZO2 gene is associated with an autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis.\n2. The PIEZO2 gene is associated with distal arthrogryposis type 1.\n3. The PIEZO2 gene is associated with distal arthrogryposis type 2 and 3.",
    "vicuna-13b_fact": [
      "The PIEZO2 gene is associated with an autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis.",
      "The PIEZO2 gene is associated with distal arthrogryposis type 1.",
      "The PIEZO2 gene is associated with distal arthrogryposis type 2 and 3."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: The PIEZO2 gene is not typically associated with distal arthrogryposis type 1. Distal arthrogryposis type 1 is usually not associated with specific genetic mutations and is characterized by congenital contractures of the hands and feet without additional abnormalities.\n3. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "vicuna-13b_response": "Based on the given information, it is suggested that the promoted activity by ERAP1-ERAP2 dimerization is the modulation of ERAP1/2 activity, which is a novel immunological strategy for cancer immunotherapy. The dimerization topology allows access to the active site of both enzymes, and this is consistent with a previously reported construct in which ERAP1 and ERAP2 were linked by Fos/Jun zipper tags. The proposed model constitutes a tentative structural template to help understand the physiological role and significance of ERAP1/ERAP2 molecular interactions in the immune system.",
    "vicuna-13b_fact_raw": "1. ERAP1-ERAP2 dimerization is suggested to modulate ERAP1/2 activity.\n2. The modulation of ERAP1/2 activity by dimerization is considered a novel immunological strategy for cancer immunotherapy.\n3. Dimerization topology allows access to the active site of both ERAP1 and ERAP2 enzymes.\n4. ERAP1 and ERAP2 were previously reported to be linked by Fos/Jun zipper tags.\n5. The proposed model serves as a structural template to understand the role of ERAP1/ERAP2 interactions in the immune system.",
    "vicuna-13b_fact": [
      "ERAP1-ERAP2 dimerization is suggested to modulate ERAP1/2 activity.",
      "The modulation of ERAP1/2 activity by dimerization is considered a novel immunological strategy for cancer immunotherapy.",
      "Dimerization topology allows access to the active site of both ERAP1 and ERAP2 enzymes.",
      "ERAP1 and ERAP2 were previously reported to be linked by Fos/Jun zipper tags.",
      "The proposed model serves as a structural template to understand the role of ERAP1/ERAP2 interactions in the immune system."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: ERAP1 and ERAP2 were previously reported to be linked by leucine zipper-like interactions, not specifically by Fos/Jun zipper tags.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "vicuna-13b_response": "Based on the provided information, R-spondin 1 and noggin play a role in the growth and differentiation of gallbladder-derived organoids. They stimulate the growth of these organoids, but their removal leads to partial differentiation toward the hepatocyte fate. Additionally, human gallbladders are a source of organoid-forming stem/progenitor cells. It is also reported that RSPO2 copy number amplifications or enhanced RSPO2 mRNA expression associated with Wnt/β-catenin activation are found in subsets of hepatocellular carcinoma.",
    "vicuna-13b_fact_raw": "1. R-spondin 1 and noggin stimulate the growth of gallbladder-derived organoids.\n2. The removal of R-spondin 1 and noggin leads to partial differentiation of gallbladder-derived organoids toward the hepatocyte fate.\n3. Human gallbladders contain organoid-forming stem/progenitor cells.\n4. RSPO2 copy number amplifications or enhanced RSPO2 mRNA expression are associated with Wnt/β-catenin activation in subsets of hepatocellular carcinoma.",
    "vicuna-13b_fact": [
      "R-spondin 1 and noggin stimulate the growth of gallbladder-derived organoids.",
      "The removal of R-spondin 1 and noggin leads to partial differentiation of gallbladder-derived organoids toward the hepatocyte fate.",
      "Human gallbladders contain organoid-forming stem/progenitor cells.",
      "RSPO2 copy number amplifications or enhanced RSPO2 mRNA expression are associated with Wnt/β-catenin activation in subsets of hepatocellular carcinoma."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe statements provided are specific and technical, and without additional context, they seem plausible based on current scientific understanding. R-spondin 1 and noggin are known to be involved in the growth and differentiation of various types of organoids, including those derived from the gastrointestinal tract. It is also known that the human gallbladder contains cells with regenerative potential that can form organoids. RSPO2 (related to R-spondin) is involved in Wnt signaling, which is often implicated in cancer, including hepatocellular carcinoma. However, without the specific passage or scientific references, the accuracy of these statements cannot be independently verified, but they are consistent with general scientific knowledge as of my last update.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "vicuna-13b_response": "Based on the information provided, it is not clear whether NOX5 requires any subunit for function. Document 0 states that NOX5 is the last member of the NADPH oxidase (NOXs) family to be identified and has some specific characteristics differing from the rest of the NOXs. It also mentions that NOX5 contains four Ca2+ binding domains at the N-terminus and that its activity is regulated by the intracellular concentration of Ca2+. However, it does not mention whether NOX5 requires any specific subunits for function.\nOn the other hand, Document 1 states that NOX is a multisubunit enzyme complex composed of five essential subunits, two of which are localized in the membrane, while three are localized in the cytosol. However, it does not mention whether NOX5 is a part of this complex or if it has any specific subunits.\nTherefore, based on the information provided, it is not clear whether NOX5 requires any subunit for function. Further research or additional information is needed to answer this question.",
    "vicuna-13b_fact_raw": "1. NADPH oxidase 5 (NOX5) is the last member of the NADPH oxidase (NOXs) family to be identified.\n2. NOX5 contains four Ca2+ binding domains at the N-terminus.\n3. The activity of NOX5 is regulated by the intracellular concentration of Ca2+.\n4. The NOX enzyme complex is composed of five essential subunits.\n5. Two subunits of the NOX enzyme complex are localized in the membrane, and three are localized in the cytosol.",
    "vicuna-13b_fact": [
      "NADPH oxidase 5 (NOX5) is the last member of the NADPH oxidase (NOXs) family to be identified.",
      "NOX5 contains four Ca2+ binding domains at the N-terminus.",
      "The activity of NOX5 is regulated by the intracellular concentration of Ca2+.",
      "The NOX enzyme complex is composed of five essential subunits.",
      "Two subunits of the NOX enzyme complex are localized in the membrane, and three are localized in the cytosol."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: NADPH oxidase 5 (NOX5) is indeed the last member of the NADPH oxidase (NOXs) family to be identified.\n2. TRUE: NOX5 contains four Ca2+ binding domains, known as EF-hands, at the N-terminus.\n3. TRUE: The activity of NOX5 is regulated by the intracellular concentration of Ca2+, which binds to the EF-hand domains.\n4. FALSE [correction]: The NOX enzyme complex does not have a fixed number of essential subunits across all its variants. For example, NOX2 requires several subunits (gp91phox, p22phox, p40phox, p47phox, and p67phox), but NOX5 does not require these cytosolic components for its activity.\n5. FALSE [correction]: This statement is not universally true for all NOX enzymes. For NOX2, two subunits are membrane-bound (gp91phox and p22phox), and at least three are cytosolic (p40phox, p47phox, and p67phox). However, NOX5 does not require cytosolic subunits for its activity, as it is regulated by calcium binding directly to the enzyme itself.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "vicuna-13b_response": "Document 0 states that hepcidin binds to the only known iron export protein, ferroportin (FPN), inducing its internalization and degradation, thus limiting the amount of iron released into the blood. The major factors that are implicated in hepcidin regulation include iron stores, hypoxia, inflammation and erythropoiesis. Document 1 also states that hepcidin is thought to be the key regulator of iron metabolism in humans through its inhibition of the iron-exporting protein ferroportin. Based on these two documents, it can be inferred that there is a connection between furin and hepcidin in that both are involved in the regulation of iron metabolism. Specifically, furin has been implicated in the processing of hepcidin, which is thought to play a key role in regulating iron metabolism by inhibiting the iron-exporting protein ferroportin.",
    "vicuna-13b_fact_raw": "1. Hepcidin binds to ferroportin, inducing its internalization and degradation.\n2. The regulation of hepcidin is influenced by factors such as iron stores, hypoxia, inflammation, and erythropoiesis.\n3. Hepcidin is considered the key regulator of iron metabolism in humans.\n4. Hepcidin inhibits the iron-exporting protein ferroportin.\n5. Furin is implicated in the processing of hepcidin.",
    "vicuna-13b_fact": [
      "Hepcidin binds to ferroportin, inducing its internalization and degradation.",
      "The regulation of hepcidin is influenced by factors such as iron stores, hypoxia, inflammation, and erythropoiesis.",
      "Hepcidin is considered the key regulator of iron metabolism in humans.",
      "Hepcidin inhibits the iron-exporting protein ferroportin.",
      "Furin is implicated in the processing of hepcidin."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "vicuna-13b_response": "The largest metabolic gene cluster in yeast is the DAL cluster, which consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source. Although most eukaryotic genomes lack operons, they contain some physical clusters of genes that are related in function despite being unrelated in sequence. The formation of these clusters during evolution is still unknown.",
    "vicuna-13b_fact_raw": "1. The largest metabolic gene cluster in yeast is the DAL cluster.\n2. The DAL cluster consists of six adjacent genes.\n3. These genes encode proteins that allow Saccharomyces cerevisiae to utilize allantoin as a nitrogen source.\n4. Most eukaryotic genomes do not have operons but contain clusters of functionally related genes.\n5. The process by which these gene clusters formed during evolution is not known.",
    "vicuna-13b_fact": [
      "The largest metabolic gene cluster in yeast is the DAL cluster.",
      "The DAL cluster consists of six adjacent genes.",
      "These genes encode proteins that allow Saccharomyces cerevisiae to utilize allantoin as a nitrogen source.",
      "Most eukaryotic genomes do not have operons but contain clusters of functionally related genes.",
      "The process by which these gene clusters formed during evolution is not known."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: The DAL cluster consists of seven adjacent genes.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While the exact processes are complex and not fully understood, there are hypotheses and models that suggest mechanisms by which gene clusters could have formed during evolution, such as through gene duplication and divergence, horizontal gene transfer, or the clustering of genes with related functions due to selective advantages.",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "vicuna-13b_response": "The role of LIMT lncRNA is not specified in the given documents. However, it is known that long non-coding RNAs (lncRNAs) are involved in various cellular processes, such as gene regulation, chromatin modification, and protein synthesis [4]. The specific function of LIMT lncRNA may depend on its sequence, structural features, and interactions with other RNAs and proteins. LIMT lncRNA may also play a role in telomere maintenance, as telomerase RNA template component (TERC) is a lncRNA required for telomere maintenance [0]. However, more research is needed to determine the specific function of LIMT lncRNA in the cell.",
    "vicuna-13b_fact_raw": "1. Long non-coding RNAs (lncRNAs) are involved in various cellular processes such as gene regulation, chromatin modification, and protein synthesis.\n2. The specific function of LIMT lncRNA may depend on its sequence, structural features, and interactions with other RNAs and proteins.\n3. Telomerase RNA template component (TERC) is a long non-coding RNA required for telomere maintenance.\n4. More research is needed to determine the specific function of LIMT lncRNA in the cell.",
    "vicuna-13b_fact": [
      "Long non-coding RNAs (lncRNAs) are involved in various cellular processes such as gene regulation, chromatin modification, and protein synthesis.",
      "The specific function of LIMT lncRNA may depend on its sequence, structural features, and interactions with other RNAs and proteins.",
      "Telomerase RNA template component (TERC) is a long non-coding RNA required for telomere maintenance.",
      "More research is needed to determine the specific function of LIMT lncRNA in the cell."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "vicuna-13b_response": "The R/Bioconductor package used for performing SNP enrichment analysis is traseR.",
    "vicuna-13b_fact_raw": "1. The R/Bioconductor package traseR is used for performing SNP enrichment analysis.",
    "vicuna-13b_fact": [
      "The R/Bioconductor package traseR is used for performing SNP enrichment analysis."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The R/Bioconductor package traseR is used for trajectory inference in single-cell RNA-seq data analysis, not for SNP enrichment analysis.",
    "vicuna-13b_judge": [
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "vicuna-13b_response": "Answer: The key players in radial glial specification to ependymal cells are Mcidas and GemC1/Lynkeas. These proteins were initially described as cell cycle regulators and have sequence similarity to Geminin. Recent findings suggest that they play a key role in radial glial specification to ependymal cells.",
    "vicuna-13b_fact_raw": "1. Mcidas and GemC1/Lynkeas are key players in radial glial specification to ependymal cells.\n2. Mcidas and GemC1/Lynkeas were initially described as cell cycle regulators.\n3. Mcidas and GemC1/Lynkeas have sequence similarity to Geminin.",
    "vicuna-13b_fact": [
      "Mcidas and GemC1/Lynkeas are key players in radial glial specification to ependymal cells.",
      "Mcidas and GemC1/Lynkeas were initially described as cell cycle regulators.",
      "Mcidas and GemC1/Lynkeas have sequence similarity to Geminin."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "vicuna-13b_response": "Triple negative gliomas are a subtype of glioma, a type of brain cancer, that lack the three major genetic alterations typically found in gliomas: epidermal growth factor receptor (EGFR) amplification, mutations in the isocitrate dehydrogenase (IDH) gene, and high-level copy number gains of the anaplastic lymphoma kinase (ALK) gene. These tumors are characterized by the presence of the MYB oncogene. Document 0 states that the remaining gliomas are glioblastoma and triple-negative gliomas. Document 1 states that triple-negative gliomas are enigmatic tumors with clinically relevant subtypes that are characterized by abnormalities in different genes, including the aforementioned genetic alterations.",
    "vicuna-13b_fact_raw": "1. Triple negative gliomas are a subtype of glioma, which is a type of brain cancer.\n2. Triple negative gliomas lack amplification of the epidermal growth factor receptor (EGFR) gene.\n3. Triple negative gliomas do not have mutations in the isocitrate dehydrogenase (IDH) gene.\n4. Triple negative gliomas do not have high-level copy number gains of the anaplastic lymphoma kinase (ALK) gene.\n5. Triple negative gliomas are characterized by the presence of the MYB oncogene.",
    "vicuna-13b_fact": [
      "Triple negative gliomas are a subtype of glioma, which is a type of brain cancer.",
      "Triple negative gliomas lack amplification of the epidermal growth factor receptor (EGFR) gene.",
      "Triple negative gliomas do not have mutations in the isocitrate dehydrogenase (IDH) gene.",
      "Triple negative gliomas do not have high-level copy number gains of the anaplastic lymphoma kinase (ALK) gene.",
      "Triple negative gliomas are characterized by the presence of the MYB oncogene."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Triple negative gliomas often have mutations in the isocitrate dehydrogenase (IDH) gene.\n4. TRUE\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "vicuna-13b_response": "TOPAZ1 is a clinical trial that evaluated the use of durvalumab plus chemotherapy for patients with advanced biliary tract cancer. The trial included patients with both intrahepatic and extrahepatic bile duct cancer, as well as gallbladder cancer (excluding ampullary cancer). The trial took place in 145 centers across 17 countries, including the United States, Europe, South America, Asia, and Australia. The primary endpoint was overall survival, with secondary endpoints including progression-free survival, objective response rate, and safety. The results of the trial were announced at the 2022 ASCO GI meeting and showed that the addition of durvalumab to chemotherapy did not improve overall survival compared to chemotherapy alone in patients with advanced biliary tract cancer.",
    "vicuna-13b_fact_raw": "1. TOPAZ1 is a clinical trial that evaluated the use of durvalumab plus chemotherapy in patients with advanced biliary tract cancer.\n2. The trial included patients with intrahepatic and extrahepatic bile duct cancer, as well as gallbladder cancer.\n3. The trial was conducted in 145 centers across 17 countries.\n4. The primary endpoint of the TOPAZ1 trial was overall survival.\n5. The results of the TOPAZ1 trial were announced at the 2022 ASCO GI meeting.",
    "vicuna-13b_fact": [
      "TOPAZ1 is a clinical trial that evaluated the use of durvalumab plus chemotherapy in patients with advanced biliary tract cancer.",
      "The trial included patients with intrahepatic and extrahepatic bile duct cancer, as well as gallbladder cancer.",
      "The trial was conducted in 145 centers across 17 countries.",
      "The primary endpoint of the TOPAZ1 trial was overall survival.",
      "The results of the TOPAZ1 trial were announced at the 2022 ASCO GI meeting."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "vicuna-13b_response": "Based on the given information, it is not explicitly stated which gene controls the expression of GATA-1 isoforms. Document 0 suggests that hematopoietic development is regulated by transcription factors that coordinate temporal and lineage-specific patterns of gene expression, but does not specify which gene controls GATA-1 isoforms. Document 1 mentions the use of K562 cells expressing GATA1s or GATA1FL transgenes to model the effects of the two isoforms on in vitro haematopoietic differentiation, but does not provide information on the gene that controls the expression of GATA-1 isoforms.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "vicuna-13b_response": "MIRA-seq is a high-throughput DNA methylation analysis platform that uses the Methylated-CpG Island Recovery Assay (MIRA) technology to score DNA methylation differences at CpG-rich genomic regions. The MIRA technology takes advantage of the high affinity of a methylated-CpG-binding protein complex (MBD2B and MBD3L1) to enrich regions with methylated CpG dinucleotides. This approach can be applied to both array-based DNA analysis and NGS sequencing, which are sometimes distinguished as MIRA-chip and MIRA-Seq. MIRA-seq is a reliable and cost-effective method for genome-scale DNA methylation analysis and is not limited by primer or probe design. It is widely used to study DNA methylation patterns in various biological samples and is useful for identifying methylated CpG islands, which are important for gene silencing and X-chromosome inactivation.",
    "vicuna-13b_fact_raw": "1. MIRA-seq uses the Methylated-CpG Island Recovery Assay (MIRA) technology for DNA methylation analysis.\n2. The MIRA technology employs a methylated-CpG-binding protein complex (MBD2B and MBD3L1) to enrich methylated CpG dinucleotides.\n3. MIRA-seq can be applied to both array-based DNA analysis and next-generation sequencing (NGS).\n4. MIRA-seq is used for genome-scale DNA methylation analysis.\n5. MIRA-seq helps in identifying methylated CpG islands, which play a role in gene silencing and X-chromosome inactivation.",
    "vicuna-13b_fact": [
      "MIRA-seq uses the Methylated-CpG Island Recovery Assay (MIRA) technology for DNA methylation analysis.",
      "The MIRA technology employs a methylated-CpG-binding protein complex (MBD2B and MBD3L1) to enrich methylated CpG dinucleotides.",
      "MIRA-seq can be applied to both array-based DNA analysis and next-generation sequencing (NGS).",
      "MIRA-seq is used for genome-scale DNA methylation analysis.",
      "MIRA-seq helps in identifying methylated CpG islands, which play a role in gene silencing and X-chromosome inactivation."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "vicuna-13b_response": "The indication of ARCALYST is the treatment of recurrent pericarditis and reduction of the risk of recurrence in adults and pediatric patients 12 years and older. It is also used to treat some of the symptoms of rare genetic conditions such as Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS), which are inflammatory disorders that cause certain symptoms in response to cold, heat, stress, or tiredness.",
    "vicuna-13b_fact_raw": "1. ARCALYST is indicated for the treatment of recurrent pericarditis.\n2. ARCALYST is used to reduce the risk of recurrence of pericarditis in adults and pediatric patients 12 years and older.\n3. ARCALYST is used to treat symptoms of Familial Cold Auto-inflammatory Syndrome (FCAS).\n4. ARCALYST is used to treat symptoms of Muckle-Wells Syndrome (MWS).\n5. FCAS and MWS are rare genetic inflammatory disorders.",
    "vicuna-13b_fact": [
      "ARCALYST is indicated for the treatment of recurrent pericarditis.",
      "ARCALYST is used to reduce the risk of recurrence of pericarditis in adults and pediatric patients 12 years and older.",
      "ARCALYST is used to treat symptoms of Familial Cold Auto-inflammatory Syndrome (FCAS).",
      "ARCALYST is used to treat symptoms of Muckle-Wells Syndrome (MWS).",
      "FCAS and MWS are rare genetic inflammatory disorders."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "vicuna-13b_response": "Based on the given information, the human acrocentric chromosomes involved in Robertsonian translocation are chromosomes 13, 14, 15, 21, and 22. These chromosomes are acrocentric and contain numerous copies of genes coding for ribosomal RNA. All of these chromosomes are capable of participating in ROB formation, producing 5 types of homologous ROBs and 10 types of heterologous ROBs. The distribution of different ROBs in the general population is nonrandom, with der (13q14q) and der (14q21q) constituting ∼85% of all ROBs.",
    "vicuna-13b_fact_raw": "1. Human acrocentric chromosomes involved in Robertsonian translocation are chromosomes 13, 14, 15, 21, and 22.\n2. These acrocentric chromosomes contain numerous copies of genes coding for ribosomal RNA.\n3. Chromosomes 13, 14, 15, 21, and 22 can participate in the formation of Robertsonian translocations (ROBs).\n4. There are 5 types of homologous ROBs possible with these chromosomes.\n5. There are 10 types of heterologous ROBs possible with these chromosomes.",
    "vicuna-13b_fact": [
      "Human acrocentric chromosomes involved in Robertsonian translocation are chromosomes 13, 14, 15, 21, and 22.",
      "These acrocentric chromosomes contain numerous copies of genes coding for ribosomal RNA.",
      "Chromosomes 13, 14, 15, 21, and 22 can participate in the formation of Robertsonian translocations (ROBs).",
      "There are 5 types of homologous ROBs possible with these chromosomes.",
      "There are 10 types of heterologous ROBs possible with these chromosomes."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: There are 10 types of homologous ROBs possible with these chromosomes, as each chromosome can pair with each of the other four, giving a total of 10 possible combinations (13-14, 13-15, 13-21, 13-22, 14-15, 14-21, 14-22, 15-21, 15-22, 21-22).\n5. FALSE [correction]: There are no homologous ROBs because homologous chromosomes do not pair in Robertsonian translocations. The term \"heterologous\" refers to the involvement of non-identical chromosomes, so all 10 possible combinations mentioned in the correction for statement 4 are heterologous ROBs.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "vicuna-13b_response": "The R package that could be used for the identification of pediatric brain tumors is MethPed. It is available via Bioconductor and utilizes DNA methylation data from the 450K array to classify various types of pediatric brain tumors using a Random Forest classifier. The package can identify Glioblastoma, Medulloblastoma, Ependymoma, Astrocytoma, and other types of brain tumors.",
    "vicuna-13b_fact_raw": "1. MethPed is an R package that can be used for the identification of pediatric brain tumors.\n2. MethPed is available through Bioconductor.\n3. The MethPed package uses DNA methylation data from the 450K array.\n4. MethPed employs a Random Forest classifier for tumor classification.\n5. MethPed can identify various types of pediatric brain tumors, including Glioblastoma, Medulloblastoma, Ependymoma, and Astrocytoma.",
    "vicuna-13b_fact": [
      "MethPed is an R package that can be used for the identification of pediatric brain tumors.",
      "MethPed is available through Bioconductor.",
      "The MethPed package uses DNA methylation data from the 450K array.",
      "MethPed employs a Random Forest classifier for tumor classification.",
      "MethPed can identify various types of pediatric brain tumors, including Glioblastoma, Medulloblastoma, Ependymoma, and Astrocytoma."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: While the statements provided are consistent with what might be expected from an R package designed for tumor classification based on DNA methylation data, without access to the most current and specific information about the MethPed package, I cannot verify the details such as the types of tumors it can identify or the specific algorithms it employs. The responses are based on the assumption that the statements accurately reflect the capabilities of the MethPed package as of the knowledge cutoff date. Users should refer to the latest documentation or publications related to MethPed for the most accurate information.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "vicuna-13b_response": "Based on the information provided, it can be inferred that NEMO is a zinc finger protein. Document 0 states that \"The Zinc Finger of NEMO Is a Functional Ubiquitin-binding Domain\" and Document 1 states that \"Inhibitor of κB kinase gamma (IKKγ) protein, a key component of the NF-κB pathway\" which implies that NEMO is a zinc finger protein.",
    "vicuna-13b_fact_raw": "1. NEMO is a zinc finger protein.\n2. The Zinc Finger of NEMO is a functional ubiquitin-binding domain.\n3. NEMO is also known as Inhibitor of κB kinase gamma (IKKγ).\n4. NEMO is a key component of the NF-κB pathway.",
    "vicuna-13b_fact": [
      "NEMO is a zinc finger protein.",
      "The Zinc Finger of NEMO is a functional ubiquitin-binding domain.",
      "NEMO is also known as Inhibitor of κB kinase gamma (IKKγ).",
      "NEMO is a key component of the NF-κB pathway."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: The Zinc Finger of NEMO is not a ubiquitin-binding domain; instead, it contains a coiled-coil domain and a leucine zipper that are important for its function.\n3. TRUE\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "vicuna-13b_response": "Based on the information provided, it appears that TFIIS can affect nucleosome positioning. Document 0 states that lack of TFIIS influences nucleosome occupancy across the genome, and this influence is particularly strong in genes that contain a canonical TATA box. Document 1 also states that TFIIS generally contributes to nucleosome positioning in both gene promoters and bodies. These findings suggest that TFIIS plays a role in regulating the positioning of nucleosomes in the genome.",
    "vicuna-13b_fact_raw": "1. TFIIS can affect nucleosome positioning.\n2. Lack of TFIIS influences nucleosome occupancy across the genome.\n3. The influence of TFIIS is particularly strong in genes that contain a canonical TATA box.\n4. TFIIS contributes to nucleosome positioning in gene promoters and bodies.",
    "vicuna-13b_fact": [
      "TFIIS can affect nucleosome positioning.",
      "Lack of TFIIS influences nucleosome occupancy across the genome.",
      "The influence of TFIIS is particularly strong in genes that contain a canonical TATA box.",
      "TFIIS contributes to nucleosome positioning in gene promoters and bodies."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "vicuna-13b_response": "Based on the given information, it is not clear whether origins of replication close to yeast centromeres fire early or late. Document 0 states that eukaryotic DNA replication begins with multiple origins of replication, but it does not specify whether origins of replication close to yeast centromeres fire early or late. Document 1 mentions that the early replication of baker's yeast centromeres is one example of temporal regulation, but it does not provide information on whether origins of replication close to these centromeres fire early or late.",
    "vicuna-13b_fact_raw": "1. Eukaryotic DNA replication begins with multiple origins of replication.\n2. The early replication of baker's yeast centromeres is an example of temporal regulation.",
    "vicuna-13b_fact": [
      "Eukaryotic DNA replication begins with multiple origins of replication.",
      "The early replication of baker's yeast centromeres is an example of temporal regulation."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "vicuna-13b_response": "The properties of mammalian GA-sequences are described in the article as DNA sequences of mammalian genomes that are longer than 50 bases, but consist exclusively of G's and A's. These sequences are referred to as \"pure GA-sequences\". The article states that the frequency of incidence of these sequences should be 10^-16 or smaller, but they are found ubiquitously located along the chromosomes of various mammalian species, with a species-dependent distribution. The article is written by Guenter Albrecht-Buehler from the Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.",
    "vicuna-13b_fact_raw": "1. Mammalian GA-sequences are DNA sequences that are longer than 50 bases and consist exclusively of G's and A's.\n2. These sequences are referred to as \"pure GA-sequences.\"\n3. The expected frequency of incidence for these sequences is 10^-16 or smaller.\n4. Pure GA-sequences are found ubiquitously along the chromosomes of various mammalian species.\n5. The distribution of pure GA-sequences is species-dependent.",
    "vicuna-13b_fact": [
      "Mammalian GA-sequences are DNA sequences that are longer than 50 bases and consist exclusively of G's and A's.",
      "These sequences are referred to as \"pure GA-sequences.\"",
      "The expected frequency of incidence for these sequences is 10^-16 or smaller.",
      "Pure GA-sequences are found ubiquitously along the chromosomes of various mammalian species.",
      "The distribution of pure GA-sequences is species-dependent."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Mammalian GA-sequences are not defined by their length or by consisting exclusively of G's and A's. GA-sequences refer to sequences that contain a high proportion of guanine (G) and adenine (A) nucleotides, but they are not exclusively made up of these bases nor are they defined by a specific length.\n2. UNKNOWN: The term \"pure GA-sequences\" is not a standard term in genetics, and without additional context, it is unclear whether this term is commonly used or what it specifically refers to.\n3. FALSE [correction]: Without specific context, it is not possible to accurately state the expected frequency of incidence for these sequences. The frequency of any given sequence depends on various factors, including sequence length, composition, and genome size.\n4. UNKNOWN: Without additional context, it is not possible to determine the ubiquity of these sequences along the chromosomes of various mammalian species.\n5. TRUE: The distribution of specific DNA sequences, including those rich in guanine (G) and adenine (A), can be species-dependent due to differences in genome structure and evolutionary history.",
    "vicuna-13b_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "vicuna-13b_response": "Based on the information provided, it is not clear how many Groucho-related genes (GRGs) are contained in the mouse genome. Document 0 mentions a specific gene called GRG5, but does not provide information on the total number of GRGs in the mouse genome. Document 1 discusses the role of Groucho-related genes in regulating the gonadotropin-releasing hormone gene, but again, does not provide information on the total number of GRGs in the mouse genome.\nIt is possible that more research would be needed to determine the total number of GRGs in the mouse genome.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "vicuna-13b_response": "Based on the given information, it is not explicitly stated which RNA polymerase II subunit carries RNA cleavage activity. However, it is known that RNA polymerase II (RNAPII) is a multi-subunit complex that contains 12 subunits, and five of these subunits are shared by all RNA polymerases (RNAPI, II, and III) (Vannini and Cramer, 2012; Werner et al., 2009) (Table 1).",
    "vicuna-13b_fact_raw": "1. RNA polymerase II is a multi-subunit complex.\n2. RNA polymerase II contains 12 subunits.\n3. Five subunits of RNA polymerase II are shared by all RNA polymerases (RNAPI, II, and III).\n4. The sources cited for the information are Vannini and Cramer (2012) and Werner et al. (2009).",
    "vicuna-13b_fact": [
      "RNA polymerase II is a multi-subunit complex.",
      "RNA polymerase II contains 12 subunits.",
      "Five subunits of RNA polymerase II are shared by all RNA polymerases (RNAPI, II, and III).",
      "The sources cited for the information are Vannini and Cramer (2012) and Werner et al. (2009)."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "vicuna-13b_response": "Answer: The genetic basis of Ohdo syndrome is not yet fully understood, but it is thought to be related to abnormalities in certain genes. The SBBYS variant of Ohdo syndrome is caused by mutations in the SBDS gene, while the Maat-Kievit-Brunner type of Ohdo syndrome is caused by mutations in the MKBL1 gene. These genes are responsible for regulating the development and function of certain cells and tissues in the body, and mutations in these genes can lead to the characteristic features of Ohdo syndrome.",
    "vicuna-13b_fact_raw": "1. Ohdo syndrome is thought to be related to abnormalities in certain genes.\n2. The SBBYS variant of Ohdo syndrome is caused by mutations in the SBDS gene.\n3. The Maat-Kievit-Brunner type of Ohdo syndrome is caused by mutations in the MKBL1 gene.\n4. Mutations in the SBDS and MKBL1 genes can lead to the characteristic features of Ohdo syndrome.",
    "vicuna-13b_fact": [
      "Ohdo syndrome is thought to be related to abnormalities in certain genes.",
      "The SBBYS variant of Ohdo syndrome is caused by mutations in the SBDS gene.",
      "The Maat-Kievit-Brunner type of Ohdo syndrome is caused by mutations in the MKBL1 gene.",
      "Mutations in the SBDS and MKBL1 genes can lead to the characteristic features of Ohdo syndrome."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: The SBBYS variant of Ohdo syndrome is caused by mutations in the KAT6B gene, not the SBDS gene.\n3. TRUE\n4. FALSE [correction]: Mutations in the KAT6B and MED12 genes can lead to the characteristic features of Ohdo syndrome, not the SBDS gene. The MKBL1 gene is not known to be associated with Ohdo syndrome; instead, mutations in the MED12 gene are associated with the Maat-Kievit-Brunner type of Ohdo syndrome.",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "vicuna-13b_response": "The R/Bioconductor package for the analysis of psychiatric disease genes is Psygenet2r. It is implemented in R and is available under the MIT license from Bioconductor (<http://bioconductor.org/packages/release/bioc/html/psygenet2r.html>).",
    "vicuna-13b_fact_raw": "1. Psygenet2r is an R/Bioconductor package developed for the analysis of psychiatric disease genes.\n2. Psygenet2r is implemented in the R programming language.\n3. Psygenet2r is available under the MIT license.\n4. Psygenet2r can be obtained from Bioconductor.",
    "vicuna-13b_fact": [
      "Psygenet2r is an R/Bioconductor package developed for the analysis of psychiatric disease genes.",
      "Psygenet2r is implemented in the R programming language.",
      "Psygenet2r is available under the MIT license.",
      "Psygenet2r can be obtained from Bioconductor."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Psygenet2r is available under the Artistic-2.0 license.\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "vicuna-13b_response": "The swirl sign is a non-contrast CT appearance that refers to the acute extravasation of blood into a hematoma, such as an intracerebral hemorrhage (ICH), extradural hematoma, or subdural hematoma. It is characterized by unclotted fresh blood which is of lower attenuation than the clotted blood surrounding it. The swirl sign has been previously described in epidural hematomas as areas of low attenuation, radiolucency, or irregular density.\nIn a study to describe the swirl sign in ICH, the prevalence of the sign was evaluated, as well as the reliability of subjective evaluation on CT. The study also aimed to explore the prognostic value of the swirl sign in ICH. The study used non-contrast CT scans to evaluate the presence of the swirl sign in patients with ICH. The results of the study showed that the swirl sign was present in a significant number of patients with ICH and that it was associated with a higher mortality rate. The study also found that the swirl sign was a reliable indicator of the severity of ICH and that it could be used to predict the outcome of patients with ICH.\nIn conclusion, the swirl sign is a non-contrast CT appearance that refers to the acute extravasation of blood into a hematoma, such as an intracerebral hemorrhage. It is characterized by unclotted fresh blood which is of lower attenuation than the clotted blood surrounding it. The swirl sign has been previously described in epidural hematomas as areas of low attenuation, radiolucency, or irregular density. In a study to describe the swirl sign in ICH, the prevalence of the sign was evaluated, as well as the reliability of subjective evaluation on CT. The study also aimed to explore the prognostic value of the swirl sign in ICH. The results of the study showed that the swirl sign was present in a significant number of patients with ICH and that it was associated with a higher mortality rate. The study also found that the swirl sign was a reliable indicator of the severity of ICH and that it could be used to predict the outcome of patients with ICH.",
    "vicuna-13b_fact_raw": "1. The swirl sign is a non-contrast CT appearance indicating acute extravasation of blood into a hematoma.\n2. The swirl sign is characterized by unclotted fresh blood of lower attenuation than the surrounding clotted blood.\n3. The swirl sign has been described in epidural hematomas as areas of low attenuation, radiolucency, or irregular density.\n4. A study found that the swirl sign was present in a significant number of patients with intracerebral hemorrhage (ICH).\n5. The presence of the swirl sign in patients with ICH was associated with a higher mortality rate.",
    "vicuna-13b_fact": [
      "The swirl sign is a non-contrast CT appearance indicating acute extravasation of blood into a hematoma.",
      "The swirl sign is characterized by unclotted fresh blood of lower attenuation than the surrounding clotted blood.",
      "The swirl sign has been described in epidural hematomas as areas of low attenuation, radiolucency, or irregular density.",
      "A study found that the swirl sign was present in a significant number of patients with intracerebral hemorrhage (ICH).",
      "The presence of the swirl sign in patients with ICH was associated with a higher mortality rate."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe swirl sign is indeed associated with acute blood on a non-contrast CT scan and is characterized by the appearance of lower attenuation fresh blood within a hematoma. It has been described in various types of hematomas, including epidural hematomas. Studies have found that the presence of the swirl sign in patients with intracerebral hemorrhage can be indicative of ongoing bleeding and is associated with worse outcomes, including higher mortality rates.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "vicuna-13b_response": "Based on the given documents, it appears that the expression of Arabidopsis ROF1 is induced by heat stress and is also developmentally regulated. Additionally, it has been shown that ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain and localizes in the cytoplasm under normal conditions. It is also known that the plant co-chaperones FK506-binding proteins (FKBPs) are peptidyl prolyl cis-trans isomerases that function in protein folding, signal transduction and chaperone activity. The documents also mention the characterization of the Arabidopsis large FKBPs ROF1 (AtFKBP62) and ROF2 (AtFKBP65) expression and protein accumulation in response to heat stress.",
    "vicuna-13b_fact_raw": "1. Arabidopsis ROF1 expression is induced by heat stress.\n2. Arabidopsis ROF1 expression is developmentally regulated.\n3. ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.\n4. ROF1 localizes in the cytoplasm under normal conditions.\n5. Arabidopsis large FKBPs ROF1 (AtFKBP62) and ROF2 (AtFKBP65) show changes in expression and protein accumulation in response to heat stress.",
    "vicuna-13b_fact": [
      "Arabidopsis ROF1 expression is induced by heat stress.",
      "Arabidopsis ROF1 expression is developmentally regulated.",
      "ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.",
      "ROF1 localizes in the cytoplasm under normal conditions.",
      "Arabidopsis large FKBPs ROF1 (AtFKBP62) and ROF2 (AtFKBP65) show changes in expression and protein accumulation in response to heat stress."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Arabidopsis ROF1 (AtFKBP62) expression is known to be induced by heat stress, which is a common response in plants to cope with increased temperatures.\n2. TRUE: The expression of Arabidopsis ROF1 is developmentally regulated, as it is with many genes that play a role in plant growth and development.\n3. TRUE: ROF1 (AtFKBP62) has been reported to interact with heat shock proteins such as HSP90.1 through its tetratricopeptide repeat (TPR) domain, which is a common protein-protein interaction motif.\n4. TRUE: Under normal conditions, ROF1 is predominantly localized in the cytoplasm, although it can also be found in the nucleus.\n5. TRUE: Arabidopsis large FKBPs like ROF1 (AtFKBP62) and ROF2 (AtFKBP65) do show changes in expression and protein accumulation in response to heat stress, as part of the cellular response to protect against heat damage.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "vicuna-13b_response": "The most common cause of hereditary renal amyloidosis is Leukocyte cell-derived chemotaxin 2 (LECT2) amyloidosis. It is a recently discovered form of amyloidosis that most often affects the kidneys and liver. Hereditary amyloidosis can be passed down from a parent to a child through rare gene mutations.",
    "vicuna-13b_fact_raw": "1. Leukocyte cell-derived chemotaxin 2 (LECT2) amyloidosis is the most common cause of hereditary renal amyloidosis.\n2. LECT2 amyloidosis often affects the kidneys and liver.\n3. Hereditary amyloidosis is passed down from parent to child through rare gene mutations.",
    "vicuna-13b_fact": [
      "Leukocyte cell-derived chemotaxin 2 (LECT2) amyloidosis is the most common cause of hereditary renal amyloidosis.",
      "LECT2 amyloidosis often affects the kidneys and liver.",
      "Hereditary amyloidosis is passed down from parent to child through rare gene mutations."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Leukocyte cell-derived chemotaxin 2 (LECT2) amyloidosis is not the most common cause of hereditary renal amyloidosis. The most common form of hereditary renal amyloidosis is typically associated with mutations in the genes encoding for transthyretin (ATTR), fibrinogen A alpha-chain (AFib), apolipoprotein AI (AApoAI), and lysozyme (ALys).\n2. TRUE\n3. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "vicuna-13b_response": "Based on the information provided in Document 0 and Document 1, it can be inferred that the proteome of mice hippocampus has been analyzed. In Document 0, the authors state that they analyzed the hippocampal proteome at two ages (5 and 10 months) to reveal the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus. In Document 1, the authors present an in-depth, multiomic characterization of the acute stress response in the mouse HC, which includes the hippocampus. Therefore, it can be inferred that the proteome of mice hippocampus has been analyzed.",
    "vicuna-13b_fact_raw": "1. The proteome of mice hippocampus has been analyzed at two ages, 5 and 10 months, according to Document 0.\n2. Document 0's analysis was conducted to reveal the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus.\n3. Document 1 presents a multiomic characterization of the acute stress response in the mouse HC, which includes the hippocampus.",
    "vicuna-13b_fact": [
      "The proteome of mice hippocampus has been analyzed at two ages, 5 and 10 months, according to Document 0.",
      "Document 0's analysis was conducted to reveal the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus.",
      "Document 1 presents a multiomic characterization of the acute stress response in the mouse HC, which includes the hippocampus."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "vicuna-13b_response": "Answer: Yes, mouse chromosomes are acrocentric. This is supported by Document 0, which states that in mice, all chromosomes are acrocentric, while other mammalian species carry a mixture of acrocentric and metacentric chromosomes. Additionally, Document 1 states that unlike human chromosomes, which are mostly metacentric, all mouse chromosomes are acrocentric.",
    "vicuna-13b_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. Other mammalian species carry a mixture of acrocentric and metacentric chromosomes.\n3. Human chromosomes are mostly metacentric.",
    "vicuna-13b_fact": [
      "Mouse chromosomes are acrocentric.",
      "Other mammalian species carry a mixture of acrocentric and metacentric chromosomes.",
      "Human chromosomes are mostly metacentric."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Human chromosomes are a mixture of metacentric, submetacentric, and acrocentric chromosomes.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "vicuna-13b_response": "Based on the given information, it is not possible to determine which siRNA-based drug is in clinical trials for the treatment of pancreatic cancer. The information provided only mentions several siRNA-loaded nanotherapeutics that have shown partial stabilization in patients, but does not specify which one is in clinical trials for pancreatic cancer treatment. Additionally, the information does not mention any specific siRNA-based drug that is in clinical trials for pancreatic cancer treatment.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "vicuna-13b_response": "The HPG pore is a toolkit for exploring and analyzing nanopore sequencing data. It can run on both individual computers and in the Hadoop distributed computing framework, which allows for easy scale-up to manage large amounts of data that may result from the use of nanopore technologies in the future.",
    "vicuna-13b_fact_raw": "1. The HPG pore is a toolkit designed for exploring and analyzing nanopore sequencing data.\n2. The HPG pore can be operated on individual computers.\n3. The HPG pore is compatible with the Hadoop distributed computing framework.\n4. The HPG pore is designed to scale up for managing large amounts of data.",
    "vicuna-13b_fact": [
      "The HPG pore is a toolkit designed for exploring and analyzing nanopore sequencing data.",
      "The HPG pore can be operated on individual computers.",
      "The HPG pore is compatible with the Hadoop distributed computing framework.",
      "The HPG pore is designed to scale up for managing large amounts of data."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The HPG Pore is not a toolkit; it is a hypothetical protein group pore, which is a concept related to cellular biology and has nothing to do with nanopore sequencing data.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nNote: The statements seem to confuse the HPG Pore with a bioinformatics tool. Without additional context, it's unclear whether there is a tool named \"HPG Pore\" related to nanopore sequencing data. If such a tool exists, statements 2, 3, and 4 could potentially be true, but without specific information about the tool, their accuracy cannot be determined.",
    "vicuna-13b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "vicuna-13b_response": "The 959 Nematode Genomes initiative is a community-led effort to coordinate the sequencing of 959 nematode genomes across the phylum Nematoda. The initiative is tracked through a semantic wiki, which serves as a central hub for information about ongoing and completed sequencing projects. The goal of the initiative is to advance our understanding of nematode biology through the use of whole-organism, systems-level analyses, similar to the approach taken with the successful sequencing of the nematode Caenorhabditis elegans genome.",
    "vicuna-13b_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence 959 nematode genomes.\n2. The initiative covers the phylum Nematoda.\n3. A semantic wiki is used to track the initiative's progress.\n4. The initiative's goal is to improve understanding of nematode biology through systems-level analyses.\n5. The initiative follows a similar approach to the sequencing of the Caenorhabditis elegans genome.",
    "vicuna-13b_fact": [
      "The 959 Nematode Genomes initiative aims to sequence 959 nematode genomes.",
      "The initiative covers the phylum Nematoda.",
      "A semantic wiki is used to track the initiative's progress.",
      "The initiative's goal is to improve understanding of nematode biology through systems-level analyses.",
      "The initiative follows a similar approach to the sequencing of the Caenorhabditis elegans genome."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "vicuna-13b_response": "The R package developed for analyzing Non-invasive prenatal testing (NIPT) data is NIPTeR.",
    "vicuna-13b_fact_raw": "1. An R package called NIPTeR has been developed for analyzing Non-invasive prenatal testing (NIPT) data.",
    "vicuna-13b_fact": [
      "An R package called NIPTeR has been developed for analyzing Non-invasive prenatal testing (NIPT) data."
    ],
    "vicuna-13b_judge_raw": "1. TRUE",
    "vicuna-13b_judge": [
      "true"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "vicuna-13b_response": "Achenbach's syndrome, also known as paroxysmal finger hematoma, is a rare condition characterized by recurrent episodes of painful bruising on the fingers or palm. The condition is not associated with any serious underlying medical conditions. It typically affects middle-aged females, with a median age of onset of 48-50 years (range 22-76). The condition is often underdiagnosed, and patients may experience alarm and anxiety due to the alarming appearance of the blue-purple discoloration on the volar aspect of one or more digits, which is associated with pain and paresthesia.",
    "vicuna-13b_fact_raw": "1. Achenbach's syndrome is characterized by recurrent episodes of painful bruising on the fingers or palm.\n2. Achenbach's syndrome is also known as paroxysmal finger hematoma.\n3. The condition typically affects middle-aged females.\n4. The median age of onset for Achenbach's syndrome is between 48-50 years.\n5. Achenbach's syndrome is not associated with any serious underlying medical conditions.",
    "vicuna-13b_fact": [
      "Achenbach's syndrome is characterized by recurrent episodes of painful bruising on the fingers or palm.",
      "Achenbach's syndrome is also known as paroxysmal finger hematoma.",
      "The condition typically affects middle-aged females.",
      "The median age of onset for Achenbach's syndrome is between 48-50 years.",
      "Achenbach's syndrome is not associated with any serious underlying medical conditions."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "vicuna-13b_response": "The algorithm used for detection of long repeat expansions is not specified in the given information. However, based on the information provided in the documents, it can be inferred that the ExpansionHunter algorithm is commonly used for detecting repeat expansions in humans. ExpansionHunter is a bioinformatic tool that can be used to identify new repeat expansions in humans by analyzing short-read sequencing data. It is capable of accurately detecting known pathogenic repeat expansions and can be used to identify new pathogenic repeat expansions. The software is licensed under GPL v3.0 and the source code is freely available on GitHub.",
    "vicuna-13b_fact_raw": "1. The ExpansionHunter algorithm is commonly used for detecting repeat expansions in humans.\n2. ExpansionHunter is a bioinformatic tool designed to identify new repeat expansions in humans.\n3. ExpansionHunter analyzes short-read sequencing data to detect repeat expansions.\n4. The software can accurately detect known pathogenic repeat expansions.\n5. ExpansionHunter is licensed under GPL v3.0 and its source code is available on GitHub.",
    "vicuna-13b_fact": [
      "The ExpansionHunter algorithm is commonly used for detecting repeat expansions in humans.",
      "ExpansionHunter is a bioinformatic tool designed to identify new repeat expansions in humans.",
      "ExpansionHunter analyzes short-read sequencing data to detect repeat expansions.",
      "The software can accurately detect known pathogenic repeat expansions.",
      "ExpansionHunter is licensed under GPL v3.0 and its source code is available on GitHub."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: ExpansionHunter is not primarily designed to identify new repeat expansions, but rather to detect known repeat expansions in humans.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "vicuna-13b_response": "Based on the given documents, neuroligin-3 promotes the proliferation of glioma cells. Specifically, activity-dependent cleavage and secretion of neuroligin-3 promotes the growth of brain cancer, and soluble NLGN3 was found to be sufficient and necessary to promote robust proliferation of glioma cells. Additionally, neuroligin-3 was found to induce PI3K-mTOR pathway activity and feedforward expression of NLGN3 in glioma cells.",
    "vicuna-13b_fact_raw": "1. Neuroligin-3 promotes the proliferation of glioma cells.\n2. Activity-dependent cleavage and secretion of neuroligin-3 promote the growth of brain cancer.\n3. Soluble neuroligin-3 (NLGN3) is sufficient and necessary to promote the proliferation of glioma cells.\n4. Neuroligin-3 induces PI3K-mTOR pathway activity in glioma cells.\n5. Neuroligin-3 causes feedforward expression of itself in glioma cells.",
    "vicuna-13b_fact": [
      "Neuroligin-3 promotes the proliferation of glioma cells.",
      "Activity-dependent cleavage and secretion of neuroligin-3 promote the growth of brain cancer.",
      "Soluble neuroligin-3 (NLGN3) is sufficient and necessary to promote the proliferation of glioma cells.",
      "Neuroligin-3 induces PI3K-mTOR pathway activity in glioma cells.",
      "Neuroligin-3 causes feedforward expression of itself in glioma cells."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Neuroligin-3 has been shown to promote the proliferation of glioma cells in various studies.\n2. TRUE: Activity-dependent cleavage and secretion of neuroligin-3 have been reported to promote the growth of brain cancer, specifically glioma.\n3. TRUE: Research indicates that soluble neuroligin-3 (NLGN3) is both sufficient and necessary to promote the proliferation of glioma cells, acting as a mitogen.\n4. TRUE: Neuroligin-3 has been implicated in inducing PI3K-mTOR pathway activity in glioma cells, which is a pathway known to be involved in cell growth and proliferation.\n5. UNKNOWN: Without specific evidence or studies to reference, it is unclear whether neuroligin-3 causes feedforward expression of itself in glioma cells. This statement requires more context or specific research to determine its validity.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "vicuna-13b_response": "Based on the information provided in Document 0 and Document 1, the approximate size of gas vesicles is 0.045-0.2 μm wide and 0.1-2 μm long.",
    "vicuna-13b_fact_raw": "1. Gas vesicles are approximately 0.045-0.2 μm wide.\n2. Gas vesicles are approximately 0.1-2 μm long.",
    "vicuna-13b_fact": [
      "Gas vesicles are approximately 0.045-0.2 μm wide.",
      "Gas vesicles are approximately 0.1-2 μm long."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "vicuna-13b_response": "Based on the given information, it can be inferred that the following are BET proteins:\n* BRD2\n* BRD3\n* BRD4\n* BRDT\nThese are the four conserved mammalian members of the BET family of proteins that regulate the expression of many genes involved in various cellular processes such as cell cycle progression, neurogenesis, differentiation, and maturation of erythroids and spermatogenesis. Research-based evidence suggests that BET proteins, mainly BRD4, are associated with various pathological ailments, including cancer, inflammation, infections, and renal disease.",
    "vicuna-13b_fact_raw": "1. BRD2 is a member of the BET family of proteins.\n2. BRD3 is a member of the BET family of proteins.\n3. BRD4 is a member of the BET family of proteins.\n4. BRDT is a member of the BET family of proteins.\n5. BET proteins are associated with various pathological ailments, including cancer, inflammation, infections, and renal disease.",
    "vicuna-13b_fact": [
      "BRD2 is a member of the BET family of proteins.",
      "BRD3 is a member of the BET family of proteins.",
      "BRD4 is a member of the BET family of proteins.",
      "BRDT is a member of the BET family of proteins.",
      "BET proteins are associated with various pathological ailments, including cancer, inflammation, infections, and renal disease."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "vicuna-13b_response": "Based on the information provided, it seems that the algorithm developed for prediction of protein subcellular localization using deep learning is the one presented in Document 0, which uses deep neural networks to predict protein subcellular localization relying only on sequence information. However, it is also mentioned in Document 1 that the authors propose a deep learning based predictor called DeepPSL, which uses Stacked Auto-Encoder (SAE) networks to accurately predict protein subcellular locations. So, both of these documents seem to be related to the development of algorithms for prediction of protein subcellular localization using deep learning.",
    "vicuna-13b_fact_raw": "1. An algorithm for prediction of protein subcellular localization using deep learning has been developed as presented in Document 0.\n2. The algorithm in Document 0 uses deep neural networks to predict protein subcellular localization based on sequence information.\n3. Document 1 proposes a deep learning based predictor called DeepPSL.\n4. DeepPSL uses Stacked Auto-Encoder (SAE) networks to predict protein subcellular locations.",
    "vicuna-13b_fact": [
      "An algorithm for prediction of protein subcellular localization using deep learning has been developed as presented in Document 0.",
      "The algorithm in Document 0 uses deep neural networks to predict protein subcellular localization based on sequence information.",
      "Document 1 proposes a deep learning based predictor called DeepPSL.",
      "DeepPSL uses Stacked Auto-Encoder (SAE) networks to predict protein subcellular locations."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout access to the actual content of \"Document 0\" and \"Document 1,\" it is impossible to verify the accuracy of these statements.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "vicuna-13b_response": "MULTOVL is a software application suite that is used to detect and statistically analyze multiple overlaps of genomic regions. It is designed to be fast and efficient, and it supports the detection of multiple region intersections, unions, and \"solitary\" genomic regions. The software is useful for analyzing genomic data and identifying patterns or trends in the overlaps of genomic regions. It is likely used by researchers in the field of genomics and bioinformatics.",
    "vicuna-13b_fact_raw": "1. MULTOVL is a software application suite used for detecting and analyzing multiple overlaps of genomic regions.\n2. MULTOVL is designed to be fast and efficient.\n3. The software supports the detection of multiple region intersections, unions, and \"solitary\" genomic regions.\n4. MULTOVL is used for analyzing genomic data.\n5. The software is likely used by researchers in the field of genomics and bioinformatics.",
    "vicuna-13b_fact": [
      "MULTOVL is a software application suite used for detecting and analyzing multiple overlaps of genomic regions.",
      "MULTOVL is designed to be fast and efficient.",
      "The software supports the detection of multiple region intersections, unions, and \"solitary\" genomic regions.",
      "MULTOVL is used for analyzing genomic data.",
      "The software is likely used by researchers in the field of genomics and bioinformatics."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "vicuna-13b_response": "Based on the information provided, it appears that GDF15 may be a potential biomarker for metformin treatment. Document 0 states that GDF15 is expressed in multiple cell types and can be increased by cellular stressors, including hypoxia, mitochondrial dysfunction, metformin, and endurance exercise. Additionally, Document 1 suggests that evidence has emerged in the past 6 years that the weight-lowering effects of metformin might involve GDF15, a stress-responsive hormone that signals through the activin receptor-like kinase 5 (ALK5) receptor. However, further research is needed to confirm the role of GDF15 as a biomarker for metformin treatment.",
    "vicuna-13b_fact_raw": "1. GDF15 is expressed in multiple cell types.\n2. GDF15 can be increased by cellular stressors such as hypoxia, mitochondrial dysfunction, metformin, and endurance exercise.\n3. Evidence suggests that the weight-lowering effects of metformin might involve GDF15.\n4. GDF15 is a stress-responsive hormone that signals through the activin receptor-like kinase 5 (ALK5) receptor.\n5. Further research is needed to confirm the role of GDF15 as a biomarker for metformin treatment.",
    "vicuna-13b_fact": [
      "GDF15 is expressed in multiple cell types.",
      "GDF15 can be increased by cellular stressors such as hypoxia, mitochondrial dysfunction, metformin, and endurance exercise.",
      "Evidence suggests that the weight-lowering effects of metformin might involve GDF15.",
      "GDF15 is a stress-responsive hormone that signals through the activin receptor-like kinase 5 (ALK5) receptor.",
      "Further research is needed to confirm the role of GDF15 as a biomarker for metformin treatment."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GDF15 is a stress-responsive hormone that signals through the GDNF family receptor alpha-like (GFRAL) receptor.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "vicuna-13b_response": "Based on the information provided, it is not clear whether recursive splicing is more common in short introns or not. Document 0 mentions that recursive splicing often involves non-canonical splicing elements positioned deep within introns, but does not provide any information about the length of the introns involved. Document 1 mentions that eukaryotic genomes have evolved to host genes carrying multiple exons separated by increasingly larger intronic sequences, but does not provide any information about the frequency or distribution of recursive splicing in these intronic sequences.\nWithout further information, it is not possible to determine whether recursive splicing is more common in short introns or not.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "vicuna-13b_response": "The TALE-iD method is used for genome editing. It is a type of genome editing technology that uses TALE nucleases, activators, transposases, recombinases, epigenomic modifiers, and base editors to make precise changes to the genome. TALENs (Transcription Activator-Like Effector Nucleases) were the first easy-to-use genome editing technology and sparked the genome editing revolution. The TALE-iD method involves the design of TALENs for specific genome editing applications. The Cys 2-His 2 zinc-finger domain is a type of DNA-binding motif found in eukaryotes that is commonly used in the TALE-iD method for genome editing.",
    "vicuna-13b_fact_raw": "1. The TALE-iD method is used for genome editing.\n2. TALE nucleases, activators, transposases, recombinases, epigenomic modifiers, and base editors are used in the TALE-iD method.\n3. TALENs (Transcription Activator-Like Effector Nucleases) were the first easy-to-use genome editing technology.\n4. The TALE-iD method involves designing TALENs for specific genome editing applications.\n5. The Cys 2-His 2 zinc-finger domain, a type of DNA-binding motif found in eukaryotes, is commonly used in the TALE-iD method.",
    "vicuna-13b_fact": [
      "The TALE-iD method is used for genome editing.",
      "TALE nucleases, activators, transposases, recombinases, epigenomic modifiers, and base editors are used in the TALE-iD method.",
      "TALENs (Transcription Activator-Like Effector Nucleases) were the first easy-to-use genome editing technology.",
      "The TALE-iD method involves designing TALENs for specific genome editing applications.",
      "The Cys 2-His 2 zinc-finger domain, a type of DNA-binding motif found in eukaryotes, is commonly used in the TALE-iD method."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ZFNs (Zinc Finger Nucleases) were among the first easy-to-use genome editing technologies before TALENs.\n4. TRUE\n5. FALSE [correction]: The TALE-iD method typically uses TALE (Transcription Activator-Like Effector) domains for DNA binding, not Cys2-His2 zinc-finger domains.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "vicuna-13b_response": "Based on the information provided in the documents, FunImageJ is a Lisp framework for scientific image processing built upon the ImageJ software ecosystem. It provides a natural functional-style for programming, while accounting for the performance requirements necessary in big data processing commonly encountered in biological image analysis. The framework is available and its implementation is based on the ImageJ software ecosystem.",
    "vicuna-13b_fact_raw": "1. FunImageJ is a Lisp framework for scientific image processing.\n2. FunImageJ is built upon the ImageJ software ecosystem.\n3. FunImageJ is designed with a functional programming style.\n4. FunImageJ is used for big data processing in biological image analysis.\n5. The implementation of FunImageJ is based on the ImageJ software ecosystem.",
    "vicuna-13b_fact": [
      "FunImageJ is a Lisp framework for scientific image processing.",
      "FunImageJ is built upon the ImageJ software ecosystem.",
      "FunImageJ is designed with a functional programming style.",
      "FunImageJ is used for big data processing in biological image analysis.",
      "The implementation of FunImageJ is based on the ImageJ software ecosystem."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "vicuna-13b_response": "Based on the information provided in Document 0 and Document 1, it is stated that many duplicate genes have been found in Saccharomyces cerevisiae and that a total of 1,625,809 high-quality reference-based SNPs were detected across the 1,011 genomes. However, it is not explicitly stated in the documents how many of these genes are the result of an ancient whole genome duplication.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "vicuna-13b_response": "Based on the information provided, it is not clear which complex is bound by estrogen-related receptor β (Esrrb). The first document mentions that genetic inactivation of Esrrb leads to illegitimate expression of mesendoderm and extra-embryonic markers, impaired formative expression and failure to self-organize in 3D. It also states that functionally, this leads to impaired embryonic development. The second document mentions that estrogen-related receptors (ERRs) are founding members of the orphan nuclear receptor (ONR) subgroup of the nuclear receptor superfamily, and that ERRα (ESRRA) and ERRγ (ESRRG) have been firmly placed at the intersection of cellular metabolism and oncogenesis. However, it does not mention which complex Esrrb is bound to.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "vicuna-13b_response": "Based on the given information, there is no direct mention of the role of ZCCHC17 in the context of hepatocellular carcinoma (HCC). However, it is mentioned that ZCCHC17 acts as a negative regulator of rDNA transcription. It is also stated that ZCCHC20/SRSF7 is also an RBP and it regulates trans-splicing.",
    "vicuna-13b_fact_raw": "1. ZCCHC17 acts as a negative regulator of rDNA transcription.\n2. ZCCHC20/SRSF7 is an RBP (RNA-binding protein).\n3. ZCCHC20/SRSF7 regulates trans-splicing.",
    "vicuna-13b_fact": [
      "ZCCHC17 acts as a negative regulator of rDNA transcription.",
      "ZCCHC20/SRSF7 is an RBP (RNA-binding protein).",
      "ZCCHC20/SRSF7 regulates trans-splicing."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n\nThe statements provided are very specific and pertain to molecular biology. Without the specific context or access to the relevant scientific literature, it is not possible to accurately verify the claims about ZCCHC17 and ZCCHC20/SRSF7. However, SRSF7 is known to be an RNA-binding protein (RBP), so the second statement is true. The other statements would require specific knowledge or research to confirm.",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "vicuna-13b_response": "Based on the provided documents, the proteins that form the nuclear pore basket in human cells are not explicitly stated. However, Document 0 suggests that proteins related to nuclear division and tRNA ligases are preferentially cargoes of TNPO1, while proteins related to DNA repair and HMG proteins are not. Additionally, Document 1 mentions that the nuclear pore complex (NPC) serves as the sole bidirectional gateway of macromolecules in and out of the nucleus, but does not specify which proteins form the nuclear pore basket.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "vicuna-13b_response": "Based on the given information, it can be inferred that gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic with a unique mechanism of action that is not anticipated to have the same risks to bone growth as those of fluoroquinolones. Additionally, it is known that the Novel Bacterial Topoisomerase Inhibitors (NBTIs) bind to a different site to that of the fluoroquinolones with a novel mechanism of action to evade the existing target-mediated bacterial resistance associated with fluoroquinolones. Therefore, it can be concluded that gepotidacin is a topoisomerase inhibitor that belongs to the Novel Bacterial Topoisomerase Inhibitors (NBTIs) class of antibiotics.",
    "vicuna-13b_fact_raw": "1. Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic.\n2. Gepotidacin has a unique mechanism of action.\n3. Gepotidacin is not anticipated to have the same risks to bone growth as fluoroquinolones.\n4. Novel Bacterial Topoisomerase Inhibitors (NBTIs), including gepotidacin, bind to a different site than fluoroquinolones.\n5. Gepotidacin is designed to evade the existing target-mediated bacterial resistance associated with fluoroquinolones.",
    "vicuna-13b_fact": [
      "Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic.",
      "Gepotidacin has a unique mechanism of action.",
      "Gepotidacin is not anticipated to have the same risks to bone growth as fluoroquinolones.",
      "Novel Bacterial Topoisomerase Inhibitors (NBTIs), including gepotidacin, bind to a different site than fluoroquinolones.",
      "Gepotidacin is designed to evade the existing target-mediated bacterial resistance associated with fluoroquinolones."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGepotidacin is indeed a novel antibiotic with a unique mechanism of action, and it is designed to avoid the resistance mechanisms that affect fluoroquinolones. It is also anticipated to have a different risk profile regarding bone growth compared to fluoroquinolones, and as an NBTI, it binds to a different site than fluoroquinolones.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "vicuna-13b_response": "Canvas SPW is a tool for the identification of copy number changes from diverse sequencing experiments, including whole-genome matched tumor-normal, small pedigree, and single-sample normal resequencing, as well as whole-exome matched and unmatched tumor-normal studies. It provides a wide range of scoring and filtering options to automate and streamline the identification of de novo variants. Canvas SPW is available for download from <https://github.com/Illumina/canvas>. For more information, please contact sivakhno@illumina.com.",
    "vicuna-13b_fact_raw": "1. Canvas SPW is a tool used for identifying copy number changes from various sequencing experiments.\n2. It supports sequencing experiments including whole-genome matched tumor-normal, small pedigree, single-sample normal resequencing, and whole-exome matched and unmatched tumor-normal studies.\n3. Canvas SPW offers scoring and filtering options to automate the identification of de novo variants.\n4. Canvas SPW can be downloaded from the website https://github.com/Illumina/canvas.\n5. For more information about Canvas SPW, contact can be made via the email sivakhno@illumina.com.",
    "vicuna-13b_fact": [
      "Canvas SPW is a tool used for identifying copy number changes from various sequencing experiments.",
      "It supports sequencing experiments including whole-genome matched tumor-normal, small pedigree, single-sample normal resequencing, and whole-exome matched and unmatched tumor-normal studies.",
      "Canvas SPW offers scoring and filtering options to automate the identification of de novo variants.",
      "Canvas SPW can be downloaded from the website https://github.com/Illumina/canvas.",
      "For more information about Canvas SPW, contact can be made via the email sivakhno@illumina.com."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Canvas SPW is used for identifying copy number changes, not specifically for automating the identification of de novo variants.\n4. TRUE\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "vicuna-13b_response": "Answer: SHR1032 is a novel STING agonist that has been shown to stimulate anti-tumor immunity and directly induce apoptosis in acute myeloid leukemia (AML) cells. It is a potential cancer immunotherapy treatment that could be used to target cancer cells that have a low pre-existence of anti-tumor immunity.",
    "vicuna-13b_fact_raw": "1. SHR1032 is a STING agonist.\n2. SHR1032 has been shown to stimulate anti-tumor immunity.\n3. SHR1032 can directly induce apoptosis in acute myeloid leukemia (AML) cells.\n4. SHR1032 is considered a potential cancer immunotherapy treatment.",
    "vicuna-13b_fact": [
      "SHR1032 is a STING agonist.",
      "SHR1032 has been shown to stimulate anti-tumor immunity.",
      "SHR1032 can directly induce apoptosis in acute myeloid leukemia (AML) cells.",
      "SHR1032 is considered a potential cancer immunotherapy treatment."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "vicuna-13b_response": "SLIC-CAGE (System for Long-read Information from Cells by High-throughput CAGE) is a method for generating high-quality, complex libraries for genome-wide promoterome analysis. The SLIC-CAGE method was developed to generate data with 1000-fold less material than is required by existing CAGE (Cap Analysis of Gene Expression) methods. The method was demonstrated by generating a complex, high-quality library from mouse embryonic day 11.5 primordial germ cells. The study was published in Cold Spring Harbor Laboratory Press in 2018 by Cvetesic et al.\nThe RNA-seq protocols are widely used to profile different aspects of the transcriptome, from strand-specific coverage of gene bodies to selective amplification of RNA 5′ ends. These protocols have been developed to provide a comprehensive understanding of the transcriptome, including information on gene expression, alternative splicing, and promoter usage. The SLIC-CAGE method provides a valuable tool for studying the promoterome, as it allows for the generation of high-quality libraries with reduced sample amounts. This can be particularly useful for studying rare cell types or samples with limited material.",
    "vicuna-13b_fact_raw": "1. SLIC-CAGE stands for System for Long-read Information from Cells by High-throughput CAGE.\n2. SLIC-CAGE is a method used for genome-wide promoterome analysis.\n3. The SLIC-CAGE method requires 1000-fold less material than traditional CAGE methods.\n4. A complex, high-quality library from mouse embryonic day 11.5 primordial germ cells was generated using SLIC-CAGE.\n5. The study on SLIC-CAGE was published by Cvetesic et al. in Cold Spring Harbor Laboratory Press in 2018.",
    "vicuna-13b_fact": [
      "SLIC-CAGE stands for System for Long-read Information from Cells by High-throughput CAGE.",
      "SLIC-CAGE is a method used for genome-wide promoterome analysis.",
      "The SLIC-CAGE method requires 1000-fold less material than traditional CAGE methods.",
      "A complex, high-quality library from mouse embryonic day 11.5 primordial germ cells was generated using SLIC-CAGE.",
      "The study on SLIC-CAGE was published by Cvetesic et al. in Cold Spring Harbor Laboratory Press in 2018."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: SLIC-CAGE stands for Single-cell Long-read Information from CAGE.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The study on SLIC-CAGE was published by Cvetesic et al. in Nature Communications in 2018.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "vicuna-13b_response": "Based on the given documents, the role of LEM-3 is related to the regulation of meiotic recombination repair and chromosome segregation in Caenorhabditis elegans. Specifically, LEM-3 is involved in processing chromatin bridges that arise from incomplete DNA replication, unresolved recombination intermediates, or the perturbance of chromosome structure. Additionally, LEM-3/Ankle1 nuclease is a conserved protein that plays a crucial role in the regulation of meiotic recombination repair and chromosome segregation in this organism.",
    "vicuna-13b_fact_raw": "1. LEM-3 is involved in the regulation of meiotic recombination repair in Caenorhabditis elegans.\n2. LEM-3 plays a role in chromosome segregation in Caenorhabditis elegans.\n3. LEM-3 is involved in processing chromatin bridges that can arise from incomplete DNA replication.\n4. LEM-3 processes chromatin bridges that can result from unresolved recombination intermediates.\n5. LEM-3/Ankle1 nuclease is a conserved protein that is crucial for meiotic recombination repair and chromosome segregation in Caenorhabditis elegans.",
    "vicuna-13b_fact": [
      "LEM-3 is involved in the regulation of meiotic recombination repair in Caenorhabditis elegans.",
      "LEM-3 plays a role in chromosome segregation in Caenorhabditis elegans.",
      "LEM-3 is involved in processing chromatin bridges that can arise from incomplete DNA replication.",
      "LEM-3 processes chromatin bridges that can result from unresolved recombination intermediates.",
      "LEM-3/Ankle1 nuclease is a conserved protein that is crucial for meiotic recombination repair and chromosome segregation in Caenorhabditis elegans."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: LEM-3 is indeed involved in the regulation of meiotic recombination repair in Caenorhabditis elegans.\n2. TRUE: LEM-3 plays a role in chromosome segregation in Caenorhabditis elegans.\n3. TRUE: LEM-3 is involved in processing chromatin bridges that can arise from incomplete DNA replication.\n4. TRUE: LEM-3 processes chromatin bridges that can result from unresolved recombination intermediates.\n5. TRUE: LEM-3/Ankle1 nuclease is a conserved protein that is crucial for meiotic recombination repair and chromosome segregation in Caenorhabditis elegans.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "vicuna-13b_response": "Based on the given information, it appears that there have been multiple releases of the tmVar tool. The most recent release is tmVar 3.0, which provides advanced variant normalization options and has demonstrated state-of-the-art performance in variant recognition and normalization, with over 90% in F-measure on three independent benchmarking datasets.\nAdditionally, the Java code for tmVar 2.0 is publicly available, and it was also a part of PubTator Central, a web-based system for automatic annotation of biomedical concepts in PubMed and PMC articles. However, it is not specified whether tmVar 2.0 is still actively maintained or if it has been superseded by newer versions.",
    "vicuna-13b_fact_raw": "1. tmVar 3.0 is the most recent release of the tmVar tool.\n2. tmVar 3.0 provides advanced variant normalization options.\n3. tmVar 3.0 has achieved over 90% in F-measure on three independent benchmarking datasets.\n4. The Java code for tmVar 2.0 is publicly available.\n5. tmVar 2.0 was a part of PubTator Central, a system for automatic annotation of biomedical concepts in PubMed and PMC articles.",
    "vicuna-13b_fact": [
      "tmVar 3.0 is the most recent release of the tmVar tool.",
      "tmVar 3.0 provides advanced variant normalization options.",
      "tmVar 3.0 has achieved over 90% in F-measure on three independent benchmarking datasets.",
      "The Java code for tmVar 2.0 is publicly available.",
      "tmVar 2.0 was a part of PubTator Central, a system for automatic annotation of biomedical concepts in PubMed and PMC articles."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: Without current information on the version history of the tmVar tool, it is not possible to confirm whether tmVar 3.0 is the most recent release.\n2. UNKNOWN: The specific features of tmVar 3.0, such as advanced variant normalization options, cannot be confirmed without additional information.\n3. UNKNOWN: The performance metrics such as the F-measure of tmVar 3.0 on benchmarking datasets cannot be verified without access to relevant studies or benchmarking results.\n4. UNKNOWN: The availability of the Java code for tmVar 2.0 is not something that can be confirmed without checking the appropriate repositories or sources where the code would be published.\n5. UNKNOWN: The association of tmVar 2.0 with PubTator Central requires specific knowledge about the tool's integration with the system, which cannot be confirmed without additional information.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "vicuna-13b_response": "The database of somatic mutations in normal cells is DSMNC (Document 0 and 1). It is a collection of somatic mutations in individual normal cells that allows for the analysis of burdens and signatures of somatic mutations in various types of heterogeneous normal cells.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "vicuna-13b_response": "Yes, there are graph kernel libraries implemented in Java that are available for use. One such library is the graphkernels package, which can be used to compute graph kernels. To use this library, you need to include the header file \"graphKernels.h\" in your program and have the Eigen and igraph libraries installed. The main function of the library, \"graphKernelMatrix,\" takes in a vector of input graphs, a vector of parameters, the name of the kernel, and a MatrixXd to store the kernel matrix. The package also provides a tutorial for basic usage and an example script for computing graph kernels on a benchmark dataset. It is requested that you cite the work of the graphkernels package if you use it in your projects.",
    "vicuna-13b_fact_raw": "1. The graphkernels package is a graph kernel library implemented in Java.\n2. The graphkernels package requires the inclusion of the header file \"graphKernels.h\" in the user's program.\n3. The Eigen and igraph libraries must be installed to use the graphkernels package.\n4. The \"graphKernelMatrix\" function of the graphkernels package requires a vector of input graphs, a vector of parameters, the name of the kernel, and a MatrixXd to store the kernel matrix.\n5. The graphkernels package provides a tutorial and an example script for computing graph kernels.",
    "vicuna-13b_fact": [
      "The graphkernels package is a graph kernel library implemented in Java.",
      "The graphkernels package requires the inclusion of the header file \"graphKernels.h\" in the user's program.",
      "The Eigen and igraph libraries must be installed to use the graphkernels package.",
      "The \"graphKernelMatrix\" function of the graphkernels package requires a vector of input graphs, a vector of parameters, the name of the kernel, and a MatrixXd to store the kernel matrix.",
      "The graphkernels package provides a tutorial and an example script for computing graph kernels."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The graphkernels package is a graph kernel library implemented in Python, not Java.\n2. FALSE [correction]: The inclusion of a header file \"graphKernels.h\" would be indicative of a C or C++ library, not a Python package like graphkernels.\n3. TRUE: The graphkernels package indeed requires the Eigen library for linear algebra operations and the igraph library for graph manipulation and analysis.\n4. UNKNOWN: Without specific documentation or source code, it is not possible to confirm the exact signature of the \"graphKernelMatrix\" function in the graphkernels package.\n5. TRUE: It is common for packages like graphkernels to provide tutorials and example scripts to help users understand how to compute graph kernels using the library.",
    "vicuna-13b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "vicuna-13b_response": "The four advances integrated into the SHERLOCKv2 platform are:\n1. 4-channel single reaction multiplexing using orthogonal CRISPR enzymes.\n2. Quantitative measurement of input down to 2 aM.\n3. 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxiliary CRISPR-associated protein.\n4. Improved specificity and sensitivity of RNA detection through the use of a novel RNA detection system.",
    "vicuna-13b_fact_raw": "1. SHERLOCKv2 platform integrates 4-channel single reaction multiplexing using orthogonal CRISPR enzymes.\n2. SHERLOCKv2 platform can quantitatively measure input down to 2 attomolar (aM).\n3. The platform achieves a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6.\n4. SHERLOCKv2 platform has improved specificity and sensitivity of RNA detection through a novel RNA detection system.",
    "vicuna-13b_fact": [
      "SHERLOCKv2 platform integrates 4-channel single reaction multiplexing using orthogonal CRISPR enzymes.",
      "SHERLOCKv2 platform can quantitatively measure input down to 2 attomolar (aM).",
      "The platform achieves a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6.",
      "SHERLOCKv2 platform has improved specificity and sensitivity of RNA detection through a novel RNA detection system."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe statements provided are consistent with the advancements made in the SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) technology, particularly in its version 2 (v2). The SHERLOCKv2 platform is known for integrating multiple CRISPR enzymes for enhanced multiplexing capabilities, achieving attomolar sensitivity, and improving signal sensitivity through the combination of Cas13 with other enzymes like Csm6. It also aims to improve specificity and sensitivity for RNA detection. Without specific contradictory information, these statements are assumed to be accurate descriptions of the SHERLOCKv2 platform's capabilities.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "vicuna-13b_response": "The Bartender algorithm is a clustering algorithm designed for counting high-complexity deeply sequenced barcode reads. It is known for its accuracy and speed, which is comparable to other existing algorithms. The accuracy of Bartender is due to its new statistical test schema that utilizes both nucleotide sequence and cluster size information to prevent over-clustering. The algorithm is fast and efficient, making it a popular choice in the field of bioinformatics. The Bartender algorithm has been published in the journal Bioinformatics and given the DOI number 10.1093/bioinformatics/btx655. The authors of the paper are Lu Zhao, Zhimin Liu, Sasha F Levy, and Song Wu.",
    "vicuna-13b_fact_raw": "1. The Bartender algorithm is designed for counting high-complexity deeply sequenced barcode reads.\n2. The Bartender algorithm is known for its accuracy and speed.\n3. The algorithm uses a new statistical test schema that utilizes both nucleotide sequence and cluster size information.\n4. The Bartender algorithm is used in the field of bioinformatics.\n5. The Bartender algorithm has been published in the journal Bioinformatics with the DOI number 10.1093/bioinformatics/btx655.",
    "vicuna-13b_fact": [
      "The Bartender algorithm is designed for counting high-complexity deeply sequenced barcode reads.",
      "The Bartender algorithm is known for its accuracy and speed.",
      "The algorithm uses a new statistical test schema that utilizes both nucleotide sequence and cluster size information.",
      "The Bartender algorithm is used in the field of bioinformatics.",
      "The Bartender algorithm has been published in the journal Bioinformatics with the DOI number 10.1093/bioinformatics/btx655."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "vicuna-13b_response": "Answer:\nThere are several web-based pedigree editors available, but one of the most popular options is Pedigreejs. This editor provides an easily configurable, extensible, and lightweight solution for creating and editing pedigree charts. It uses an open-source Javascript library to define a hierarchical layout and produce images in scalable vector graphics (SVG) format that can be viewed and edited in web browsers. While there are several standalone graphical pedigree editors and drawing applications available, there are currently no freely available lightweight graphical pedigree editors that can be easily configured and incorporated into web applications.",
    "vicuna-13b_fact_raw": "1. Pedigreejs is a popular web-based pedigree editor.\n2. Pedigreejs provides a configurable and extensible solution for creating and editing pedigree charts.\n3. Pedigreejs uses an open-source Javascript library.\n4. Pedigreejs produces images in scalable vector graphics (SVG) format.\n5. Pedigreejs can be viewed and edited in web browsers.",
    "vicuna-13b_fact": [
      "Pedigreejs is a popular web-based pedigree editor.",
      "Pedigreejs provides a configurable and extensible solution for creating and editing pedigree charts.",
      "Pedigreejs uses an open-source Javascript library.",
      "Pedigreejs produces images in scalable vector graphics (SVG) format.",
      "Pedigreejs can be viewed and edited in web browsers."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "vicuna-13b_response": "Answer: ArachnoServer (<www.arachnoserver.org>) is a manually curated database that provides information on the sequence, structure, and biological activity of protein toxins from spider venoms. It is a valuable resource for researchers in various fields, including medicine, neuroscience, pharmacology, drug discovery, and agriculture. ArachnoServer features a new molecular target ontology designed specifically for venom toxins, up-to-date taxonomic information, and a powerful advanced search interface.",
    "vicuna-13b_fact_raw": "1. ArachnoServer is a manually curated database for spider-venom toxins.\n2. ArachnoServer provides information on the sequence, structure, and biological activity of protein toxins from spider venoms.\n3. ArachnoServer serves researchers in fields such as medicine, neuroscience, pharmacology, drug discovery, and agriculture.\n4. The database includes a molecular target ontology designed specifically for venom toxins.\n5. ArachnoServer offers up-to-date taxonomic information and an advanced search interface.",
    "vicuna-13b_fact": [
      "ArachnoServer is a manually curated database for spider-venom toxins.",
      "ArachnoServer provides information on the sequence, structure, and biological activity of protein toxins from spider venoms.",
      "ArachnoServer serves researchers in fields such as medicine, neuroscience, pharmacology, drug discovery, and agriculture.",
      "The database includes a molecular target ontology designed specifically for venom toxins.",
      "ArachnoServer offers up-to-date taxonomic information and an advanced search interface."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "vicuna-13b_response": "Based on the given documents, it can be inferred that Axitinib may not necessarily prolong survival of Pancreatic Cancer patients. While surgical resection and systemic chemotherapy are considered the best treatment options for localized PDAC, most patients eventually relapse, even after a potential radical treatment. The 5-year survival rate for PDAC is only 2%-9%.\nWhile Axitinib is a targeted therapy used in the treatment of various types of cancer, including pancreatic cancer, its effectiveness in prolonging survival of pancreatic cancer patients is not explicitly stated in the given documents. Further research and clinical trials are needed to determine the potential benefits of Axitinib in the treatment of pancreatic cancer.",
    "vicuna-13b_fact_raw": "1. Axitinib is used in the treatment of various types of cancer, including pancreatic cancer.\n2. Surgical resection and systemic chemotherapy are considered the best treatment options for localized pancreatic ductal adenocarcinoma (PDAC).\n3. Most patients with PDAC eventually relapse, even after potential radical treatment.\n4. The 5-year survival rate for PDAC is only 2%-9%.\n5. The effectiveness of Axitinib in prolonging survival of pancreatic cancer patients is not explicitly stated in the given documents.",
    "vicuna-13b_fact": [
      "Axitinib is used in the treatment of various types of cancer, including pancreatic cancer.",
      "Surgical resection and systemic chemotherapy are considered the best treatment options for localized pancreatic ductal adenocarcinoma (PDAC).",
      "Most patients with PDAC eventually relapse, even after potential radical treatment.",
      "The 5-year survival rate for PDAC is only 2%-9%.",
      "The effectiveness of Axitinib in prolonging survival of pancreatic cancer patients is not explicitly stated in the given documents."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Axitinib is used in the treatment of advanced renal cell carcinoma and not typically for pancreatic cancer.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "vicuna-13b_response": "Based on the given documents, it is not directly mentioned how MLP specifically regulates F-actin dynamics. Document 0 discusses the interplay between actin-binding proteins and how the actin-regulatory machinery responds to regulate force production, but does not mention MLP specifically. Document 1 discusses the regulation of protein homeostasis, including mRNA transcription, degradation, and localization, but also does not mention MLP specifically. Without further information or context, it is difficult to provide a specific answer to this question.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "vicuna-13b_response": "Based on the information provided in Document 0, there are 518 protein kinases in the human kinome, which is approximately 1.7% of all human genes. Additionally, Document 1 states that there are 518 protein kinases in the human kinome. Therefore, there are 518 pseudokinases in the human kinome.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "vicuna-13b_response": "Answers:\n1. Apolipoprotein E (apoE) mimetics.\n2. Other important and well-studied peptide mimetics include those based on apolipoprotein A-I (apoA-I) and apolipoprotein C-II (apoC-II).\n3. The protein components of lipoprotein particles include apoA-I, apoA-II, apoA-IV, apoC-I, apoC-II, apoC-III, apoJ, and apoE.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "vicuna-13b_response": "Answer: Based on the two documents, it can be inferred that there are sex differences in SAMHD1 activity. Specifically, SAMHD1 exhibits increased activity in macrophages from female donors compared to males, which correlates with the lower infectivity of HIV-1 in female-derived macrophages. Additionally, the depletion of SAMHD1 abrogates the sex-dependent differences in viral restriction imposed by SAMHD1, suggesting that it is an essential modulator of infectivity in a sex-dependent manner in macrophages. These findings suggest that SAMHD1 is a novel component of sex differences in innate immune control of HIV-1.",
    "vicuna-13b_fact_raw": "1. SAMHD1 exhibits increased activity in macrophages from female donors compared to males.\n2. There is a correlation between the increased activity of SAMHD1 in female-derived macrophages and the lower infectivity of HIV-1 in these cells.\n3. The depletion of SAMHD1 removes the sex-dependent differences in viral restriction.\n4. SAMHD1 is suggested to be an essential modulator of infectivity in a sex-dependent manner in macrophages.\n5. SAMHD1 is considered a novel component of sex differences in innate immune control of HIV-1.",
    "vicuna-13b_fact": [
      "SAMHD1 exhibits increased activity in macrophages from female donors compared to males.",
      "There is a correlation between the increased activity of SAMHD1 in female-derived macrophages and the lower infectivity of HIV-1 in these cells.",
      "The depletion of SAMHD1 removes the sex-dependent differences in viral restriction.",
      "SAMHD1 is suggested to be an essential modulator of infectivity in a sex-dependent manner in macrophages.",
      "SAMHD1 is considered a novel component of sex differences in innate immune control of HIV-1."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific scientific claims that would require access to the relevant research or scientific literature to verify. Without the specific context or data from the studies that investigated the role of SAMHD1 in macrophages and its relationship to HIV-1 infectivity, it is not possible to determine the truthfulness of these statements.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "vicuna-13b_response": "Based on the information provided in Document 0, NFIA and ATF3 are transcription factors that promote astrocyte differentiation from neural precursor cells, while RUNX2 promotes astrocyte maturation.\nHowever, the information in Document 1 suggests that RUNX2 is a master transcription factor of osteoblast differentiation, and its expression is associated with the bone and osteogenic front of a suture. There is no direct mention of RUNX2 inhibiting astrocyte differentiation in this document.\nTherefore, based on the available information, it is unclear whether RUNX2 inhibits astrocyte differentiation or not. Further research and experiments may be necessary to determine this.",
    "vicuna-13b_fact_raw": "1. NFIA and ATF3 are transcription factors that promote astrocyte differentiation from neural precursor cells.\n2. RUNX2 promotes astrocyte maturation.\n3. RUNX2 is a master transcription factor of osteoblast differentiation.\n4. RUNX2 expression is associated with bone and the osteogenic front of a suture.\n5. There is no direct mention of RUNX2 inhibiting astrocyte differentiation in the provided document.",
    "vicuna-13b_fact": [
      "NFIA and ATF3 are transcription factors that promote astrocyte differentiation from neural precursor cells.",
      "RUNX2 promotes astrocyte maturation.",
      "RUNX2 is a master transcription factor of osteoblast differentiation.",
      "RUNX2 expression is associated with bone and the osteogenic front of a suture.",
      "There is no direct mention of RUNX2 inhibiting astrocyte differentiation in the provided document."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: RUNX2 does not promote astrocyte maturation; it is involved in osteoblast differentiation.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "vicuna-13b_response": "The Cobb-Stainsby excision arthroplasty is a surgical procedure performed to treat dislocated metatarsophalangeal joints from clawed or hammer toes. The procedure involves partial phalangectomy (removal of a portion of the toe bone) and extensor tendon transfer to the metatarsal head. The procedure is named after the two surgeons who developed the technique, Cobb and Stainsby. The procedure aims to relieve the pain and restore the function of the affected joint.",
    "vicuna-13b_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is performed to treat dislocated metatarsophalangeal joints.\n2. The procedure is used for conditions such as clawed or hammer toes.\n3. It involves partial phalangectomy, which is the removal of a portion of the toe bone.\n4. The procedure also includes extensor tendon transfer to the metatarsal head.\n5. The Cobb-Stainsby excision arthroplasty is named after the surgeons Cobb and Stainsby who developed the technique.",
    "vicuna-13b_fact": [
      "The Cobb-Stainsby excision arthroplasty is performed to treat dislocated metatarsophalangeal joints.",
      "The procedure is used for conditions such as clawed or hammer toes.",
      "It involves partial phalangectomy, which is the removal of a portion of the toe bone.",
      "The procedure also includes extensor tendon transfer to the metatarsal head.",
      "The Cobb-Stainsby excision arthroplasty is named after the surgeons Cobb and Stainsby who developed the technique."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is performed to treat dislocated metatarsophalangeal joints in conditions such as hallux valgus, not specifically for dislocated metatarsophalangeal joints.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "vicuna-13b_response": "Based on the provided information, it is suggested that over-expression of GRHL2 may lead to EMT. Document 0 states that epithelial genes are subject to epigenetic control during intermediate phases of EMT/MET involving GRHL2. Additionally, Document 1 mentions that GRHL2 suppresses EMT, which is required for migration and invasion of carcinoma, implicating GRHL2 in carcinogenesis. Therefore, it can be inferred that over-expression of GRHL2 may result in the suppression of epithelial characteristics and the promotion of mesenchymal characteristics, leading to EMT.",
    "vicuna-13b_fact_raw": "1. Over-expression of GRHL2 may lead to epithelial-mesenchymal transition (EMT).\n2. Epithelial genes are subject to epigenetic control during intermediate phases of EMT/MET involving GRHL2, as stated in Document 0.\n3. GRHL2 suppresses EMT, which is necessary for migration and invasion of carcinoma, according to Document 1.\n4. Over-expression of GRHL2 may result in the suppression of epithelial characteristics.\n5. Over-expression of GRHL2 may promote mesenchymal characteristics.",
    "vicuna-13b_fact": [
      "Over-expression of GRHL2 may lead to epithelial-mesenchymal transition (EMT).",
      "Epithelial genes are subject to epigenetic control during intermediate phases of EMT/MET involving GRHL2, as stated in Document 0.",
      "GRHL2 suppresses EMT, which is necessary for migration and invasion of carcinoma, according to Document 1.",
      "Over-expression of GRHL2 may result in the suppression of epithelial characteristics.",
      "Over-expression of GRHL2 may promote mesenchymal characteristics."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Over-expression of GRHL2 is typically associated with the suppression of epithelial-mesenchymal transition (EMT), not its promotion.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Over-expression of GRHL2 may result in the enhancement of epithelial characteristics, not their suppression.\n5. FALSE [correction]: Over-expression of GRHL2 is generally thought to suppress mesenchymal characteristics, not promote them.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "vicuna-13b_response": "Answer: Based on the given documents, it is stated that T-UCRs are implicated in lung cancer. Specifically, Document 0 mentions that T-UCRs encode long non-coding RNAs implicated in human carcinogenesis, with uc.339 being identified as an oncogene in lung cancer. Document 1 further supports this by mentioning that TUCRs are understudied in many diseases, including cancer. While the underlying mechanisms of T-UCRs in lung cancer are not fully understood, these documents suggest that T-UCRs may play a role in the development and progression of lung cancer.",
    "vicuna-13b_fact_raw": "1. T-UCRs encode long non-coding RNAs implicated in human carcinogenesis.\n2. T-UCR uc.339 has been identified as an oncogene in lung cancer.\n3. T-UCRs are understudied in many diseases, including cancer.\n4. T-UCRs may play a role in the development and progression of lung cancer.",
    "vicuna-13b_fact": [
      "T-UCRs encode long non-coding RNAs implicated in human carcinogenesis.",
      "T-UCR uc.339 has been identified as an oncogene in lung cancer.",
      "T-UCRs are understudied in many diseases, including cancer.",
      "T-UCRs may play a role in the development and progression of lung cancer."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "vicuna-13b_response": "Answer: Document 0 states that the mu opioid receptor (MOR) and the orphan GPR151 receptor are inhibitory G protein coupled receptors that are enriched in the habenula, a small brain region involved in aversion. Document 1 mentions a rare, putative loss-of-function mutation in the orphan G-protein coupled receptor 151 (GPR151) being found to be associated with lower odds ratio for type 2 diabetes, but no further information is given about the receptor itself.",
    "vicuna-13b_fact_raw": "1. The mu opioid receptor (MOR) and the orphan GPR151 receptor are inhibitory G protein-coupled receptors.\n2. Both MOR and GPR151 receptors are enriched in the habenula, a brain region involved in aversion.\n3. A rare, putative loss-of-function mutation in GPR151 is associated with lower odds ratio for type 2 diabetes.",
    "vicuna-13b_fact": [
      "The mu opioid receptor (MOR) and the orphan GPR151 receptor are inhibitory G protein-coupled receptors.",
      "Both MOR and GPR151 receptors are enriched in the habenula, a brain region involved in aversion.",
      "A rare, putative loss-of-function mutation in GPR151 is associated with lower odds ratio for type 2 diabetes."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: The mu opioid receptor (MOR) is indeed an inhibitory G protein-coupled receptor. While GPR151 is also a G protein-coupled receptor, it is not as well characterized as MOR. However, it is generally considered to be inhibitory based on its homology to other G protein-coupled receptors.\n2. UNKNOWN: Without specific scientific literature or studies to confirm the enrichment of both MOR and GPR151 receptors in the habenula, it is difficult to determine the accuracy of this statement.\n3. UNKNOWN: The association of a mutation in GPR151 with type 2 diabetes would require specific genetic or epidemiological research to confirm, and without that information provided, the truth of this statement cannot be determined.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "vicuna-13b_response": "Based on the given documents, the Fluzone intradermal quadrivalent vaccine contains attenuated live viruses of the following subtypes:\n* Influenza A subtype viruses: H1N1, H3N2, and two B viruses (Yamagata and Victoria)\nIt is important to note that the attenuated live viruses in the vaccine have been weakened to prevent serious illness or death, but they are still alive and can cause mild symptoms, such as fever and soreness at the injection site. The vaccine is administered using a unique microinjection system that delivers the viruses into the skin, where they stimulate the immune system to produce antibodies that provide protection against influenza disease.",
    "vicuna-13b_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses.\n2. The vaccine includes Influenza A subtype viruses H1N1 and H3N2.\n3. The vaccine also contains two Influenza B viruses from the Yamagata and Victoria lineages.\n4. The attenuated live viruses in the vaccine are weakened to prevent serious illness or death.\n5. The Fluzone intradermal quadrivalent vaccine is administered using a microinjection system that delivers the vaccine into the skin.",
    "vicuna-13b_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses.",
      "The vaccine includes Influenza A subtype viruses H1N1 and H3N2.",
      "The vaccine also contains two Influenza B viruses from the Yamagata and Victoria lineages.",
      "The attenuated live viruses in the vaccine are weakened to prevent serious illness or death.",
      "The Fluzone intradermal quadrivalent vaccine is administered using a microinjection system that delivers the vaccine into the skin."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains inactivated (killed) viruses, not attenuated live viruses.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Since the Fluzone intradermal quadrivalent vaccine contains inactivated viruses, it does not contain live viruses that are weakened. The inactivated viruses cannot cause the flu but can still provoke an immune response.\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "vicuna-13b_response": "The genetic association between the TNFR2 gene and Systemic Lupus Erythematosus (SLE) is not mentioned in the given documents. The first document discusses the role of TNF in inflammation and its protective role in infectious diseases. The second document suggests that the TNFR2 rs1061624 polymorphism is associated with hepatitis B virus (HBV) related chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) in the Chinese population, particularly in males.",
    "vicuna-13b_fact_raw": "1. The TNFR2 gene is involved in inflammation and has a protective role in infectious diseases.\n2. The TNFR2 rs1061624 polymorphism is associated with hepatitis B virus (HBV) related chronic hepatitis B (CHB).\n3. The TNFR2 rs1061624 polymorphism is associated with liver cirrhosis (LC).\n4. The TNFR2 rs1061624 polymorphism is associated with hepatocellular carcinoma (HCC).\n5. The association of the TNFR2 rs1061624 polymorphism with HBV related diseases is particularly noted in the Chinese male population.",
    "vicuna-13b_fact": [
      "The TNFR2 gene is involved in inflammation and has a protective role in infectious diseases.",
      "The TNFR2 rs1061624 polymorphism is associated with hepatitis B virus (HBV) related chronic hepatitis B (CHB).",
      "The TNFR2 rs1061624 polymorphism is associated with liver cirrhosis (LC).",
      "The TNFR2 rs1061624 polymorphism is associated with hepatocellular carcinoma (HCC).",
      "The association of the TNFR2 rs1061624 polymorphism with HBV related diseases is particularly noted in the Chinese male population."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: The TNFR2 gene is known to be involved in inflammation and can play a protective role in infectious diseases by modulating the immune response.\n2. TRUE: Some studies have suggested that the TNFR2 rs1061624 polymorphism is associated with chronic hepatitis B, although the strength of this association can vary between studies.\n3. UNKNOWN: The association of the TNFR2 rs1061624 polymorphism with liver cirrhosis is not universally established and may depend on various factors, including the population studied and the presence of other risk factors.\n4. UNKNOWN: Similar to the association with liver cirrhosis, the association of the TNFR2 rs1061624 polymorphism with hepatocellular carcinoma may not be conclusively established and could vary based on different research findings.\n5. UNKNOWN: The specificity of the association of the TNFR2 rs1061624 polymorphism with HBV-related diseases in the Chinese male population would require specific epidemiological data to confirm, and such data is not provided in the context of these statements.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "vicuna-13b_response": "Yes, there is a vaccine for peanut allergy. The vaccine is called Palforzia and it is a therapy that uses antibodies to help people with severe peanut allergies build up tolerance to peanuts. According to Document 0, a small pilot study showed that one injection of Palforzia let people with severe peanut allergies eat a nut's worth of peanut protein two weeks later. Document 1 also mentions that Allergen immunotherapy is a form of therapeutic vaccination for established IgE-mediated hypersensitivity to common allergen sources such as pollens, house dust mites and the venom of stinging insects, which includes peanut allergy.",
    "vicuna-13b_fact_raw": "1. There is a vaccine for peanut allergy called Palforzia.\n2. Palforzia is a therapy that uses antibodies to help build up tolerance to peanuts in people with severe peanut allergies.\n3. A small pilot study indicated that one injection of Palforzia allowed individuals with severe peanut allergies to consume a nut's worth of peanut protein two weeks later.\n4. Allergen immunotherapy is a therapeutic vaccination for established IgE-mediated hypersensitivity to common allergens, including peanut allergy.",
    "vicuna-13b_fact": [
      "There is a vaccine for peanut allergy called Palforzia.",
      "Palforzia is a therapy that uses antibodies to help build up tolerance to peanuts in people with severe peanut allergies.",
      "A small pilot study indicated that one injection of Palforzia allowed individuals with severe peanut allergies to consume a nut's worth of peanut protein two weeks later.",
      "Allergen immunotherapy is a therapeutic vaccination for established IgE-mediated hypersensitivity to common allergens, including peanut allergy."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: Palforzia is not a therapy that uses antibodies. It is an oral immunotherapy that involves ingesting small, gradually increasing amounts of peanut protein to build up tolerance.\n3. FALSE [correction]: Palforzia is not administered by injection. It is an oral treatment, and the statement about the results of a pilot study cannot be verified without additional context.\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "vicuna-13b_response": "The mouse Fxy gene has a unique chromosomal position in that it spans the PAB in C57BL/6 mice, with the 5' end of the gene being X-unique but the 3' end present on both the X and Y chromosomes. This is in contrast to humans and M. spretus, where the entire Fxy gene is X-unique. Additionally, the Fxy gene was found to have been translocated into the highly recombining pseudoautosomal region in mice, resulting in an increase in GC content. This was investigated further by sequencing exons and introns of Fxy in various rodent species.",
    "vicuna-13b_fact_raw": "1. The mouse Fxy gene spans the pseudoautosomal boundary (PAB) in C57BL/6 mice.\n2. The 5' end of the mouse Fxy gene is unique to the X chromosome, while the 3' end is present on both the X and Y chromosomes.\n3. In humans and M. spretus, the entire Fxy gene is unique to the X chromosome.\n4. The Fxy gene has been translocated into the pseudoautosomal region in mice.\n5. The translocation of the Fxy gene into the pseudoautosomal region in mice resulted in an increase in GC content.",
    "vicuna-13b_fact": [
      "The mouse Fxy gene spans the pseudoautosomal boundary (PAB) in C57BL/6 mice.",
      "The 5' end of the mouse Fxy gene is unique to the X chromosome, while the 3' end is present on both the X and Y chromosomes.",
      "In humans and M. spretus, the entire Fxy gene is unique to the X chromosome.",
      "The Fxy gene has been translocated into the pseudoautosomal region in mice.",
      "The translocation of the Fxy gene into the pseudoautosomal region in mice resulted in an increase in GC content."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: The mouse Fxy gene, also known as Fxyd5, does span the pseudoautosomal boundary in C57BL/6 mice, meaning it is present on both the X and Y chromosomes in the region where they can recombine.\n2. TRUE: The 5' end of the mouse Fxy gene is indeed unique to the X chromosome, and the 3' end is present on both the X and Y chromosomes, which is consistent with the gene spanning the pseudoautosomal boundary.\n3. FALSE [correction]: In humans, the FXYD5 gene (the human homolog of the mouse Fxy gene) is not unique to the X chromosome; it is located on chromosome 19. Therefore, it is not analogous to the mouse Fxy gene in terms of chromosomal location. Without specific information about M. spretus (a species of wild mouse), it is difficult to confirm the statement for this species, but if the statement is meant to parallel the human condition, it would be incorrect for humans.\n4. TRUE: The statement that the Fxy gene has been translocated into the pseudoautosomal region in mice implies that it was not originally in that region, which is consistent with the nature of the pseudoautosomal region as a site of evolutionary gene translocations.\n5. UNKNOWN: Without specific scientific data or references regarding the GC content of the Fxy gene after its translocation into the pseudoautosomal region in mice, it is not possible to determine the truthfulness of this statement. Changes in GC content can be a consequence of such translocations due to the recombination-rich environment of the pseudoautosomal region, but this is a generalization and may not apply to every gene translocation event.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "vicuna-13b_response": "The basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method is the treatment of nuclei with a complex of methidiumpropyl-EDTA (MPE) and ferrous iron. This leads to the digestion of nuclei with MPE-Fe (II) followed by massively parallel sequencing. The MPE-Fe (II) preferentially cleaves the linker DNA between nucleosomes, similar to micrococcal nuclease (MNase), which allows for the genome-wide characterization of chromatin.",
    "vicuna-13b_fact_raw": "1. Methidiumpropyl-EDTA sequencing (MPE-seq) involves the treatment of nuclei with a complex of methidiumpropyl-EDTA (MPE) and ferrous iron.\n2. The MPE-Fe (II) complex is used to digest nuclei in the MPE-seq method.\n3. Massively parallel sequencing follows the digestion of nuclei with MPE-Fe (II) in the MPE-seq method.\n4. MPE-Fe (II) preferentially cleaves the linker DNA between nucleosomes in the MPE-seq method.\n5. The MPE-seq method allows for the genome-wide characterization of chromatin, similar to the action of micrococcal nuclease (MNase).",
    "vicuna-13b_fact": [
      "Methidiumpropyl-EDTA sequencing (MPE-seq) involves the treatment of nuclei with a complex of methidiumpropyl-EDTA (MPE) and ferrous iron.",
      "The MPE-Fe (II) complex is used to digest nuclei in the MPE-seq method.",
      "Massively parallel sequencing follows the digestion of nuclei with MPE-Fe (II) in the MPE-seq method.",
      "MPE-Fe (II) preferentially cleaves the linker DNA between nucleosomes in the MPE-seq method.",
      "The MPE-seq method allows for the genome-wide characterization of chromatin, similar to the action of micrococcal nuclease (MNase)."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the general principles of a sequencing method like MPE-seq, which is designed to probe chromatin structure and would involve the steps of digestion, sequencing, and preferential cleavage similar to micrococcal nuclease. However, without specific literature or scientific references to confirm the exact details of the MPE-seq method, it is assumed that the statements are accurate based on the context given.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "vicuna-13b_response": "Based on the given information, it is not explicitly stated which programming language has been used for implementing GWAR. However, Document 1 mentions Python as an object-oriented, high-level programming language that is popular and ideal for rapid development. Therefore, it is possible that Python was used for implementing GWAR.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "vicuna-13b_response": "Based on the information provided, it is not clear whether xaliproden improves the prognosis of amyotrophic lateral sclerosis. The first document mentions that improved prognosis could inform the patient and their family about disease course and improve end-of-life planning, but does not specifically mention xaliproden. The second document describes the characteristics of amyotrophic lateral sclerosis and its fatal outcome, but again, does not provide any information about xaliproden.\nIt is important to note that the development of effective treatments for amyotrophic lateral sclerosis is a complex and ongoing process, and it is possible that xaliproden or other therapies may be studied in clinical trials in the future. However, at this time, there is no evidence to suggest that xaliproden specifically improves the prognosis of amyotrophic lateral sclerosis.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "vicuna-13b_response": "Based on the information provided in Document 0, the LiPS-A3S line has a transgene inserted in the 3' untranslated region (3' UTR) of a gene on chromosome 15. The document also states that they did not detect any perturbation of expression of the gene or of any other coding genes located within 300 kb on either side of the integration site.\nDocument 1 provides a visual representation of the LiPS-A3S locus on chromosome 15. It shows that the LiPS-A3S site is located within the 3' UTR region of an unknown gene. Therefore, the answer to the question is that the transgene in the LiPS-A3S line is inserted in an unknown gene on chromosome 15 within its 3' UTR region.",
    "vicuna-13b_fact_raw": "1. The LiPS-A3S line has a transgene inserted in the 3' untranslated region (3' UTR) of a gene on chromosome 15.\n2. There was no detected perturbation of expression of the gene where the transgene was inserted in the LiPS-A3S line.\n3. No perturbation of expression was detected for any coding genes located within 300 kb on either side of the integration site in the LiPS-A3S line.\n4. Document 1 provides a visual representation of the LiPS-A3S locus on chromosome 15.\n5. The LiPS-A3S site is located within the 3' UTR region of an unknown gene on chromosome 15.",
    "vicuna-13b_fact": [
      "The LiPS-A3S line has a transgene inserted in the 3' untranslated region (3' UTR) of a gene on chromosome 15.",
      "There was no detected perturbation of expression of the gene where the transgene was inserted in the LiPS-A3S line.",
      "No perturbation of expression was detected for any coding genes located within 300 kb on either side of the integration site in the LiPS-A3S line.",
      "Document 1 provides a visual representation of the LiPS-A3S locus on chromosome 15.",
      "The LiPS-A3S site is located within the 3' UTR region of an unknown gene on chromosome 15."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The LiPS-A3S site is not located within the 3' UTR region of an unknown gene; the statement implies that the gene is known since it specifies the gene is on chromosome 15 and has a transgene inserted in its 3' UTR.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "vicuna-13b_response": "Answer: There are several tools that use deep learning for predicting drug synergy. One such tool is DeepSynergy, which is available for download at [www.bioinf.jku.at/software/DeepSynergy](http://www.bioinf.jku.at/software/DeepSynergy). DeepSynergy could be a valuable tool for selecting novel synergistic drug combinations. Additionally, supplementary data and information are available at Bioinformatics online.",
    "vicuna-13b_fact_raw": "1. DeepSynergy is a tool that uses deep learning for predicting drug synergy.\n2. DeepSynergy is available for download online.\n3. The website for downloading DeepSynergy is [www.bioinf.jku.at/software/DeepSynergy](http://www.bioinf.jku.at/software/DeepSynergy).\n4. Supplementary data and information about DeepSynergy are available at Bioinformatics online.",
    "vicuna-13b_fact": [
      "DeepSynergy is a tool that uses deep learning for predicting drug synergy.",
      "DeepSynergy is available for download online.",
      "The website for downloading DeepSynergy is [www.bioinf.jku.at/software/DeepSynergy](http://www.bioinf.jku.at/software/DeepSynergy).",
      "Supplementary data and information about DeepSynergy are available at Bioinformatics online."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "vicuna-13b_response": "The cloud-based platform for comparing GWAS is called \"easyGWAS\".",
    "vicuna-13b_fact_raw": "1. \"easyGWAS\" is a cloud-based platform developed for comparing GWAS (Genome-Wide Association Studies).",
    "vicuna-13b_fact": [
      "\"easyGWAS\" is a cloud-based platform developed for comparing GWAS (Genome-Wide Association Studies)."
    ],
    "vicuna-13b_judge_raw": "1. TRUE",
    "vicuna-13b_judge": [
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "vicuna-13b_response": "Based on the information provided, it appears that CMB305 is a vaccination regimen that is designed to prime NY-ESO-1–specific CD8 T-cell populations and then activate the immune response with a potent TLR-4 agonist. The article accompanying the editorial reports on a trial assessing the efficacy of CMB305 plus atezolizumab or atezolizumab alone in patients with NY-ESO-1–expressing synovial or myxoid round cell liposarcoma.\nThere is no information provided in the given documents that specifically mentions the use of CMB305 against sarcomas. However, the trial mentioned in the article did include patients with synovial or myxoid round cell liposarcoma, which is a type of sarcoma. It is possible that CMB305 may be effective against other types of sarcomas as well, but this would need to be further studied.",
    "vicuna-13b_fact_raw": "1. CMB305 is a vaccination regimen designed to prime NY-ESO-1–specific CD8 T-cell populations.\n2. CMB305 uses a TLR-4 agonist to activate the immune response.\n3. A trial assessed the efficacy of CMB305 in combination with atezolizumab.\n4. The trial included patients with NY-ESO-1–expressing synovial or myxoid round cell liposarcoma.\n5. Synovial or myxoid round cell liposarcoma is a type of sarcoma.",
    "vicuna-13b_fact": [
      "CMB305 is a vaccination regimen designed to prime NY-ESO-1–specific CD8 T-cell populations.",
      "CMB305 uses a TLR-4 agonist to activate the immune response.",
      "A trial assessed the efficacy of CMB305 in combination with atezolizumab.",
      "The trial included patients with NY-ESO-1–expressing synovial or myxoid round cell liposarcoma.",
      "Synovial or myxoid round cell liposarcoma is a type of sarcoma."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "vicuna-13b_response": "The manifestations of the Saint's Triad are the concurrence of hiatal hernia, gallbladder disease, and diverticulosis. This medical condition is named after the British-South African general surgeon, Charles Frederick Morris Saint, who emphasized the importance of considering the possibility of multiple separate diseases in a patient whenever his or her history and the results of the physical examination were indicative of such conditions. The first publication of the Saint's Triad was in 1948 by CJ B Muller, later Head of the Department of Radiology at the University of Stellenbosch in the Western Cape, South Africa.",
    "vicuna-13b_fact_raw": "1. The Saint's Triad consists of hiatal hernia, gallbladder disease, and diverticulosis.\n2. The Saint's Triad is named after Charles Frederick Morris Saint, a British-South African general surgeon.\n3. Charles Frederick Morris Saint emphasized the importance of considering multiple separate diseases in a patient.\n4. The first publication of the Saint's Triad was in 1948.\n5. CJ B Muller, who first published about the Saint's Triad, later became the Head of the Department of Radiology at the University of Stellenbosch in the Western Cape, South Africa.",
    "vicuna-13b_fact": [
      "The Saint's Triad consists of hiatal hernia, gallbladder disease, and diverticulosis.",
      "The Saint's Triad is named after Charles Frederick Morris Saint, a British-South African general surgeon.",
      "Charles Frederick Morris Saint emphasized the importance of considering multiple separate diseases in a patient.",
      "The first publication of the Saint's Triad was in 1948.",
      "CJ B Muller, who first published about the Saint's Triad, later became the Head of the Department of Radiology at the University of Stellenbosch in the Western Cape, South Africa."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The first publication of the Saint's Triad was in 1953.\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "vicuna-13b_response": "Based on the information provided, it is not clear whether overexpression of LY6K is associated with a better prognosis for non-small cell lung cancer patients. While Document 0 suggests that high expression of LY6K is negatively correlated with poor prognosis, Document 1 describes a relationship between overexpression of the immunoproteasome components PSMB8 and PSMB9 and better survival and improved response to immune-checkpoint inhibitors. It is possible that LY6K may have different effects on prognosis depending on the specific context and other factors. Further research is needed to determine the relationship between LY6K and prognosis in non-small cell lung cancer patients.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "vicuna-13b_response": "Based on the information provided, it appears that the following Cdk targets are dephosphorylated during cytokinesis:\n* These are the targets identified through phosphoproteome analysis of mitotic exit:\n\t+ Identified through the use of a new and widely applicable tool to generate conditionally phosphorylated proteins\n* These are the targets whose dephosphorylation is required for cytokinesis:\n\t+ Identified through the use of the same tool mentioned above.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "vicuna-13b_response": "Xanamem is an investigational therapy for Alzheimer's disease that is being developed by Actinogen Medical. It is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme in the hypothalamic-pituitary-adrenal (HPA) axis of the body's stress response. 11β-HSD1 converts the stress hormone cortisol to its active form, which binds to glucocorticoid receptors. The therapy is being investigated for its potential to improve cognitive function and slow the progression of Alzheimer's disease.",
    "vicuna-13b_fact_raw": "1. Xanamem is an investigational therapy for Alzheimer's disease.\n2. Actinogen Medical is developing Xanamem.\n3. Xanamem is an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).\n4. 11β-HSD1 is involved in the hypothalamic-pituitary-adrenal (HPA) axis of the body's stress response.\n5. The therapy aims to improve cognitive function and slow the progression of Alzheimer's disease.",
    "vicuna-13b_fact": [
      "Xanamem is an investigational therapy for Alzheimer's disease.",
      "Actinogen Medical is developing Xanamem.",
      "Xanamem is an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).",
      "11β-HSD1 is involved in the hypothalamic-pituitary-adrenal (HPA) axis of the body's stress response.",
      "The therapy aims to improve cognitive function and slow the progression of Alzheimer's disease."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "vicuna-13b_response": "The Hof1-Cyk3 interaction plays a role in yeast cytokinesis. It is mediated by a direct binding of the Hof1 SH3 domain to a proline-rich motif in Cyk3. This interaction occurs specifically at the time of cytokinesis and is independent of the (hyper)phosphorylation of both proteins that occurs at about the same time. The interaction is dispensable for the normal localization of both proteins. Additionally, the paper \"Role of the Hof1–Cyk3 interaction in cleavage-furrow ingression and primary-septum formation during yeast cytokinesis\" by Meng Wang, R. Nishihama, and J. Pringle, published in Molecular Biology of the Cell on January 10, 2018, suggests that the Hof1-Cyk3 interaction is important for cleavage-furrow ingression and primary-septum formation during yeast cytokinesis.",
    "vicuna-13b_fact_raw": "1. The Hof1-Cyk3 interaction is involved in yeast cytokinesis.\n2. The Hof1 SH3 domain directly binds to a proline-rich motif in Cyk3.\n3. The Hof1-Cyk3 interaction occurs specifically at the time of cytokinesis.\n4. The interaction between Hof1 and Cyk3 is independent of the (hyper)phosphorylation of both proteins.\n5. The paper titled \"Role of the Hof1–Cyk3 interaction in cleavage-furrow ingression and primary-septum formation during yeast cytokinesis\" was published in Molecular Biology of the Cell on January 10, 2018.",
    "vicuna-13b_fact": [
      "The Hof1-Cyk3 interaction is involved in yeast cytokinesis.",
      "The Hof1 SH3 domain directly binds to a proline-rich motif in Cyk3.",
      "The Hof1-Cyk3 interaction occurs specifically at the time of cytokinesis.",
      "The interaction between Hof1 and Cyk3 is independent of the (hyper)phosphorylation of both proteins.",
      "The paper titled \"Role of the Hof1–Cyk3 interaction in cleavage-furrow ingression and primary-septum formation during yeast cytokinesis\" was published in Molecular Biology of the Cell on January 10, 2018."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The interaction between Hof1 and Cyk3 is likely dependent on the (hyper)phosphorylation of both proteins, as phosphorylation often plays a regulatory role in protein interactions during cell processes such as cytokinesis.\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "vicuna-13b_response": "Answer: Based on the given documents, it is stated that the regulatory mechanism of T-UCRs in tumourigenesis and the development of cancer is largely unclear, but current studies have found that T-UCRs are involved in three different regulatory mechanisms in tumours: CpG island methylation, interaction with miRNAs, and direct binding to the target mRNAs. Therefore, it can be inferred that T-UCRs have been implicated in gastric cancer. However, it is important to note that the information provided in the documents is limited and more research is needed to fully understand the role of T-UCRs in gastric cancer.",
    "vicuna-13b_fact_raw": "1. T-UCRs are involved in the regulatory mechanisms of tumorigenesis and cancer development.\n2. T-UCRs have been implicated in gastric cancer.\n3. T-UCRs are involved in three different regulatory mechanisms in tumors: CpG island methylation, interaction with miRNAs, and direct binding to target mRNAs.\n4. The role of T-UCRs in gastric cancer is not fully understood and requires more research.",
    "vicuna-13b_fact": [
      "T-UCRs are involved in the regulatory mechanisms of tumorigenesis and cancer development.",
      "T-UCRs have been implicated in gastric cancer.",
      "T-UCRs are involved in three different regulatory mechanisms in tumors: CpG island methylation, interaction with miRNAs, and direct binding to target mRNAs.",
      "The role of T-UCRs in gastric cancer is not fully understood and requires more research."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "vicuna-13b_response": "The Lupus Severity Index (LSI) is a tool used to predict the likelihood of immunosuppressive use and early mortality in patients with lupus. It was derived from the American College of Rheumatology (ACR) classification criteria and has been found to be highly predictive in independent validation datasets. The LSI has also been strongly correlated with a previously existing severity score for lupus. The Kruskal-Wallis test and Spearman correlations were used to examine the association between the LSI and other variables.",
    "vicuna-13b_fact_raw": "1. The Lupus Severity Index (LSI) is used to predict the likelihood of immunosuppressive use and early mortality in lupus patients.\n2. The LSI was derived from the American College of Rheumatology (ACR) classification criteria.\n3. The LSI has been validated as highly predictive in independent validation datasets.\n4. There is a strong correlation between the LSI and a previously existing severity score for lupus.\n5. The Kruskal-Wallis test and Spearman correlations were utilized to examine the association between the LSI and other variables.",
    "vicuna-13b_fact": [
      "The Lupus Severity Index (LSI) is used to predict the likelihood of immunosuppressive use and early mortality in lupus patients.",
      "The LSI was derived from the American College of Rheumatology (ACR) classification criteria.",
      "The LSI has been validated as highly predictive in independent validation datasets.",
      "There is a strong correlation between the LSI and a previously existing severity score for lupus.",
      "The Kruskal-Wallis test and Spearman correlations were utilized to examine the association between the LSI and other variables."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: Without specific medical literature or research data, it is not possible to confirm the purpose and use of the Lupus Severity Index (LSI).\n2. UNKNOWN: The origin of the LSI and whether it was derived from the American College of Rheumatology (ACR) classification criteria cannot be confirmed without access to the relevant medical literature or research data.\n3. UNKNOWN: The validation of the LSI as highly predictive in independent validation datasets cannot be confirmed without reviewing the specific studies or validation reports.\n4. UNKNOWN: The correlation between the LSI and any previously existing severity score for lupus cannot be determined without specific data or research findings.\n5. UNKNOWN: The use of the Kruskal-Wallis test and Spearman correlations to examine the association between the LSI and other variables cannot be confirmed without access to the research methodology or study that utilized these statistical tests.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "vicuna-13b_response": "Based on the provided information, it is known that a recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 was previously reported to cause acromelic frontonasal dysostosis (AFND), an autosomal-dominant severe frontonasal and limb malformation syndrome, associated with neurocognitive and motor delay, via a proposed gain-of-function effect. Additionally, in 2014, a de novo variant in the zinc finger SWIM-type containing 6 gene (ZSWIM6) was commonly identified in four patients with acromelic frontonasal dysostosis (MIM #603671). It is not specified in the given information which disorders are caused by de novo mutations in ZSWIM6.",
    "vicuna-13b_fact_raw": "1. A recurrent de novo missense variant in ZSWIM6 is reported to cause acromelic frontonasal dysostosis (AFND).\n2. Acromelic frontonasal dysostosis is an autosomal-dominant syndrome.\n3. Acromelic frontonasal dysostosis is associated with severe frontonasal and limb malformation.\n4. Acromelic frontonasal dysostosis is associated with neurocognitive and motor delay.\n5. In 2014, a de novo variant in ZSWIM6 was identified in four patients with acromelic frontonasal dysostosis (MIM #603671).",
    "vicuna-13b_fact": [
      "A recurrent de novo missense variant in ZSWIM6 is reported to cause acromelic frontonasal dysostosis (AFND).",
      "Acromelic frontonasal dysostosis is an autosomal-dominant syndrome.",
      "Acromelic frontonasal dysostosis is associated with severe frontonasal and limb malformation.",
      "Acromelic frontonasal dysostosis is associated with neurocognitive and motor delay.",
      "In 2014, a de novo variant in ZSWIM6 was identified in four patients with acromelic frontonasal dysostosis (MIM #603671)."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: Acromelic frontonasal dysostosis is typically caused by a de novo mutation, meaning it is not inherited in an autosomal-dominant manner but occurs spontaneously.\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "vicuna-13b_response": "The Koos grading scale is a classification system for vestibular schwannoma (VS) used to characterize the tumor and its effects on adjacent brain structures. The Koos classification captures many of the characteristics of treatment decisions and is often used to determine treatment plans. The Koos grading scale is a frequently used classification system for vestibular schwannoma (VS) that accounts for extrameatal tumor dimension and compression of the brain stem. Based on the information provided, it is not specified which disease can be classified using the Koos Classification.",
    "vicuna-13b_fact_raw": "1. The Koos grading scale is a classification system for vestibular schwannoma (VS).\n2. The Koos classification is used to characterize the tumor and its effects on adjacent brain structures.\n3. The Koos classification is often used to determine treatment plans for vestibular schwannoma.\n4. The Koos grading scale accounts for extrameatal tumor dimension and compression of the brain stem.",
    "vicuna-13b_fact": [
      "The Koos grading scale is a classification system for vestibular schwannoma (VS).",
      "The Koos classification is used to characterize the tumor and its effects on adjacent brain structures.",
      "The Koos classification is often used to determine treatment plans for vestibular schwannoma.",
      "The Koos grading scale accounts for extrameatal tumor dimension and compression of the brain stem."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Koos grading scale classifies vestibular schwannoma based on tumor size and location, particularly focusing on the involvement of the cerebellopontine angle and the degree of brainstem compression, but it does not specifically account for extrameatal tumor dimension as a separate criterion.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "vicuna-13b_response": "Based on the given documents, AZD8601 is a novel, investigational mRNA-based therapy that encodes for VEGF-A for local administration in patients undergoing CABG. The therapy improves vascularization and tissue oxygenation of the wound bed, leading to accelerated healing. The therapy is administered through a boron nanoparticle-based tissue oxygen sensor. mRNA is responsible for carrying genetic instructions transcribed from DNA, which cells then translate to produce proteins.",
    "vicuna-13b_fact_raw": "1. AZD8601 is an investigational mRNA-based therapy.\n2. AZD8601 encodes for VEGF-A.\n3. AZD8601 is intended for local administration in patients undergoing CABG (Coronary Artery Bypass Grafting).\n4. The therapy aims to improve vascularization and tissue oxygenation of the wound bed.\n5. AZD8601 is administered through a boron nanoparticle-based tissue oxygen sensor.",
    "vicuna-13b_fact": [
      "AZD8601 is an investigational mRNA-based therapy.",
      "AZD8601 encodes for VEGF-A.",
      "AZD8601 is intended for local administration in patients undergoing CABG (Coronary Artery Bypass Grafting).",
      "The therapy aims to improve vascularization and tissue oxygenation of the wound bed.",
      "AZD8601 is administered through a boron nanoparticle-based tissue oxygen sensor."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: There is no information provided that AZD8601 is administered through a boron nanoparticle-based tissue oxygen sensor. AZD8601 is an mRNA therapy, and the method of administration mentioned in the context is local administration, but it does not specify the use of boron nanoparticle-based tissue oxygen sensors.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "vicuna-13b_response": "Answers:\nSAHFs (Senescence Associated Heterochromatic Foci) are created as a result of cellular senescence, which is a stress response triggered by DNA damage, telomere erosion, and activation of oncogenic signaling. This response leads to the permanent cell cycle exit of cells [1]. Aging is accompanied by the accumulation of senescent cells in tissues, which was first discovered in cultured fibroblast cells where prolonged passaging and replicative exhaustion led to growth arrest due to critically short telomeres [2].",
    "vicuna-13b_fact_raw": "1. SAHFs are created as a result of cellular senescence.\n2. Cellular senescence can be triggered by DNA damage, telomere erosion, and activation of oncogenic signaling.\n3. Cellular senescence leads to the permanent cell cycle exit of cells.\n4. Aging is accompanied by the accumulation of senescent cells in tissues.\n5. The phenomenon of senescent cells accumulating due to critically short telomeres was first discovered in cultured fibroblast cells.",
    "vicuna-13b_fact": [
      "SAHFs are created as a result of cellular senescence.",
      "Cellular senescence can be triggered by DNA damage, telomere erosion, and activation of oncogenic signaling.",
      "Cellular senescence leads to the permanent cell cycle exit of cells.",
      "Aging is accompanied by the accumulation of senescent cells in tissues.",
      "The phenomenon of senescent cells accumulating due to critically short telomeres was first discovered in cultured fibroblast cells."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "vicuna-13b_response": "The function of the PDZ domain in SATB1 is to mediate interactions with several chromatin proteins. This information is derived from Document 0 which states that functionally characterized domains of SATB1 include the N-terminal PDZ-like domain and a C-terminal DNA-binding region comprising a CUT domain and a homeodomain. Additionally, Document 1 states that the N-terminal PSD95/Dlg-A/ZO-1 (PDZ)-like domain of SATB1 mediates interactions with several chromatin proteins.",
    "vicuna-13b_fact_raw": "1. The PDZ domain in SATB1 mediates interactions with several chromatin proteins.\n2. SATB1 contains a functionally characterized N-terminal PDZ-like domain.\n3. SATB1 also has a C-terminal DNA-binding region.\n4. The C-terminal DNA-binding region of SATB1 comprises a CUT domain and a homeodomain.\n5. The N-terminal PDZ-like domain of SATB1 is also referred to as PSD95/Dlg-A/ZO-1 (PDZ)-like domain.",
    "vicuna-13b_fact": [
      "The PDZ domain in SATB1 mediates interactions with several chromatin proteins.",
      "SATB1 contains a functionally characterized N-terminal PDZ-like domain.",
      "SATB1 also has a C-terminal DNA-binding region.",
      "The C-terminal DNA-binding region of SATB1 comprises a CUT domain and a homeodomain.",
      "The N-terminal PDZ-like domain of SATB1 is also referred to as PSD95/Dlg-A/ZO-1 (PDZ)-like domain."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: SATB1 contains a functionally characterized N-terminal PDZ-like domain, but it is not referred to as a PDZ domain because it lacks critical residues for canonical PDZ domain function.\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "vicuna-13b_response": "The BLISS technique is a method developed by Deepak Chopra, as described in his book \"Quantum Healing\", that aims to relieve and dissolve pain, improve healing, and create a stronger immune system by addressing imbalances that could lead to sickness and disease. The technique involves adding a specific practice to your meditation routine, which includes a Sanskrit mantra, to enhance bliss into the mind-body system. The technique is taught in two parts during a single session.",
    "vicuna-13b_fact_raw": "1. The BLISS technique was developed by Deepak Chopra.\n2. Deepak Chopra described the BLISS technique in his book \"Quantum Healing\".\n3. The BLISS technique aims to relieve and dissolve pain, improve healing, and create a stronger immune system.\n4. The technique addresses imbalances that could lead to sickness and disease.\n5. The BLISS technique involves adding a specific practice with a Sanskrit mantra to a meditation routine.",
    "vicuna-13b_fact": [
      "The BLISS technique was developed by Deepak Chopra.",
      "Deepak Chopra described the BLISS technique in his book \"Quantum Healing\".",
      "The BLISS technique aims to relieve and dissolve pain, improve healing, and create a stronger immune system.",
      "The technique addresses imbalances that could lead to sickness and disease.",
      "The BLISS technique involves adding a specific practice with a Sanskrit mantra to a meditation routine."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The BLISS technique was not developed by Deepak Chopra; it is not a known technique associated with him or his teachings.\n2. FALSE [correction]: Since the BLISS technique was not developed by Deepak Chopra, he did not describe it in his book \"Quantum Healing\".\n3. UNKNOWN: Without accurate information on what the BLISS technique is, it's unclear what its aims are.\n4. UNKNOWN: Similarly, without clear information on the BLISS technique, it's not possible to confirm what it addresses.\n5. UNKNOWN: The details of the BLISS technique, including whether it involves a Sanskrit mantra, cannot be confirmed without proper context or information about the technique.",
    "vicuna-13b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "vicuna-13b_response": "Based on the given information, here are three NK3R antagonists mentioned in the documents:\n1. Sabatier et al. (2020) - In a randomized, double-blind, placebo-controlled trial, sabatier et al. (2020) evaluated the efficacy and safety of a novel oral neurokinin-3 receptor antagonist (NK3RA) in postmenopausal women with moderate to severe hot flashes. The study found that the NK3RA was effective in reducing the frequency and severity of hot flashes, with a safety profile similar to placebo.\n2. Soares et al. (2021) - Soares et al. (2021) conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy and safety of NK3R antagonists for the treatment of menopausal vasomotor symptoms. The study found that NK3R antagonists were effective in reducing the frequency and severity of hot flashes, with a favorable safety profile.\n3. Lee et al. (2021) - In a randomized, double-blind, placebo-controlled trial, Lee et al. (2021) evaluated the efficacy and safety of a novel oral NK3R antagonist in postmenopausal women with moderate to severe hot flashes. The study found that the NK3R antagonist was effective in reducing the frequency and severity of hot flashes, with a safety profile similar to placebo.\nIt is important to note that these are just a few examples of NK3R antagonists and there may be other drugs that also act as NK3R antagonists. Additionally, the effectiveness and safety of these drugs may vary depending on the individual and the specific condition being treated.",
    "vicuna-13b_fact_raw": "1. A study by Sabatier et al. (2020) evaluated the efficacy and safety of a novel oral neurokinin-3 receptor antagonist in postmenopausal women with moderate to severe hot flashes.\n2. Soares et al. (2021) conducted a systematic review and meta-analysis of randomized controlled trials on NK3R antagonists for the treatment of menopausal vasomotor symptoms.\n3. Lee et al. (2021) conducted a randomized, double-blind, placebo-controlled trial on a novel oral NK3R antagonist for postmenopausal women with moderate to severe hot flashes.\n4. The study by Sabatier et al. (2020) found that the NK3R antagonist was effective in reducing the frequency and severity of hot flashes.\n5. The study by Lee et al. (2021) reported that the NK3R antagonist had a safety profile similar to placebo.",
    "vicuna-13b_fact": [
      "A study by Sabatier et al. (2020) evaluated the efficacy and safety of a novel oral neurokinin-3 receptor antagonist in postmenopausal women with moderate to severe hot flashes.",
      "Soares et al. (2021) conducted a systematic review and meta-analysis of randomized controlled trials on NK3R antagonists for the treatment of menopausal vasomotor symptoms.",
      "Lee et al. (2021) conducted a randomized, double-blind, placebo-controlled trial on a novel oral NK3R antagonist for postmenopausal women with moderate to severe hot flashes.",
      "The study by Sabatier et al. (2020) found that the NK3R antagonist was effective in reducing the frequency and severity of hot flashes.",
      "The study by Lee et al. (2021) reported that the NK3R antagonist had a safety profile similar to placebo."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the specific studies by Sabatier et al. (2020), Soares et al. (2021), and Lee et al. (2021), it is not possible to verify the accuracy of the statements regarding the efficacy, safety, and findings of the studies on NK3R antagonists for the treatment of menopausal vasomotor symptoms. Therefore, all statements are marked as UNKNOWN.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "vicuna-13b_response": "Based on the information provided in the documents, the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is PF-05190457. This is indicated in Document 1, which states that PF-05190457 is a potent ghrelin receptor antagonist with inverse agonist activity and has been reported to increase calcium in dispersed rat islets, increase insulin secretion from human islets and increases rat vagal afferent firing ex vivo. Additionally, Document 0 states that PF-05190457 is a well-tolerated first-in-class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing, and that blocking ghrelin receptors inhibits ghrelin-induced GH, and increases heart rate, effects that underwent tachyphylaxis with chronic dosing.",
    "vicuna-13b_fact_raw": "1. PF-05190457 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. PF-05190457 has been reported to increase calcium in dispersed rat islets.\n3. PF-05190457 has been reported to increase insulin secretion from human islets.\n4. PF-05190457 has been reported to increase rat vagal afferent firing ex vivo.\n5. PF-05190457 is described as having acceptable pharmacokinetics for oral daily dosing.",
    "vicuna-13b_fact": [
      "PF-05190457 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "PF-05190457 has been reported to increase calcium in dispersed rat islets.",
      "PF-05190457 has been reported to increase insulin secretion from human islets.",
      "PF-05190457 has been reported to increase rat vagal afferent firing ex vivo.",
      "PF-05190457 is described as having acceptable pharmacokinetics for oral daily dosing."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information on PF-05190457 and the results of scientific studies or clinical trials related to it, it is not possible to determine the truthfulness of these statements. They are highly technical and would require access to the relevant research data or publications.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "vicuna-13b_response": "Based on the information provided, it is not possible to answer the question about the protective efficacy of Vaxchora against moderate to severe cholera. The documents provided do not contain any information about Vaxchora or its efficacy against cholera.\nTo obtain an answer to the question, additional information about Vaxchora and its use in the treatment of cholera would be required.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "vicuna-13b_response": "The first cholera vaccine approved in the US is Vaxchora, which was approved by the Food and Drug Administration (FDA) for the prophylaxis of cholera infection. This was announced in Document 0 and confirmed in Document 1.",
    "vicuna-13b_fact_raw": "1. Vaxchora is the first cholera vaccine approved in the US.\n2. The Food and Drug Administration (FDA) approved Vaxchora for the prophylaxis of cholera infection.",
    "vicuna-13b_fact": [
      "Vaxchora is the first cholera vaccine approved in the US.",
      "The Food and Drug Administration (FDA) approved Vaxchora for the prophylaxis of cholera infection."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "vicuna-13b_response": "Based on the given documents, the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous loss-of-function variants in NFKB1.",
    "vicuna-13b_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous loss-of-function variants in NFKB1.",
    "vicuna-13b_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous loss-of-function variants in NFKB1."
    ],
    "vicuna-13b_judge_raw": "1. TRUE",
    "vicuna-13b_judge": [
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "vicuna-13b_response": "The IFIT1 gene is known to play a role in the pathogenesis of Systemic Lupus Erythematosus (SLE). It is an interferon-induced gene that is upregulated in response to type I interferon (IFN-I) signaling, which is involved in the regulation of inflammation in SLE. The overexpression of IFIT1 has been associated with the development of SLE and is thought to contribute to the disease's heterogeneous clinical symptoms and severity. Additionally, IFIT1 has been shown to regulate the expression of other IFN-stimulated genes (ISGs) and impact immune responses and inflammatory factors, suggesting that it may play a key role in the regulation of inflammation in SLE.",
    "vicuna-13b_fact_raw": "1. The IFIT1 gene plays a role in the pathogenesis of Systemic Lupus Erythematosus (SLE).\n2. IFIT1 is an interferon-induced gene that is upregulated in response to type I interferon (IFN-I) signaling.\n3. Overexpression of IFIT1 has been associated with the development of Systemic Lupus Erythematosus.\n4. IFIT1 is thought to contribute to the heterogeneous clinical symptoms and severity of SLE.\n5. IFIT1 regulates the expression of other IFN-stimulated genes (ISGs) and impacts immune responses and inflammatory factors in SLE.",
    "vicuna-13b_fact": [
      "The IFIT1 gene plays a role in the pathogenesis of Systemic Lupus Erythematosus (SLE).",
      "IFIT1 is an interferon-induced gene that is upregulated in response to type I interferon (IFN-I) signaling.",
      "Overexpression of IFIT1 has been associated with the development of Systemic Lupus Erythematosus.",
      "IFIT1 is thought to contribute to the heterogeneous clinical symptoms and severity of SLE.",
      "IFIT1 regulates the expression of other IFN-stimulated genes (ISGs) and impacts immune responses and inflammatory factors in SLE."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: The IFIT1 gene has been implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE) through its role in the interferon signaling pathway, which is known to be dysregulated in SLE.\n2. TRUE: IFIT1 is indeed an interferon-induced gene that is upregulated in response to type I interferon (IFN-I) signaling.\n3. TRUE: Overexpression of IFIT1 has been associated with the development of Systemic Lupus Erythematosus, as it is part of the interferon signature often found in patients with SLE.\n4. TRUE: IFIT1 is thought to contribute to the heterogeneous clinical symptoms and severity of SLE due to its role in the immune response and inflammation.\n5. TRUE: IFIT1 does regulate the expression of other IFN-stimulated genes (ISGs) and can impact immune responses and inflammatory factors, which are relevant in the context of SLE.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "vicuna-13b_response": "The Liverpool Elbow Score (LES) is a valid elbow-specific scoring system used to evaluate joint functions in patients with elbow stiffness. It contains both subjective and objective parameters and is based on a 15-item tool with a scale ranging from 0 to 10 points, with higher scores indicating better function. The LES was found to be a valid scoring system in a study conducted by the authors.",
    "vicuna-13b_fact_raw": "1. The Liverpool Elbow Score (LES) is used to evaluate joint functions in patients with elbow stiffness.\n2. The LES includes both subjective and objective parameters.\n3. It is a 15-item tool.\n4. The scale of the LES ranges from 0 to 10 points.\n5. Higher scores on the LES indicate better function.",
    "vicuna-13b_fact": [
      "The Liverpool Elbow Score (LES) is used to evaluate joint functions in patients with elbow stiffness.",
      "The LES includes both subjective and objective parameters.",
      "It is a 15-item tool.",
      "The scale of the LES ranges from 0 to 10 points.",
      "Higher scores on the LES indicate better function."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Liverpool Elbow Score (LES) is a 10-item tool.\n4. FALSE [correction]: The scale of the LES ranges from 0 to 100 points.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "vicuna-13b_response": "The 100,000 Genomes Project, initiated in the UK in 2015, was a large-scale whole genome sequencing (WGS) endeavor aimed at cancer and rare disease patients. Sarcoma was one of the rare diseases included in the project, and it was among the top three diseases in terms of the number of patient samples sent for sequencing. The project aimed to achieve five main objectives, including establishing a genomic medicine service for the National Health Service (NHS), providing clinical diagnosis with new personalized treatment options, enabling scientific discovery, facilitating the development of new diagnostics and therapies, and promoting the adoption of genomic medicine by the NHS. The project was successful in achieving these objectives and has led to significant advances in the understanding and treatment of sarcoma and other rare diseases.",
    "vicuna-13b_fact_raw": "1. The 100,000 Genomes Project was initiated in the UK in 2015.\n2. The project was a large-scale whole genome sequencing endeavor focused on cancer and rare disease patients.\n3. Sarcoma was one of the rare diseases included in the 100,000 Genomes Project.\n4. One of the objectives of the project was to establish a genomic medicine service for the National Health Service (NHS).\n5. The project aimed to provide clinical diagnosis with new personalized treatment options for diseases like sarcoma.",
    "vicuna-13b_fact": [
      "The 100,000 Genomes Project was initiated in the UK in 2015.",
      "The project was a large-scale whole genome sequencing endeavor focused on cancer and rare disease patients.",
      "Sarcoma was one of the rare diseases included in the 100,000 Genomes Project.",
      "One of the objectives of the project was to establish a genomic medicine service for the National Health Service (NHS).",
      "The project aimed to provide clinical diagnosis with new personalized treatment options for diseases like sarcoma."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "vicuna-13b_response": "Based on the information provided, it is not clear whether protein ALEX1 contains armadillo repeats. Document 0 mentions armadillo (arm) repeat-containing proteins, but does not specifically mention ALEX1. Document 1 mentions the cloning and expression of armadillo repeat-containing proteins, but again, does not specifically mention ALEX1. Without further information or a specific reference to ALEX1, it is not possible to determine whether it contains armadillo repeats.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "vicuna-13b_response": "An enzyme that removes histone modifications is a deacetylase (HDAC). According to Document 0, histone acetylation is largely targeted to promoter regions and is regulated by histone acetyltransferases (HAT) and deacetylases (HDAC). In Document 1, it is mentioned that epigenetic regulatory mechanisms, including histone modification, play critical roles in cellular processes. However, it does not specifically list enzymes that remove histone modifications.",
    "vicuna-13b_fact_raw": "1. Deacetylases (HDAC) are enzymes that remove histone modifications.\n2. Histone acetylation is targeted to promoter regions.\n3. Histone acetylation is regulated by histone acetyltransferases (HAT) and deacetylases (HDAC).\n4. Epigenetic regulatory mechanisms include histone modification.\n5. Histone modification plays a critical role in cellular processes.",
    "vicuna-13b_fact": [
      "Deacetylases (HDAC) are enzymes that remove histone modifications.",
      "Histone acetylation is targeted to promoter regions.",
      "Histone acetylation is regulated by histone acetyltransferases (HAT) and deacetylases (HDAC).",
      "Epigenetic regulatory mechanisms include histone modification.",
      "Histone modification plays a critical role in cellular processes."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Histone deacetylases (HDAC) are enzymes that remove acetyl groups from histones, not histone modifications in general.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "vicuna-13b_response": "Based on the available evidence, there is a low but non-zero risk of tumor induction in pediatric patients from head computed tomography (CT) exams. The use of computed tomography (CT) scans, which are commonly used in medical imaging, has been associated with an increased risk of brain tumors. However, the absolute risk is small and the benefit of using CT scans for diagnostic and therapeutic purposes in managing patients of all ages is generally considered to outweigh the potential risk. It is important to discuss the risks and benefits of CT scans with your doctor and consider other factors such as your individual medical needs and history before making a decision about undergoing a CT scan.",
    "vicuna-13b_fact_raw": "1. There is a low but non-zero risk of tumor induction from head computed tomography (CT) exams in pediatric patients.\n2. Computed tomography (CT) scans have been associated with an increased risk of brain tumors.\n3. The absolute risk of developing a brain tumor from CT scans is small.\n4. The benefit of using CT scans for diagnostic and therapeutic purposes is generally considered to outweigh the potential risk.\n5. It is recommended to discuss the risks and benefits of CT scans with a doctor before making a decision about undergoing a CT scan.",
    "vicuna-13b_fact": [
      "There is a low but non-zero risk of tumor induction from head computed tomography (CT) exams in pediatric patients.",
      "Computed tomography (CT) scans have been associated with an increased risk of brain tumors.",
      "The absolute risk of developing a brain tumor from CT scans is small.",
      "The benefit of using CT scans for diagnostic and therapeutic purposes is generally considered to outweigh the potential risk.",
      "It is recommended to discuss the risks and benefits of CT scans with a doctor before making a decision about undergoing a CT scan."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "vicuna-13b_response": "Based on the information provided, it is not explicitly stated in the documents which type of pluripotency Otx2 is associated with. However, it is mentioned in Document 1 that Otx2 drives enhancer activation and affects chromatin marks and the activity of associated genes, suggesting that it may be involved in maintaining or regulating pluripotency. It is also mentioned in Document 0 that Otx2 is required for efficient Oct4 recruitment to many enhancer regions, which suggests a role for Otx2 in the regulation of pluripotency transcription factors. However, without further information, it is not possible to definitively determine which type of pluripotency Otx2 is associated with.",
    "vicuna-13b_fact_raw": "1. Otx2 is involved in enhancer activation and affects chromatin marks and the activity of associated genes.\n2. Otx2 is required for efficient Oct4 recruitment to many enhancer regions.\n3. Otx2 may play a role in maintaining or regulating pluripotency.",
    "vicuna-13b_fact": [
      "Otx2 is involved in enhancer activation and affects chromatin marks and the activity of associated genes.",
      "Otx2 is required for efficient Oct4 recruitment to many enhancer regions.",
      "Otx2 may play a role in maintaining or regulating pluripotency."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "vicuna-13b_response": "Based on the given documents, it is not specified how many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region. Document 0 states that DHSs are generic markers of regulatory DNA and contain genetic variations associated with diseases and phenotypic traits, but does not provide a specific number for the murine beta globin locus region. Document 1 states that DHSs are markers of regulatory DNA and have underpinned the discovery of all classes of cis-regulatory elements including enhancers, promoters, insulators, but again, does not provide a specific number for the murine beta globin locus region.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "vicuna-13b_response": "Based on the given documents, here are some European influenza vaccines:\n* Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals)\n* Pandemic Influenza Vaccine H5N1 Baxter AG\n* Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune)\nNote that the first two vaccines are specifically designed to protect against the H5N1 strain of avian influenza, while the third vaccine is designed to protect against the H1N1 strain of influenza. It's important to keep in mind that the availability of influenza vaccines can vary depending on the country and the specific strains of influenza that are circulating.",
    "vicuna-13b_fact_raw": "1. Adjupanrix is a European influenza vaccine designed to protect against the H5N1 strain of avian influenza.\n2. Pandemic Influenza Vaccine H5N1 Baxter AG is a European influenza vaccine.\n3. Pandemic influenza vaccine H5N1 AstraZeneca is a European influenza vaccine designed to protect against the H1N1 strain of influenza.\n4. The vaccine previously known as Pandemic influenza vaccine H5N1 Medimmune is now referred to as Pandemic influenza vaccine H5N1 AstraZeneca.\n5. The availability of influenza vaccines in Europe can vary by country and the specific strains of influenza that are circulating.",
    "vicuna-13b_fact": [
      "Adjupanrix is a European influenza vaccine designed to protect against the H5N1 strain of avian influenza.",
      "Pandemic Influenza Vaccine H5N1 Baxter AG is a European influenza vaccine.",
      "Pandemic influenza vaccine H5N1 AstraZeneca is a European influenza vaccine designed to protect against the H1N1 strain of influenza.",
      "The vaccine previously known as Pandemic influenza vaccine H5N1 Medimmune is now referred to as Pandemic influenza vaccine H5N1 AstraZeneca.",
      "The availability of influenza vaccines in Europe can vary by country and the specific strains of influenza that are circulating."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Pandemic influenza vaccine H5N1 AstraZeneca is a European influenza vaccine designed to protect against the H5N1 strain of influenza, not H1N1.\n4. UNKNOWN\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "vicuna-13b_response": "Yes, the Paramyxovirus genome is segmented, negative-sense RNA. This is supported by Document 0 which states that the paramyxovirus family has a genome consisting of a single strand of negative sense RNA. Additionally, Document 1 describes the nucleocapsid of the paramyxovirus as containing one molecule of single-stranded generally negative-sense RNA, further supporting the idea that the genome is negative-sense RNA.",
    "vicuna-13b_fact_raw": "1. The Paramyxovirus genome is negative-sense RNA.\n2. The Paramyxovirus genome consists of a single strand of RNA.\n3. The nucleocapsid of the Paramyxovirus contains one molecule of single-stranded RNA.",
    "vicuna-13b_fact": [
      "The Paramyxovirus genome is negative-sense RNA.",
      "The Paramyxovirus genome consists of a single strand of RNA.",
      "The nucleocapsid of the Paramyxovirus contains one molecule of single-stranded RNA."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "vicuna-13b_response": "Roflumilast cream is effective for the treatment of plaque psoriasis. It was approved by the FDA in 2022 for the treatment of plaque psoriasis in patients aged 12 years and older. A clinical trial showed that roflumilast cream was safe and highly effective at doses of 0.5% and 0.15% for the treatment of chronic plaque psoriasis. The trial was registered on ClinicalTrials.gov with the ID NCT03392168.",
    "vicuna-13b_fact_raw": "1. Roflumilast cream is used for the treatment of plaque psoriasis.\n2. The FDA approved roflumilast cream for the treatment of plaque psoriasis in 2022.\n3. Roflumilast cream is approved for use in patients aged 12 years and older.\n4. Clinical trials showed that roflumilast cream was safe and effective at doses of 0.5% and 0.15% for treating chronic plaque psoriasis.\n5. The clinical trial for roflumilast cream was registered on ClinicalTrials.gov with the ID NCT03392168.",
    "vicuna-13b_fact": [
      "Roflumilast cream is used for the treatment of plaque psoriasis.",
      "The FDA approved roflumilast cream for the treatment of plaque psoriasis in 2022.",
      "Roflumilast cream is approved for use in patients aged 12 years and older.",
      "Clinical trials showed that roflumilast cream was safe and effective at doses of 0.5% and 0.15% for treating chronic plaque psoriasis.",
      "The clinical trial for roflumilast cream was registered on ClinicalTrials.gov with the ID NCT03392168."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: As of my knowledge cutoff in early 2023, the FDA approved roflumilast cream (brand name ARQ-151) for the treatment of plaque psoriasis in adults in 2021.\n3. UNKNOWN: Without specific information on the FDA approval details regarding age, I cannot confirm the accuracy of this statement.\n4. UNKNOWN: Without access to the specific clinical trial results, I cannot confirm the safety and effectiveness of the specific doses mentioned.\n5. UNKNOWN: Without verifying the specific clinical trial registration, I cannot confirm the accuracy of the given ClinicalTrials.gov ID.",
    "vicuna-13b_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "vicuna-13b_response": "Answer: Document 0 suggests that no methods are currently available for identifying and visualizing ncRNA promoters. However, Document 1 introduces a tool called R2DT that can predict and visualize RNA secondary structure using templates. It is not specifically mentioned if it can be used for identifying ncRNA promoters.",
    "vicuna-13b_fact_raw": "1. Document 0 suggests that there are no methods available for identifying and visualizing ncRNA promoters.\n2. Document 1 introduces a tool called R2DT.\n3. R2DT can predict and visualize RNA secondary structure using templates.\n4. It is not specified whether R2DT can be used for identifying ncRNA promoters.",
    "vicuna-13b_fact": [
      "Document 0 suggests that there are no methods available for identifying and visualizing ncRNA promoters.",
      "Document 1 introduces a tool called R2DT.",
      "R2DT can predict and visualize RNA secondary structure using templates.",
      "It is not specified whether R2DT can be used for identifying ncRNA promoters."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The statement is too absolute. While Document 0 may suggest that identifying and visualizing ncRNA promoters is challenging, it is unlikely to claim that there are no methods available at all, as scientific literature often discusses existing methods and their limitations.\n2. TRUE\n3. TRUE\n4. UNKNOWN",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "vicuna-13b_response": "Based on the information provided, some examples of genes that the SWIM tool has identified as being down-regulated in glioblastoma are:\n* CAV1\n* COL5A1\n* COL6A3\n* FLNB\n* HMMR\n* ITGA3\n* ITGA5\n* MET\n* SDC1\n* THBS1\n* VEGFC\nThese genes are involved in \"ECM-receptor interaction\" and \"focal adhesion\" pathways.",
    "vicuna-13b_fact_raw": "1. The SWIM tool has identified CAV1 as being down-regulated in glioblastoma.\n2. The SWIM tool has identified COL5A1 as being down-regulated in glioblastoma.\n3. The SWIM tool has identified COL6A3 as being down-regulated in glioblastoma.\n4. The SWIM tool has identified FLNB as being down-regulated in glioblastoma.\n5. The SWIM tool has identified HMMR as being down-regulated in glioblastoma.",
    "vicuna-13b_fact": [
      "The SWIM tool has identified CAV1 as being down-regulated in glioblastoma.",
      "The SWIM tool has identified COL5A1 as being down-regulated in glioblastoma.",
      "The SWIM tool has identified COL6A3 as being down-regulated in glioblastoma.",
      "The SWIM tool has identified FLNB as being down-regulated in glioblastoma.",
      "The SWIM tool has identified HMMR as being down-regulated in glioblastoma."
    ],
    "vicuna-13b_judge_raw": "UNKNOWN\n\nThe provided statements refer to specific findings that the SWIM (Survival Weighted by the Integration of the Margin) tool has supposedly identified regarding the regulation of certain genes in glioblastoma. Without access to the specific research or results from the SWIM tool, it is not possible to verify the accuracy of these statements. Therefore, the truthfulness of statements 1 through 5 cannot be determined from the information given.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "vicuna-13b_response": "Based on the given documents, it appears that the R package \"TADsplimer\" has been developed for studying Topologically Associated Domains (TADs). This package is the first computational tool to systematically detect TAD splits and mergers across the genome between Hi-C samples.\nAdditionally, the R package \"SpectralTAD\" has also been developed for studying TADs. This package uses spectral clustering to define a hierarchy of TADs. The authors of this package are Kellen G Cresswell, John C Stansfield, Mikhail G Dozmorov, and Virginia A Clark.",
    "vicuna-13b_fact_raw": "1. The R package \"TADsplimer\" has been developed for studying Topologically Associated Domains (TADs).\n2. \"TADsplimer\" is a computational tool designed to detect TAD splits and mergers across the genome between Hi-C samples.\n3. The R package \"SpectralTAD\" is another tool developed for studying TADs.\n4. \"SpectralTAD\" uses spectral clustering to define a hierarchy of TADs.\n5. The authors of the \"SpectralTAD\" package are Kellen G Cresswell, John C Stansfield, Mikhail G Dozmorov, and Virginia A Clark.",
    "vicuna-13b_fact": [
      "The R package \"TADsplimer\" has been developed for studying Topologically Associated Domains (TADs).",
      "\"TADsplimer\" is a computational tool designed to detect TAD splits and mergers across the genome between Hi-C samples.",
      "The R package \"SpectralTAD\" is another tool developed for studying TADs.",
      "\"SpectralTAD\" uses spectral clustering to define a hierarchy of TADs.",
      "The authors of the \"SpectralTAD\" package are Kellen G Cresswell, John C Stansfield, Mikhail G Dozmorov, and Virginia A Clark."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "vicuna-13b_response": "The bioconductor tool that has been developed for accessing bacterial regulatory networks is regulonDB. It is a database that has collected, harmonized and centralized data from hundreds of experiments for nearly two decades and is considered a point of reference for transcriptional regulation in Escherichia coli. To alleviate the lack of data, genome-scale transfer of TRNs (transcriptional regulatory networks) has been applied, providing insights into the regulatory mechanisms of bacterial organisms. In this context, a model organism is used to represent the regulatory network of a specific bacterial organism.",
    "vicuna-13b_fact_raw": "1. RegulonDB is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. RegulonDB has been collecting, harmonizing, and centralizing data from experiments for nearly two decades.\n3. RegulonDB is considered a point of reference for transcriptional regulation in Escherichia coli.\n4. Genome-scale transfer of transcriptional regulatory networks (TRNs) is used to provide insights into the regulatory mechanisms of bacterial organisms.\n5. A model organism is used in RegulonDB to represent the regulatory network of a specific bacterial organism.",
    "vicuna-13b_fact": [
      "RegulonDB is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "RegulonDB has been collecting, harmonizing, and centralizing data from experiments for nearly two decades.",
      "RegulonDB is considered a point of reference for transcriptional regulation in Escherichia coli.",
      "Genome-scale transfer of transcriptional regulatory networks (TRNs) is used to provide insights into the regulatory mechanisms of bacterial organisms.",
      "A model organism is used in RegulonDB to represent the regulatory network of a specific bacterial organism."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: RegulonDB is a database, not a bioconductor tool, developed for accessing bacterial regulatory networks, specifically for Escherichia coli.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "vicuna-13b_response": "The end products of the shikimate pathway are chorismate and aromatic amino acids. The shikimate pathway is a metabolic process that occurs in plants, fungi, and some bacteria, but is absent in animals. It involves a sequence of seven enzymatic reactions that convert phosphoenolpyruvate and erythrose 4-phosphate to chorismate, which is the precursor for the synthesis of aromatic amino acids and many aromatic secondary metabolites. The shikimate pathway is a crucial target for developing antimicrobial agents and herbicides.",
    "vicuna-13b_fact_raw": "1. Chorismate and aromatic amino acids are the end products of the shikimate pathway.\n2. The shikimate pathway occurs in plants, fungi, and some bacteria.\n3. Animals do not have the shikimate pathway.\n4. The shikimate pathway consists of seven enzymatic reactions.\n5. Chorismate is the precursor for the synthesis of aromatic amino acids and many aromatic secondary metabolites.",
    "vicuna-13b_fact": [
      "Chorismate and aromatic amino acids are the end products of the shikimate pathway.",
      "The shikimate pathway occurs in plants, fungi, and some bacteria.",
      "Animals do not have the shikimate pathway.",
      "The shikimate pathway consists of seven enzymatic reactions.",
      "Chorismate is the precursor for the synthesis of aromatic amino acids and many aromatic secondary metabolites."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Chorismate is not the end product but rather an intermediate in the shikimate pathway, which leads to the synthesis of aromatic amino acids.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "vicuna-13b_response": "Based on the given documents, it is not mentioned whether cabergoline is used for the treatment of Nelson's syndrome. Cabergoline is a medication that is used for the treatment of various conditions such as Parkinson's disease, hyperprolactinemia, and tumors such as pheochromocytoma and paraganglioma. However, there is no mention of its use in the treatment of Nelson's syndrome. The management of Nelson's syndrome can be challenging and may involve various treatments such as hormone replacement therapy, surgery, and medications to control symptoms.",
    "vicuna-13b_fact_raw": "1. Cabergoline is used for the treatment of Parkinson's disease.\n2. Cabergoline is used for the treatment of hyperprolactinemia.\n3. Cabergoline is used for the treatment of tumors such as pheochromocytoma and paraganglioma.\n4. The management of Nelson's syndrome may involve hormone replacement therapy, surgery, and medications to control symptoms.\n5. There is no mention of cabergoline being used for the treatment of Nelson's syndrome in the given documents.",
    "vicuna-13b_fact": [
      "Cabergoline is used for the treatment of Parkinson's disease.",
      "Cabergoline is used for the treatment of hyperprolactinemia.",
      "Cabergoline is used for the treatment of tumors such as pheochromocytoma and paraganglioma.",
      "The management of Nelson's syndrome may involve hormone replacement therapy, surgery, and medications to control symptoms.",
      "There is no mention of cabergoline being used for the treatment of Nelson's syndrome in the given documents."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Cabergoline is not typically used for the treatment of tumors such as pheochromocytoma and paraganglioma. It is primarily used for the treatment of disorders related to hyperprolactinemia.\n4. TRUE\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "vicuna-13b_response": "The main manifestation of Liebenberg syndrome is characteristic arm malformations that can vary in severity. In people with this condition, bones and other tissues in the elbows, forearms, wrists, and hands have characteristics of related structures in the lower limbs.",
    "vicuna-13b_fact_raw": "1. Liebenberg syndrome is characterized by arm malformations.\n2. The severity of arm malformations in Liebenberg syndrome can vary.\n3. In Liebenberg syndrome, bones and tissues in the elbows, forearms, wrists, and hands may resemble structures in the lower limbs.",
    "vicuna-13b_fact": [
      "Liebenberg syndrome is characterized by arm malformations.",
      "The severity of arm malformations in Liebenberg syndrome can vary.",
      "In Liebenberg syndrome, bones and tissues in the elbows, forearms, wrists, and hands may resemble structures in the lower limbs."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "vicuna-13b_response": "Based on the information provided in Document 0 and Document 1, orally bioavailable MPS1 kinase inhibitors include the small-molecule inhibitors based on the 1H-pyrrolo[3,2-c]pyridine scaffold that were discovered in a medicinal-chemistry program enabled by structure-based design and cellular characterization of MPS1 inhibition. These optimized compounds display potent and selective inhibition of MPS1 in vitro and translate well to cellular assays.",
    "vicuna-13b_fact_raw": "1. The MPS1 kinase inhibitors mentioned are orally bioavailable.\n2. The inhibitors are based on the 1H-pyrrolo[3,2-c]pyridine scaffold.\n3. The discovery of these inhibitors was facilitated by a medicinal-chemistry program.\n4. The program that led to the discovery of these inhibitors utilized structure-based design.\n5. The inhibitors show potent and selective inhibition of MPS1 in vitro and are effective in cellular assays.",
    "vicuna-13b_fact": [
      "The MPS1 kinase inhibitors mentioned are orally bioavailable.",
      "The inhibitors are based on the 1H-pyrrolo[3,2-c]pyridine scaffold.",
      "The discovery of these inhibitors was facilitated by a medicinal-chemistry program.",
      "The program that led to the discovery of these inhibitors utilized structure-based design.",
      "The inhibitors show potent and selective inhibition of MPS1 in vitro and are effective in cellular assays."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE\n\nWithout specific information about the MPS1 kinase inhibitors being referenced, it is not possible to confirm the oral bioavailability (statement 1) or the chemical scaffold (statement 2). However, statements 3, 4, and 5 are generally true for many kinase inhibitors discovered through medicinal chemistry programs, which often utilize structure-based design and aim to achieve potent and selective inhibition in vitro and effectiveness in cellular assays.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "vicuna-13b_response": "Based on the information provided, it is not explicitly stated in Document 0 or Document 1 whether golimumab was tested for diabetes. However, it is mentioned in Document 1 that more specific/targeted treatments have been tested in stage 3 T1D, which suggests that golimumab may have been tested for diabetes as it is a specific/targeted treatment for autoimmune diseases such as type 1 diabetes.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "vicuna-13b_response": "Yes, progeria is caused by an autosomal recessive gene. It is a genetic disorder that affects the production of a protein called lamin A, which is important for maintaining the structure of cells. Children with progeria have a mutation in the gene that codes for lamin A, which leads to the production of a faulty protein that causes the cells to age prematurely. This results in the rapid aging symptoms seen in children with progeria.",
    "vicuna-13b_fact_raw": "1. Progeria is caused by an autosomal recessive gene.\n2. Progeria affects the production of a protein called lamin A.\n3. Lamin A is important for maintaining the structure of cells.\n4. Children with progeria have a mutation in the gene that codes for lamin A.\n5. The mutation leads to the production of a faulty protein that causes cells to age prematurely.",
    "vicuna-13b_fact": [
      "Progeria is caused by an autosomal recessive gene.",
      "Progeria affects the production of a protein called lamin A.",
      "Lamin A is important for maintaining the structure of cells.",
      "Children with progeria have a mutation in the gene that codes for lamin A.",
      "The mutation leads to the production of a faulty protein that causes cells to age prematurely."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Progeria is caused by a mutation in the LMNA gene, which is a dominant mutation, not recessive.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "vicuna-13b_response": "Based on the given documents, common variants at 12q14 and 12q24 are associated with hippocampal volume. Specifically, the ENIGMA Consortium and the Cohorts for Heart and Aging Research found that these variants are associated with hippocampal volume, and a genome-wide association study (GWAS) of dementia-free persons identified 46 SNPs at four loci with P values of less than 4.0 x 10^-7 that are associated with hippocampal volume. These variants may be relevant for understanding the relationship between aging, Alzheimer's disease, and vascular risk factors and hippocampal volume.",
    "vicuna-13b_fact_raw": "1. Common variants at 12q14 and 12q24 are associated with hippocampal volume.\n2. The ENIGMA Consortium found an association between these variants and hippocampal volume.\n3. The Cohorts for Heart and Aging Research also found an association between these variants and hippocampal volume.\n4. A genome-wide association study of dementia-free persons identified 46 SNPs at four loci with P values of less than 4.0 x 10^-7 associated with hippocampal volume.\n5. These variants may be relevant for understanding the relationship between aging, Alzheimer's disease, and vascular risk factors and hippocampal volume.",
    "vicuna-13b_fact": [
      "Common variants at 12q14 and 12q24 are associated with hippocampal volume.",
      "The ENIGMA Consortium found an association between these variants and hippocampal volume.",
      "The Cohorts for Heart and Aging Research also found an association between these variants and hippocampal volume.",
      "A genome-wide association study of dementia-free persons identified 46 SNPs at four loci with P values of less than 4.0 x 10^-7 associated with hippocampal volume.",
      "These variants may be relevant for understanding the relationship between aging, Alzheimer's disease, and vascular risk factors and hippocampal volume."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: It is known that common genetic variants can be associated with brain structure, and 12q14 and 12q24 are locations on chromosome 12 that have been studied in relation to hippocampal volume.\n2. TRUE: The ENIGMA (Enhancing Neuro Imaging Genetics through Meta Analysis) Consortium is a well-known research group that has conducted studies on the genetic factors influencing brain structures, including the hippocampus.\n3. UNKNOWN: Without specific information about the \"Cohorts for Heart and Aging Research,\" it is unclear whether this group found an association between the variants at 12q14 and 12q24 and hippocampal volume. This statement would require additional context or citation to verify.\n4. UNKNOWN: The specific results of a genome-wide association study (GWAS) would need to be verified with a reference to the study itself. While the methodology described is plausible, the exact number of SNPs and loci identified cannot be confirmed without additional information.\n5. TRUE: Genetic variants that affect hippocampal volume are indeed of interest in understanding aging, Alzheimer's disease, and the impact of vascular risk factors, as the hippocampus is a critical brain region involved in memory and is affected in neurodegenerative diseases.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "vicuna-13b_response": "Based on the given information, the ligands of the Roundabout (Robo) receptors are the members of the Slit protein family, specifically SLIT1, SLIT2, and SLIT3 for the human ROBO1 and ROBO2 receptors.",
    "vicuna-13b_fact_raw": "1. The ligands of the Roundabout (Robo) receptors are members of the Slit protein family.\n2. SLIT1, SLIT2, and SLIT3 are specific ligands for the human ROBO1 and ROBO2 receptors.",
    "vicuna-13b_fact": [
      "The ligands of the Roundabout (Robo) receptors are members of the Slit protein family.",
      "SLIT1, SLIT2, and SLIT3 are specific ligands for the human ROBO1 and ROBO2 receptors."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "vicuna-13b_response": "Based on the information provided, it appears that TFII-I may have a role in megakaryopoiesis. Document 0 states that TFII-I acts as a repressor of β-globin gene transcription and is implicated in the differentiation of erythro-megakaryocytic cells. Document 1 also states that TFII-I acts as a repressor of β-globin gene transcription and is implicated in the differentiation of erythro-megakaryocytic cells. Megakaryopoiesis is the process of megakaryocyte cell development, which leads to the production of megakaryocytes and ultimately platelets. Since TFII-I is implicated in the differentiation of erythro-megakaryocytic cells, it is possible that it also plays a role in the process of megakaryopoiesis.",
    "vicuna-13b_fact_raw": "1. TFII-I acts as a repressor of β-globin gene transcription.\n2. TFII-I is implicated in the differentiation of erythro-megakaryocytic cells.\n3. Megakaryopoiesis is the process of megakaryocyte cell development.\n4. The development of megakaryocytes leads to the production of platelets.",
    "vicuna-13b_fact": [
      "TFII-I acts as a repressor of β-globin gene transcription.",
      "TFII-I is implicated in the differentiation of erythro-megakaryocytic cells.",
      "Megakaryopoiesis is the process of megakaryocyte cell development.",
      "The development of megakaryocytes leads to the production of platelets."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: TFII-I acts as an activator of β-globin gene transcription.\n2. TRUE\n3. TRUE\n4. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "vicuna-13b_response": "Based on the information provided, it appears that atenolol is not primarily metabolized by CYP2D6, but it is also metabolized by this enzyme to a clinically insignificant extent. In contrast, carvedilol is metabolized by CYP2D6, but it is also metabolized by other enzymes such as CYP3A4 and oxidation. It is important to note that the metabolism of a drug can affect its efficacy and safety, and genetic variations in CYP2D6 can impact the metabolism of many drugs.",
    "vicuna-13b_fact_raw": "1. Atenolol is not primarily metabolized by CYP2D6.\n2. Atenolol is metabolized by CYP2D6 to a clinically insignificant extent.\n3. Carvedilol is metabolized by CYP2D6.\n4. Carvedilol is also metabolized by other enzymes such as CYP3A4 and oxidation.\n5. Genetic variations in CYP2D6 can impact the metabolism of many drugs.",
    "vicuna-13b_fact": [
      "Atenolol is not primarily metabolized by CYP2D6.",
      "Atenolol is metabolized by CYP2D6 to a clinically insignificant extent.",
      "Carvedilol is metabolized by CYP2D6.",
      "Carvedilol is also metabolized by other enzymes such as CYP3A4 and oxidation.",
      "Genetic variations in CYP2D6 can impact the metabolism of many drugs."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "vicuna-13b_response": "Based on the given information, it appears that there are multiple versions of ExpansionHunter available. The latest version is v5.0.0, which introduces substantial changes to accelerate analysis of large genome-wide STR catalogs, as well as improvements to the build system, bug fixes, and catalog updates.\nIn addition, there is a document on GitHub that suggests there may be issues with the code for ExpansionHunter and Illumina. It is recommended to contact GitHub Support for assistance with any code issues.\nIt is also worth noting that the license for ExpansionHunter has been updated to the PolyForm Strict License 1.0.0.",
    "vicuna-13b_fact_raw": "1. The latest version of ExpansionHunter is v5.0.0.\n2. Version 5.0.0 of ExpansionHunter includes changes to accelerate analysis of large genome-wide STR catalogs.\n3. The latest version of ExpansionHunter also includes improvements to the build system, bug fixes, and catalog updates.\n4. There is a document on GitHub that suggests there may be issues with the code for ExpansionHunter and Illumina.\n5. The license for ExpansionHunter has been updated to the PolyForm Strict License 1.0.0.",
    "vicuna-13b_fact": [
      "The latest version of ExpansionHunter is v5.0.0.",
      "Version 5.0.0 of ExpansionHunter includes changes to accelerate analysis of large genome-wide STR catalogs.",
      "The latest version of ExpansionHunter also includes improvements to the build system, bug fixes, and catalog updates.",
      "There is a document on GitHub that suggests there may be issues with the code for ExpansionHunter and Illumina.",
      "The license for ExpansionHunter has been updated to the PolyForm Strict License 1.0.0."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: Without the current date or a reference to the latest version of ExpansionHunter at the time of the statement, it is not possible to confirm the version number.\n2. UNKNOWN: Without access to the release notes or documentation for version 5.0.0 of ExpansionHunter, it is not possible to confirm the specific changes in that version.\n3. UNKNOWN: Similar to the previous statement, without access to the release notes or documentation for the latest version of ExpansionHunter, it is not possible to confirm the improvements, bug fixes, and catalog updates.\n4. UNKNOWN: Without the specific document or additional context, it is not possible to confirm the existence of issues with the code for ExpansionHunter and Illumina.\n5. UNKNOWN: Without access to the current licensing information for ExpansionHunter, it is not possible to confirm the version of the license.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "vicuna-13b_response": "Based on the information provided, it appears that Adamts18 plays a role in hormone receptor signaling. Document 0 suggests that Adamts18 is required for stem cell activation and interacts genetically with the basal membrane-specific proteoglycan, Col18a1, pointing to its involvement in the regulation of cellular processes. Document 1 further supports this idea by suggesting that Adamts18 is a secreted protease that is involved in development and disease. However, the specific role of Adamts18 in hormone receptor signaling is not explicitly stated in the provided information. Further research may be necessary to fully understand its function in this process.",
    "vicuna-13b_fact_raw": "1. Adamts18 is required for stem cell activation.\n2. Adamts18 interacts genetically with the basal membrane-specific proteoglycan, Col18a1.\n3. Adamts18 is a secreted protease.\n4. Adamts18 is involved in development and disease.",
    "vicuna-13b_fact": [
      "Adamts18 is required for stem cell activation.",
      "Adamts18 interacts genetically with the basal membrane-specific proteoglycan, Col18a1.",
      "Adamts18 is a secreted protease.",
      "Adamts18 is involved in development and disease."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: The statement is too specific and without additional context or specific scientific references, it is not possible to determine the truthfulness of the claim that Adamts18 is required for stem cell activation.\n2. UNKNOWN: Without specific scientific literature or context, it is not possible to confirm or deny the genetic interaction between Adamts18 and Col18a1.\n3. TRUE: ADAMTS18 (A Disintegrin And Metalloproteinase with Thrombospondin motifs 18) is indeed a member of the secreted protease family known as ADAMTS.\n4. TRUE: ADAMTS proteases, including Adamts18, are known to be involved in various biological processes related to development and disease. However, the specific roles can be quite complex and varied depending on the context.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "vicuna-13b_response": "The mode of action of Thiazovivin is not specified in the given documents. However, it is mentioned that Thiazovivin can be replaced by other ROCK inhibitors such as Y27632 and HA-1077, with appropriate adjustments in concentrations. Thiazovivin was selected for this protocol due to its effectiveness at lower concentrations (2 μM) compared to Y27632 or HA-1077. Additionally, it is mentioned that small molecules improve the survival and homing of cells in the body, stimulate endogenous stem cells to enhance tissue regeneration, and are used in the field of regenerative medicine to replace or regenerate human cells, tissues or organs, to restore or establish normal function.",
    "vicuna-13b_fact_raw": "1. Thiazovivin can be replaced by other ROCK inhibitors like Y27632 and HA-1077 with adjustments in concentrations.\n2. Thiazovivin is effective at lower concentrations (2 μM) compared to Y27632 or HA-1077.\n3. Small molecules, like Thiazovivin, are used to improve the survival and homing of cells in the body.\n4. Small molecules stimulate endogenous stem cells to enhance tissue regeneration.\n5. Small molecules are used in regenerative medicine to replace or regenerate human cells, tissues, or organs.",
    "vicuna-13b_fact": [
      "Thiazovivin can be replaced by other ROCK inhibitors like Y27632 and HA-1077 with adjustments in concentrations.",
      "Thiazovivin is effective at lower concentrations (2 μM) compared to Y27632 or HA-1077.",
      "Small molecules, like Thiazovivin, are used to improve the survival and homing of cells in the body.",
      "Small molecules stimulate endogenous stem cells to enhance tissue regeneration.",
      "Small molecules are used in regenerative medicine to replace or regenerate human cells, tissues, or organs."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Thiazovivin can indeed be replaced by other ROCK inhibitors like Y27632 and HA-1077, with adjustments in concentrations, as they are all inhibitors of the Rho-associated protein kinase (ROCK) pathway.\n2. UNKNOWN: Without specific data or a reference to the efficacy of Thiazovivin at lower concentrations compared to Y27632 or HA-1077, it is not possible to determine the truthfulness of this statement.\n3. TRUE: Small molecules like Thiazovivin are used to improve the survival and homing of cells, which is particularly important in the context of cell transplantation and regenerative medicine.\n4. TRUE: Small molecules can stimulate endogenous stem cells to enhance tissue regeneration. This is one of the strategies used in regenerative medicine to promote healing and tissue repair.\n5. TRUE: Small molecules are indeed used in regenerative medicine with the goal to replace or regenerate human cells, tissues, or organs to restore or establish normal function.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  }
]